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Abstract 
Personalized medicine promises that improved information leads to improved treatments, 
that each individual has unique genetic, clinical, and environmental factors which are ultimately 
responsible for the distinct molecular mutations which drive disease as well as variation in 
treatment efficacy. The field of biomarker-based diagnostics attempts to characterize this 
variability by both identifying which biomolecules are indicative of disease condition as well as 
quantitate their abundance, thus enabling personalized and improved treatment.  The challenge is 
thus to accurately quantify the abundance of relevant biomarkers at a sufficiently large scale and 
in a sufficiently inexpensive format. While numerous biomarker quantitation methodologies 
exist, they frequently are specialized, providing either high throughput analysis in a qualitative 
fashion, or highly quantitative analysis of a single biomarker. These extremes are ill-suited to 
biomarker-based diagnostics, which require quantitative rigor to discern the often subtle 
differences in biomarker abundance, as well as the multiparameter detection capabilities that 
lend biomarker panels meaningful predictive power.   
Silicon photonic microring resonators are a promising class of sensor well suited to 
biomarker quantitation due to their sensitivity, scalability and flexibility, enabling quantitative 
multiplexed analysis. Their sensing modality arises from interactions between light and matter—
light circumnavigating the microring structure interacts via the accompanying evanescent field 
with the local environment of the ring, enabling binding events to be readily transduced as a 
change in the resonant wavelength circulating in the cavity. The resonating nature of the 
structure results in multi-pass interactions between surface bound analytes and the evanescent 
field, enabling the high sensitivity found in much larger devices, but in a small footprint 
amenable to high density sensor arrays. This architecture lends itself to scalability—the current 
chip contains 128 active sensors, with the potential for even higher plexity in the future.  
Additionally, the nearly planar sensor geometry enables facile and reproducible fabrication 
capitalizing on well-developed commercial semiconductor processes, resulting in very low costs 
per assay.  
The intrinsic flexibility of this sensing modality has enabled the development of a wide 
variety of assays quantifying DNA, RNA, and proteins, as well as the screening of more complex 
and subtle biomolecular interactions. Herein I describe assay developments using novel reagents 
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and methodologies to specifically address the quantitation challenges associated with various 
analyte classes, with emphases on subsequent applications in complex matrix environments to 
demonstrate clinical utility. Chapter 1 contains a more thorough introduction to multiparameter 
biomolecular analysis using microring resonators, with particular emphasis on recent 
developments in the field and an eye towards likely future directions. Chapter 2 gives a near-
exhaustive review of current microRNA (miRNA) analysis methodologies, emphasizing both 
advancements in classical molecular biology techniques as well as more recent in vitro 
diagnostic devices. Many of the techniques discussed, while in the context of miRNA, are used 
in slightly modified forms for general RNA or even DNA analysis. Chapter 3 describes the use 
of a novel anti-DNA:RNA antibody as a secondary label to improve the miRNA detection limit 
400-fold relative to direct detection, enabling 4-plexed miRNA quantitation in total RNA 
extracts from mouse and soybean samples. Chapter 4 demonstrates the detection of bacterial 
transfer-messenger RNA in a multiplexed assay, employing a unique RNA fragmentation 
protocol to optimize signal response. Chapter 5 describes the quantitation of full length 
messenger RNA using a novel chaperone-assisted detection strategy, coupled with nanoparticle 
tertiary labels for signal enhancement. These developments enabled mRNA expression profiling 
in total RNA extracts from a differentiating cell line. Chapter 6 describes the recapitulation of the 
RNA Induced Silencing Complex (RISC) on the ring resonator surface, and demonstrates 
modulation of Argonaute 2 catalytic activity in response to varied guide strand miRNA. Chapter 
7 explores an enzymatic enhancement strategy to achieve the highest signal response recorded on 
the ring resonator platform to date, achieving an ultrasensitive sub-pg/mL detection limit. 
Chapter 8 outlines future work, describing the importance of preconcentration, the enormous 
potential of enzymatic signal enhancement, and the capabilities of on-chip characterization of the 
biomolecular interactions of RISC.    
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Chapter 1 
Biomolecular Analysis with Microring Resonators: 
Applications in Multiplexed Diagnostics and 
Interaction Screening 
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1.1 Abstract 
Silicon photonic microring resonators are a promising class of sensor whose value in 
bioanalytical applications has only begun to be explored. Utilized in the telecommunication 
industry for signal processing applications, microring resonators have more recently been re-
tasked for biosensing due to their scalability, sensitivity, and versatility. Their sensing modality 
arises from light/matter interactions—light propagating through the microring and the resultant 
evanescent field extending beyond the structure is sensitive to the refractive index of the local 
environment, which modulates the resonant wavelength of light supported by the cavity. This 
sensing capability has recently been utilized for the detection of numerous biological targets 
including proteins, nucleic acids, viruses, and small molecules. Herein we highlight some of the 
most exciting recent uses of this technology for biosensing applications, with an eye towards 
future developments in the field. 
1.2 Introduction 
Biomolecular detection technologies are invaluable in modern chemical biology, helping 
to advance fundamental studies of biophysical interactions and recognition, drug discovery, and 
the translation of new insights into clinical application. Not surprisingly, the literature is replete 
with emerging technologies offering enabling new capabilities, and the development of 
biosensing technologies has been a particularly active area of both academic research and 
industrial product development. Among the many different classes of transduction schemes, 
optical biosensors have been highly successful due to their diversity and generality.
1
 In this short 
review we narrowly focus on one particular flavor of optical biosensor that has recently emerged 
as a promising technology both for fundamental interaction screening and in vitro diagnostic 
applications. Microcavity resonators, and in particular chip-integrated microring resonator 
arrays, have generated interest due to their amenability to scalable fabrication and demonstrated 
performance metrics. To maintain focus, and to meet length constraints, we focus our discussion 
entirely to microring resonator-based assays and developments within the past 5 years. 
Microring resonators belong to a larger class of sensors known as whispering gallery 
resonators, a terminology that is fitting given the fact that these sensors are optical analogues of 
the whispering galley acoustic phenomenon first explained by Sir Rayleigh following his 
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observations in London‘s St. Paul‘s Cathedral. Optical microcavities support discrete modes in 
which light circumnavigates the structure and constructively interferes with the input source as 
described by Equation 1.1,
2
  
                                                                                         (Eq. 1.1) 
where an integer (m) multiple of the wavelength equals the circumference times the effective 
refractive index (neff). A conceptual overview of resonator operation and implementation is 
shown in Figure 1.1. 
Light from a laser source is coupled into the microstructure using diffractive grating 
couplers, or prism- or butt-end coupling via an adjacent linear waveguide structure or extruded 
fiber optic cable.
3
 Under resonance conditions, light is coupled into the microstructure and 
propagates around the cavity via total internal reflection. A resulting evanescent optical field 
extends into the local environment, providing a mechanism for detecting binding-induced 
changes in local refractive index, as sampled by the optical mode. Importantly, light circulates 
the microcavities many times, giving effective path lengths much larger than the physical 
dimensions of the sensor itself. This greatly enhances the interaction between an analyte and the 
evanescent field, amplifying the sensitivity of the sensor. Microcavity resonators can vary greatly 
both in their material composition and geometry; common examples include microrings,
4
 slot-
waveguide microrings,
5
 microdiscs,
6
 microspheres,
7
 microtoroids,
2
 and liquid core capillaries.
8
 
Of these, microrings are particularly amenable to scalable fabrication on account of their near 
planar geometry, which is compatible with widely used, batch microfabrication methods, or their 
integration into capillary structures. In terms of materials systems, polymer,
9,10
 silica, and 
silicon-based structures are the most common. In this review we focus on planar silicon and 
liquid core silica microring resonators, as these are the most common configurations. For a 
broader discussion of other optical microcavity-based sensors, the reader is referred to these 
reviews.
11-13
 
The growing interest in microring resonators for biosensing applications can be attributed 
to their unique combination of high performance sensing capabilities in a platform conducive to 
highly multiplexed, low cost measurements. The real-time data collection, label-free detection 
capabilities, and high sensitivity provide an alternative to assays requiring fluorescent or 
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enzymatic tags, or those that are incapable of providing kinetic binding information. The 
potential for high level multiplexing using arrays of many tens or hundreds of target-specific 
sensor elements also makes them attractive for clinical diagnostic assays, as well as for a range 
of bio(molecular) screening applications.  
1.3 Diagnostic Assays 
A compelling feature of microring resonators is their ability to act as ―label-free‖ sensors 
that do not require fluorescent or enzymatic tags for detection. Labels can reduce the reliability, 
reproducibility, and accuracy of biomolecular assays by introducing signal bias,
14
 a consideration 
that increasingly important as the size of target analytes is reduced. Microring sensors transduce 
the presence of analytes on the basis of binding-induced changes in the local refractive index, 
and since all biological molecules have refractive indices greater than water the sensors are 
universally responsive to all classes of biomolecular targets, given functionalization with 
appropriate capture agents.  
Numerous label-free, microring-based assays have been developed for nucleic acids, 
including DNA,
15-19
 miRNA,
20
 mRNA,
21
 and tmRNA.
22
 Highlights of these studies include low 
detection limits (10 pM), single nucleotide polymorphism (SNP) discrimination,
16
 and analysis 
of DNA methylation patterns.
17
 An impressive application of the technology paired methylation 
specific polymerase chain reaction (MS-PCR), bisulfite modifications, and microring resonators 
to quantitate methylation frequency in genomic DNA from cancer cell lines.
19
 
An even larger body of work has focused on label-free protein analysis, leading to 
numerous label-free aptamer
23,24
 and antibody-based assays on microring resonator detection 
platforms.
18,25-33
   Initial proof-of-principle reports utilized simplified biological systems such as 
biotin-streptavidin or IgG:anti-IgG;
5,10,29
 however, more recent work has focused on more 
relevant clinical biomarkers, frequently in multiplexed formats and in complex matrices. The 
first study in this vein demonstrated the detection of a colorectal cancer biomarker, 
carcinoembryonic antigen, in undiluted fetal bovine serum with a clinically-relevant detection 
limit (2 ng/mL) and very short assay time (10 min) .
30
 In another notable study, Zhu et al. 
demonstrated the detection of CA15-3, a breast cancer biomarker, in human serum samples with 
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a total assay time of 30 minutes. Importantly, this work featured a two-step blocking 
methodology that helped reduce nonspecific sensor fouling.
27
 
Given the powerful fabrication methods by which microring resonators can be created, 
multiplexed analysis is a key analytical advantage of the technology, particularly given the 
importance of multi-molecular signatures in the diagnosis and monitoring of many human 
diseases and disorders.
34
 To date, multiplexed analyses of proteins and nucleic acids have only 
been realized in simplified assay formats; however, a number of clinically-relevant 
demonstrations of multiplexed analyses should be expected in the near future. Figure 1.2 
illustrates several such examples.  
Despite the attractiveness of label-free analysis, the challenges associated with the 
complex matrices of clinical samples such as nonspecific fouling, cross-reactivity, and low-
abundance biomarkers often necessitates the use of label-based, secondary detection schemes. 
Fortunately, the refractive index-based transduction of microring resonators is amenable to a 
plethora of tag-based signal enhancement modalities. To date, secondary antibodies and sub-
micron beads have been used to enhance assay sensitivity and specificity.
21,35-37
 Specifically, a 
sequence independent antibody that recognizes DNA:RNA heteroduplexes was used in the 
simultaneous detection of four miRNAs with a detection limit of 10 pM.
38
 Antibody labels were 
also used to monitor the secretion of four cytokines from mitogenically-stimulated, primary 
human T cells.
35
 Importantly, secondary antibody-based immunoassays require two target-
specific recognition events, which greatly increases the selectivity of measurements made in 
complex, clinically-relevant sample matrices. Sub-micron beads have also been employed as 
tertiary labels in a variety of biomolecular assays. The large size of these particles, relative to 
biomolecules, large surface area, and flexibility in surface chemistry render them highly 
amenable for refractive index signal enhancement strategies in microring resonator-based protein 
and nucleic acid assays.
21,37
 Bead-based methods were employed recently for the analysis of C-
reactive protein, a cardiac biomarker known to increase abundance by a factor of up to 10
5
 
during acute cardiac events. In recognition of the extreme challenge associated with this broad 
dynamic range, a three-step assay was developed that allowed quantitation across six orders of 
magnitude with a limit of detection in the 10s of pg/mL.  
1.4 Virus and Whole Cell Detection 
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While the major thrust in microring resonator-based analyses has focused on assays for 
protein and nucleic acids, the versatility of the technology has also been extended to larger 
analytes such as virus particles and even whole cells. The binding of these analytes induces 
correspondingly large shifts in resonance frequencies, enabling rapid analysis with minimal 
sample processing.   
Two recent reports describe relatively rapid (<1 hr) viral detection assays using different 
microring resonator configurations, representing a less labor intensive and less time-consuming 
alternative to laboratory procedures such as RT-PCR or ELISA.  These developments are 
noteworthy because of the sometimes lengthy period between exposure and measurable immune 
response or infected phenotype, placing a premium on analysis time. It is anticipated that rapid 
viral analysis could have applications in agricultural monitoring, healthcare, and bioterrorism 
surveillance. Zhu et al. developed a sandwich-style immunoassay on an LCORR sensor to detect 
M13 bacteriophage over an impressive dynamic range of 7 orders of magnitude.
39
 Using silicon 
photonic microrings, a 10 ng/mL detection limit was achieved for the detection of bean pod 
mottle virus from whole soybean leaf extract.
40
 
Cell-based assays are of interest not only to further our understanding of cellular 
processes, but also represent an indirect method of sensing other analytes or conditions that 
affect cellular function and/or behavior. Wang and colleagues creatively exploited this capability 
using silicon-based microring sensors to monitor cell adhesion and growth events as well as 
motility perturbations resulting from the introduction of toxic compounds.
41
 Gohring and 
colleagues detected CD4+ and CD8+ lymphocytes in white blood cell samples isolates from 
whole blood by coating a LCORR sensor with CD4+ and CD8+ specific antibodies.
8
 This 
platform offered the benefit of near-single cell analysis, but also resulted in high ring to ring 
variability; however, accurate quantitation of cellular perturbations and cell counting was 
achieved with appropriate negative controls and data averaging. The authors envision this device 
as a companion diagnostic for anti-retroviral treatments of HIV+ patients. 
1.5 Interaction Screening  
The refractive index-based transduction methodology and multiplexing capability of 
microring resonators also make them highly promising to biomolecular screening and affinity 
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characterization applications.
23,32,42-44
 In contrast to endpoint-based methods, which only provide 
the thermodynamic binding constant, real-time monitoring technologies provide direct access to 
the kinetic rate constants that govern biomolecular interactions. Importantly, kinetic binding 
information can be used to unravel multi-step binding mechanisms, select for optimal capture 
agents, determine drug-target stability, and characterize interactions between competitive 
binders, among others.  
Carbohydrate binding studies are well suited to ring resonator-based interrogation based 
on both the diversity of binding partners and wide range of binding affinities. Several exciting 
studies have coupled high density inkjet functionalization and novel linker chemistries to create 
robust carbohydrate arrays for glycomics applications. In one such study a silicon photonic 
sensor array was functionalized with various sugars via a piezoelectric inkjet printer for 
subsequent kinetic profiling of two carbohydrate binding proteins (lectins).
42
 A similar study 
immobilized glycans to organophosphonate-modified sensors via a divinyl sulfone moiety, 
enabling multiple surface regenerations and extended storage stability, and offering additional 
advantages over the more commonly used siloxane conjugation chemistry.  This improved 
surface chemistry enabled the subsequent kinetic profiling of four lectins, as well as norovirus 
particles with a carbohydrate-dependent pathogenic mechanism.
43
 The authors anticipate 
immediate applications in glycan based drug discovery, vaccine design, and carbohydrate-
mediated host-virus interactions. 
Microring resonator arrays have also been used to interrogate the binding affinity of 
protein capture agents. Notably, a panel of 12 antibodies against two protein targets was screened 
using a DNA-encoded surface conjugation methodology that enabled rapid surface regeneration 
and robust storage properties. In a kinetic titration assay format, the association and dissociation 
rate constants (ka and kd, respectively) and equilibrium dissociation constant (KD) were 
determined, and compatible antibody sandwich pairs were also revealed.
32
 Aptamer-based 
capture agents have also been used on a microring resonator detection platform, allowing direct 
comparison in the performance of a DNA aptamer and monoclonal antibody against thrombin.
23
  
Another recent study probed the interactions of soluble proteins with cell membrane 
components by integrating the microring resonator arrays with phospholipid bilayer nanodiscs, a 
synthetic membrane construct.
44
 The authors demonstrated the multiplexing capability of this 
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detection approach by simultaneously quantitating four different protein-lipid, protein-
carbohydrate, or protein-membrane protein interactions. This synergistic combination of 
technologies should allow facile screening of protein interactions with membrane-associated 
glycans, lipids, and membrane proteins. Figure 1.3 illustrates several of the above mentioned 
interaction screening applications. 
1.6 Future Advances: Device & Fluidic Integration 
Enormous advances within the past 5 years have firmly established microring resonator 
technology as a promising tool for many bioanalytical applications, and continued developments 
will further improve the translational capabilities of this measurement technology. Initial proof-
of-principle studies using well-characterized model systems have given way to multiplexed 
assays of clinically-relevant targets in increasingly complex sample matrices. Continued 
advances will likely be propelled by ‗lab on a chip‘ integration of complementary instrumental, 
fluidic, and assay developments. Fields such as drug discovery and epitope mapping are 
particularly well-positioned to benefit from the scalable, multiplexable, and real-time, kinetic 
screening capabilities offered by microring resonators, especially as advances in accompanying 
microfluidic fluid handling further decreases the amount of sample required for analysis. 
Here we highlight two significant trends in microring resonator technology development: 
continued exploration of advanced geometries and the on-chip integration of optical components. 
A particularly promising geometry for increasing measurement sensitivity is that of ‗cascaded 
microrings‘. Claes, Bogaerts, and Bienstman developed and validated this construct in which two 
microrings are optically coupled so that a filter microring provides a spectrally-structured input 
for a sensor microring. When the two microrings are of slightly different sizes, the periodicities 
in resonances supported by each ring are slightly different, resulting in a Vernier scale effect in 
which their transmission dips periodically overlap. This creates a manifold of resonance peaks 
that can be collectively tracked and fitted, offering sensitivity advantages over monitoring single 
resonances, while retaining the fabrication benefits of a near-planar device geometry.
45
 The 
authors subsequently coupled cascaded microring sensors with an arrayed waveguide grating 
spectral filter to enable the use of a low cost, broadband light source,
46
 a significant development 
given the substantial cost associated with high resolution tunable laser sources often utilized in 
microring resonator-based measurements. In a similar effort to remove the high cost of typical 
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optical scanning instrumentation, Palit and colleagues integrated all optical components onto a 
single chip including the laser source, waveguides, microring sensors, and detector.
47
 This is an 
impressive achievement in terms of device integration; however, future work will show whether 
the increased complexity in terms of on-chip architecture can match the performance capabilities 
achieved by passive sensor chips. Figure 1.4 showcases several examples of optical and fluidic 
integration with resonator sensors. 
Perhaps the most major avenue in terms of advancing microring resonator bioanalysis 
will be efforts towards clinical translation, since the cost effective nature of many device 
geometries is well-suited to relatively low cost and high volume analytical applications. As 
highlighted above, there are numerous classes of targets that can be detected using this 
technology and significant efforts have already been invested in assay developments including 
improved sample pre-treatment, signal enhancement strategies, and robust anti-fouling surface 
chemistries.
43,48,49
 Technology advances will also be highly coupled with complementary 
technologies such as microfluidic liquid handling to reduce sample consumption,
50
 as well as 
automated printing of multiplexed sensor arrays
42
 such that the multiplexing of biological 
functionalization matches the sensor fabrication multiplexing.  
1.7 Conclusions  
The recent emergence of microring resonators as a surface sensitive, label-free detection 
technique has led to a proliferation of research in the application of the technology to a range of 
biomolecular analysis applications. The combination of high sensitivity, application versatility, 
and robust and scalable fabrication approaches make this particular resonator geometry an 
attractive candidate for high performance bioanalytics. The past five years have seen rapid 
developments within the field, as literature reports have quickly progressed beyond overly 
simplified, proof-of-principle demonstrations to, for example, multiplexed biomarker detection 
from within complex, clinically-relevant sample matrices. This progression has been permitted 
by significant advances in signal enhancement strategies, improved surface chemistries, and the 
innovative utilization of novel reagents and methodologies.  We anticipate that microring 
resonator technology will continue along this steep development trajectory as academic 
researchers and commercial efforts further demonstrate in vitro diagnostic applications, as well 
10 
 
as exciting emerging applications including drug screening, biophysical interaction 
characterization, and epitope mapping.   
11 
 
1.8 Figures 
 
Figure 1.1. a) Analyte binding to surface-immobilized capture agents results in a red-shift in the 
resonant wavelength circulating in the microring structure. This signal can be monitored in time 
for quantitative analysis of binding or determination of interaction kinetics. Adapted with 
permission;
30
 copyright (2009) American Chemical Society. b) Schematic of the optofluidic ring 
resonator geometry illustrating the seamless integration of fluidic sample delivery and optical 
interrogation. Adapted with permission;
28
 copyright (2010) Elsevier. c) Scanning electron 
micrograph image of a silicon-on-insulator microring resonator and adjacent linear waveguide, 
both visible through an annular opening in a fluoropolymer cladding layer, which coats the rest 
of the substrate to reduce non-specific biomolecular interactions. d) A cartridge assembly 
incorporating an array of silicon photonic microring resonators with a microfluidic delivery 
system. An individual resonator in a fluidic channel is shown in the inset. Adapted with 
permission;
5
 copyright (2010) Royal Society of Chemistry.  
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Figure 1.2. Multiplexed biomarker analysis demonstrations for both nucleic acid and protein 
diagnostic applications: a) Multiplexed microRNA analysis, in which a resonance shift is only 
observed when target miRNA sequences (columns) hybridize onto specific microrings array 
elements functionalized with complementary DNA capture agents (rows). Adapted with 
permission;
38
 copyright (2011) American Chemical Society. b) Quantitative analysis of five 
different protein biomarkers using an array of uniquely antibody functionalized microring 
resonators using only a 5 minute, label-free binding immunoassay format. Adapted with 
permission;
31
 copyright (2010) American Chemical Society.  
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Figure 1.3. a) An artistic rendering of an array of microring resonators utilized for the 
biomolecular analysis of kinetic parameters of antibody and aptamer capture agents. b) Binding 
of a protein biomarker to an aptamer-functionalized microring resonator results in a shift in the 
resulting resonance wavelength. Adapted with permission;
23
 copyright (2011) Royal Society of 
Chemistry. c) Protein-lipid and protein-protein interactions were quantitatively interrogated in a 
label-free binding format by combining microring resonators arrays with phospholipid bilayer 
nanodiscs, a cell membrane mimic. d) The phospholipid composition can be tailored to control 
physisorption efficiency and modulate protein interactions. Adapted with permission;
44
 copyright 
(2013) American Chemical Society. e) Multiplexed kinetic titrations of DNA-encoded antibody 
libraries enabled the rapid screening of antibody capture agents to determine kinetic rate and 
equilibrium binding constants. Adapted with permission;
32
 copyright (2011) American Chemical 
Society.  
14 
 
 
Figure 1.4. a) A schematic illustrating the generation of highly multiplexed silicon photonic 
microring arrays generated via piezoelectric spotting. Here, protein-glycan conjugates were 
printed with high spatial fidelity for use in subsequent lectin binding assays. Adapted with 
permission;
42
 copyright (2011) Royal Society of Chemistry. b) An illustration of a cascaded 
microring architecture, in which the filter microring output, which is occluded from the solution 
above, is optically coupled to the sensor microring input, resulting in ‗packets‘ of spectral 
resonances c) that can be interrogated using low-cost, broadband optical sources. Adapted with 
permission;
45
 copyright (2011) Optical Society of America. d) & e) Microring resonators 
integrated within a digital microfluidic device wherein an array of actuation electrodes enables 
manipulation of individual droplets and improved spatial-temporal control of sample delivery. 
Adapted with permission;
50
 copyright (2012) Springer-Verlag.  
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2.1 Abstract 
In less than 20 years, our appreciation for microRNA molecules (miRNAs) has grown 
from an original, curious observation in worms to their current status as incredibly important 
global regulators of gene expression that play key roles in many transformative biological 
processes. As our understanding of these small, non-coding transcripts continues to evolve, new 
approaches for their analysis are emerging. In this critical review we describe recent 
improvements to classical methods of detection as well as innovative new technologies that are 
poised to help shape the future landscape of miRNA analysis. 
2.2 Introduction 
MicroRNAs (miRNAs) constitute a critically important class of non-translated, small 
RNAs which post-transcriptionally regulate gene expression via one of multiple mechanisms.
1
 
First reported in 1993 as a curious anomaly in Caenorhabditis elegans,
2
 thousands of miRNAs 
have now been identified and shown to play key roles in many transformative biological 
processes, including developmental timing,
3-5
 stem cell differentiation,
6-8
 and disease 
development.
9,10
 Although the complete functional role that miRNAs play still remains to be 
fully elucidated, their conservation throughout Archaea,
11
 bacteria,
12
 plants,
13
 and animals
14
 
indicate their importance as key regulatory control elements during both normal and 
transformative biological processes. In contrast to small interfering RNAs (siRNAs),
15
 miRNAs 
are endogenously encoded into the genome and are initially transcribed as long primary 
transcripts ( ≥1 kb; pri-miRNAs), which are then enzymatically processed in the nucleus by 
Drosha into ~70 nt stem loop structures (pre-miRNAs). Pre-miRNAs are exported into the 
cytoplasm and processed by the enzyme Dicer into the mature 19-24 nt duplexes.  
As opposed to siRNAs, which operate almost exclusively via mRNA cleavage at regions 
having perfect sequence complementarity, miRNAs can modulate gene expression via one of 
three distinct mechanisms and do not necessarily require perfect base pairing to act upon a 
target.
1
 In the cytoplasm, the single strands form the mature miRNA duplexes are incorporated 
into the RNA-induced silencing complex (RISC). Guided by the miRNA, the RISC complex can 
then act on mRNAs through one of three distinct mechanisms: 1) cleavage of the targeted 
mRNA, a mechanism commonly observed in plants that often requires perfect complementarity 
20 
 
between miRNA and mRNA, 2) translational repression, whereby miRNA/RISCs bind to 3′ 
untranslated regions of mRNAs preventing translation by the ribosome, and 3) the recently 
discovered enhancement of translation, in which a miRNA binds to the 5′-terminal 
oligopyrimidine tract (5′-TOP) and relaxes a cis-element in the 5′ UTR that inhibits translation.16 
There are over 15,000 mature miRNA sequences listed in the recently released miRBase 
15.0 database, with ~1000 identified as human miRNAs.
17
 Through one or more of the 
aforementioned mechanisms, each miRNA can potentially regulate the expression of multiple 
mRNAs, meaning that downstream production of many gene products, ultimately proteins, can 
be tremendously influenced by alterations in the expression of a single miRNA.
18
 In fact, it is 
known that a majority of human mRNAs are regulated by one (or more) miRNAs.
19
 
Furthermore, it has recently been experimentally demonstrated that multiple miRNAs, many of 
which are expressed as clusters that are encoded in close genomic proximity to one another, can 
target the same mRNA,
20
 adding further complexity to the mechanisms through which miRNAs 
regulate gene expression. 
Given the prominent role that miRNAs play in ―normal‖ gene expression and organismal 
function, it is not surprising that the aberrant expression of miRNAs can lead to a wide range of 
human diseases and disorders, including: cancer,
21,22
 neurodegenerative diseases,
23,24
 diabetes,
25
 
heart diseases,
26
 kidney diseases,
27,28
 liver diseases,
29
 and altered immune system function,
30,31
 
amongst others. In addition to contributing to the underlying cause of a particular disease, 
miRNAs can also represent potential therapeutic targets
32-34
  and diagnostic biomarkers.
35
 
Particularly exciting are the discovery of circulating miRNAs, which are promising biomarker 
candidates since they can be detected from readily attainable blood samples.
36-38
 Remarkably, a 
recent report indicates a panel of 12 miRNA were sufficient to differentiate between Alzheimer‘s 
patients and controls with 93% accuracy, 95% specificity, and 92% sensitivity.
39
 
The analysis of miRNAs is considerably more difficult than it is for much longer 
mRNAs, due almost entirely to their short size,. In particular, the small size of miRNAs greatly 
complicates the use of standard molecular biology methods based upon the polymerase chain 
reaction (PCR), as detailed below. Furthermore, the short size also makes hybridization-based 
assays difficult as the melting temperature and binding dynamics of complementary probes 
toward their target miRNAs vary significantly with the identity of the target miRNA. 
21 
 
Furthermore, experimental parameters, such as the buffer composition, the hybridization 
temperature, and incubation time all can contribute to significant assay-to-assay variation.
40-44
 
So, what are desirable attributes for existing and emerging miRNA analysis methods? 
Clearly the most appropriate technique for a given measurement challenge varies tremendously 
based upon the application and setting. For example, in an academic laboratory setting well-
established techniques that rely upon the tools of traditional molecular biology might find favor, 
whereas emerging micro- or nanotechnology-based methods might eventually be most well-
suited for point-of-care diagnostic applications. Two other important considerations when 
selecting an existing or designing a new method for miRNA analysis include dynamic range and 
multiplexing capability. The expression level of miRNAs, as determined via intracellular copy 
number, can vary from sequence to sequence by up to a factor of 10
5
 within a single sample. 
Furthermore, the recent discoveries of multiple miRNAs targeting a single mRNA and regulated 
expression amongst entire families of miRNAs provide motivation for global miRNA analyses, 
which will require methods wherein multiple miRNAs, and perhaps the entire ―miRNA-ome‖, is 
simultaneously detected in parallel in order to fully elucidate the important and complex function 
of these tiny regulators. 
On account of the critical biological role that miRNAs play in biological function and the 
diverse range of applications in which miRNA analysis is of value, significant effort has been 
invested over the past decade to develop new detection methods. In this critical review we 
highlight a selection of existing and emerging tools for miRNA analysis, with a particular 
emphasis on the current state-of-the-art and important developments in this fast moving field, as 
reported in the primary literature in the past four years. 
2.3 Computational approaches for miRNA target prediction 
While the major focus of the review article lies in existing and emerging miRNA 
detection methods, it is worthwhile to briefly mention computational methods for predicting 
miRNA targets.
45
 Given the number of potential mRNA targets and the ability of miRNAs to 
regulate mRNAs that are not perfectly complementary in sequence, the experimental 
identification and validation of miRNA regulatory sites is a vast challenge. For this reason, 
22 
 
extensive effort has been invested in developing computational methods for predicting the 
mRNA targets of miRNAs. 
One general class of computational methods for the prediction of miRNA targets utilizes 
perfect or imperfect complementarity via Watson-Crick base-pairing between the miRNA and 
possible target candidates.
46
  Most of these approaches focus on the complimentary at seed 
sequences, 5-8mers at the 5‘ end of an miRNA that are often highly conserved.47-49 PicTar, 
utilizes the sequence complementarity to target sites with emphasis on perfect base-pairing in the 
seed region,
48,50,51
  while TargetScan, one of more established computational tools, accounts for 
both complementarity as well as evolutionary conservation to provide a relatively likelihood that 
a given sequence is a miRNA target.
49,52
   
Another general framework for prediction of miRNA targets involves energetic 
calculations.  DIANA-microT, developed by Kiriakidou et al., is an algorithm that identifies 
miRNA targets based on the binding energies between two imperfectly paired RNAs 
53-55
 and 
RNAHybrid predicts miRNA targets by finding the most energetically favorable hybridization 
sites of a small RNA in a larger RNA sequence.
56,57
  The miRanda prediction algorithm includes 
contributions from the interaction binding energy, sequence complementarity between a set of 
mature miRNAs and a given mRNA, and also weights the conservation of the target site across 
various species.
58,59
  In contrast to other energetic calculations, STarMIR, models the secondary 
structure of an mRNA to determine the likelihood of miRNA binding.
60
  
The past few years has seen incredible growth in the area of computational prediction of 
miRNA targets. However, continued progress remains to be achieved as many of the 
aforementioned tools offer too many false positive target sites. Furthermore, many of the 
approaches have been developed using experimentally validated miRNA:mRNA systems, 
therefore introducing bias against miRNAs having any unusual or uncommon sequence.  
Nonetheless, the continued evolution of miRNA target prediction methodologies will, along with 
emerging detection methods, play a key role in fully elucidating the mechanisms by which 
miRNAs regulate normal and potentiate abnormal organismal function – providing a link 
between diagnostic insight and potential therapeutic opportunities.  
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2.4 Molecular biology-based analysis methods 
Early reports featuring miRNA measurements were fueled by what was already available 
in the laboratories of researchers at the forefront of the field—traditional molecular biology 
techniques such as cloning and enzymatic ligation assays. As timing would have it, miRNA 
research began to gather momentum directly on the heels of the genome technology explosion, 
and thus technologies such as RT-PCR and cDNA microarrays were rapidly adapted to 
accommodate the needs of the miRNA researcher. This section details the current state-of-the-art 
for miRNA detection. Based upon well-established methodologies, but with the recent 
incorporation of several very important innovations, these techniques represent the most 
commonly utilized methods for miRNA analysis in the research biology laboratory setting.  
2.4.1 Cloning 
Cloning was one of the first techniques utilized to detect and discover miRNAs.
61-63
 
Although slow and laborious, cloning is still at times used for miRNA detection. A more recent 
development that has been developed for the discovery of miRNAs is miRAGE – miRNA serial 
analysis of gene expression.
64
 Similar to cloning, small RNAs are extracted and amplified via the 
reverse-transcriptase polymerase chain reaction (RT-PCR) into complementary DNAs (cDNAs). 
In this application, biotinylated primers are utilized in the PCR step allowing the cDNA products 
to be purified via affinity chromatography with streptavidin-coated beads. The cDNAs are 
enzymatically cleaved from the beads and the eluted products can be cloned and sequenced. 
miRAGE is advantageous in that it can identify up to 35 tags in a single iteration, versus about 
five using conventional cloning.
64
  However, this technique is extremely labor intensive, requires 
hundreds of µg of total RNA, and only provides information as to the presence or absence of a 
particular miRNA from within a sample.
65
 While cloning still remains a powerful technique for 
the validation and discovery of novel miRNAs, the associated shortcomings of the technique 
make it impractical for high-throughput miRNA detection and expression profiling.
37
 
2.4.2 Northern Blotting 
Currently the standard method for the detection of miRNAs is Northern blotting.
66-68
 
Northern blotting offers a number of advantages for miRNA analysis including well established 
protocols and amenability to equipment readily available in most molecular biology laboratories. 
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Additionally, since Northern blotting involves a size-based separation step, it can be used to 
detect both mature and precursor forms of a miRNA, which is appealing for studies which focus 
on the mechanisms of miRNA processing.  
Common protocols for Northern blotting involve miRNA isolation, polyacrylamide gel 
electrophoresis, transfer of the separated sample to the blotting membrane, and visualization via 
hybridization with a radioactively labeled DNA strand complementary to the miRNA of interest. 
Despite its widespread use, traditional Northern blotting is, in general, plagued by a lack of 
sensitivity (up to 20 µg of total RNA required per blot) and a laborious and time consuming 
protocols (often taking several days for complete analysis), which limits its utility in a clinical 
setting.
69
 Furthermore, the technique often displays a limited dynamic range (2-3 orders of 
magnitude depending on the visualization method) and the reliance on a radioactive tag 
(typically 
32
P) can be disadvantageous in some settings.
70
 Northern blots do allow for multiple 
samples to be analyzed in a side-by-side format, but only one miRNA can be assayed for at a 
given time, a drawback which is of increasing importance as researchers strive towards global 
analyses for a systems level understanding of miRNA function. 
A number of improvements have been made to traditional Northern blotting protocols 
that help assuage several of the aforementioned problems. Of particular significance is the 
incorporation of locked nucleic acid (LNA) hybridization probes.
71-73
 LNAs are based upon 
DNA bases but feature the addition of a methylene bridge connecting the 2′-oxygen of the ribose 
to the 4′-carbon, effectively rigidifying the strand by inducing organization of the phosphate 
backbone.
74
 As a result, oligonucleotide strands that incorporate LNAs have been shown to bind 
complementary RNA strands with considerably higher affinity and target specificity compared to 
their DNA-only analogues. Furthermore, RNA:LNA duplexes are unique from RNA:DNA or 
RNA:RNA duplexes in that they have altered interactions with several nucleic acid recognizing 
proteins, including some enzymes. In order to avoid the necessity for a radioactive tag, 
Ramkissoon et al. demonstrated that digoxigenin (DIG), a steroid hapten, could be incorporated 
into complementary RNA strands used to visualize Northern blots for three different miRNAs.
75
 
Their incorporation of DIG and the accompanying chemiluminescent readout reduced the time-
to-result from days to hours, and increased the shelf-life of the probes, compared to radioactively 
labeled strands. 
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2.4.3 Reverse-Transcriptase Polymerase Chain Reaction 
Similarly to its use in conventional studies of RNA expression, RT-PCR can also be 
applied to the analysis of miRNAs. Reverse transcription is first utilized to convert the target 
RNA into its cDNA, which is then subsequently amplified and quantified via one of several 
conventional PCR methods. However, the simple translation of these methods to miRNAs is 
complicated by the short size of the target, as the length of the primers normally used in the PCR 
step are as long as mature miRNAs themselves. Shorter primers are typically not useful as their 
low duplex melting temperature with the miRNA can introduce signal bias. To avoid these 
challenges, researchers have developed an array of creative approaches based upon enzymatic 
modification of conventional primers or altogether new primers for mature miRNA.  
 One of the first applications of RT-PCR for the detection of miRNA was reported by 
Schmittgen et. al, who examined pre-miRNA expression.
76
 Because the study did not examine 
mature miRNAs, shortened primers were not necessary and the researchers were able to 
successfully detect amplicons using a fluorescent readout. However, the assumption that the 
amount of pre-miRNA is strictly representative of mature miRNA expression does not rigorously 
hold and thus the most straight-forward application of RT-PCR is of limited utility. 
As a method to analyze mature miRNAs without modifying the target strand itself, 
Raymond and coworkers utilized miRNA-specific reverse transcription primers that featured an 
overhanging 5′ tail so that the resulting cDNA was extended in length from that of the original 
target.
77
 Following reverse transcription (RT), a LNA-containing PCR primer was added which, 
together with a universal primer contained within the 5′ tail, enabled sensitive quantitation of 
miRNAs. 
There has also been significant effort in applying enzymatic methods to the elongation of 
the miRNA itself by ligation of oligo sequences. The addition of these flanking sequences allows 
for longer primer sequences to be utilized, increasing the efficiency of RT-PCR. Separate reports 
by Miska et. al. and Barad et. al. utilized the addition 3′ and 5′ adapter oligos to the target 
miRNAs via T4 ligase prior to reverse transcription.
78,79
 A limitation of many of the ligation 
based RT-PCR techniques, however, is that the sensitivity and specificity of the method is 
ultimately dependent on the efficiency of ligation. In particular, the kinetics of T4 ligase has 
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been shown to vary with substrate sequence, and the incorporation of the ligation step can 
potentially introduce a signal bias into the measurements.
80,81
 
An alternative method for RT-PCR analysis was developed by Shi and Chiang, who used 
poly(A) polymerase to add poly(A) tails to the 3′ end of target miRNAs in solution.82 The 
corresponding RT primers included poly(T) tails to increase the Tm of the heteroduplex and 
promote reverse transcription. This method was further adapted by Andreasen et al. at Exiqon to 
include two microRNA-specific, LNA primers during the PCR amplification, drastically 
increasing the specificity and sensitivity of the assay.
83
 An advantage of poly(A) polymerase is 
that the enzyme shows no sequence preference in its activity and thus it should be a useful tool 
for high throughput miRNA analysis applications. Similar technologies are available 
commercially from Agilent and Invitrogen. 
 A recently developed approach for RT-PCR-based miRNA expression profiling that 
eliminates the need for enzymatic extension is based upon the hybridization of stem-loop RT 
primers. The stem-loops are designed so that they are complementary to the 3′ end of the miRNA 
while at the same time having a 5′ end that is derived from the pre-miRNA sequence that 
composes the antisense half of a hairpin loop, as shown in Figure 2.1. These primers offer 
heightened specificity and sensitivity for miRNAs as compared to linear RT primers, largely on 
account of the increased base stacking and steric limitations imposed by the stem loop structure. 
By incorporating stem-loop primers into their assays, Chen and co-workers were able to 
quantitatively monitor the expression profile of mature miRNAs.
84
 This procedure was further 
adapted by Varkonyi-Gasic et. al., who incorporated an additional 5-7 nucleotide extension of 
the primer to further increase the melting temperature.
85
 Applied Biosystems offers a commercial 
miRNA analysis method based upon stem-loop primer RT-PCR with TaqMan quantitation. 
 Li and colleagues developed a clever alternative to this general stem-loop procedure by 
using T4 ligase to attach two DNA stem-loop probes to one another, using the target miRNA as a 
template, as shown in Figure 2.2.
86
 The two separate stem loop probes were designed to each 
contain one half of the miRNA complementary sequence masked within the hairpin structure of 
the stem-loop. Only in the presence of the target miRNA are the stem-loops extended and 
accessible to the ligase. The resulting long DNA strand can then be detected via standard PCR 
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techniques. A major advantage of this approach is that increased specificity is achieved 
compared to methods that only utilize the 3′ specificity of a primer. 
A significant limitation of the previously mentioned RT-PCR based methods is a 
restricted ability to simultaneously quantitate multiple miRNAs from a single sample. While 
multiple RT-PCR analyses can be run in parallel, the increased sample required for such assays 
is a motivation for the development of multiplexed miRNA analysis methods. However, there 
are two factors that generally complicate the application of RT-PCR for monitoring multiple 
miRNAs within a single volume: 1) multiple, sequence specific primers (or primer sets) will be 
necessary, placing an impetus on detection specificity, and 2) the presence of each strand must 
be uniquely encoded by a sequence-specific read-out mechanism, such as an independent 
fluorophore signal in a qPCR experiment. 
To tackle the first issue, Lao et al. proposed a pseudo-multiplexed RT-PCR method for 
the high-throughput detection of miRNAs in which carefully designed stem-loop primers 
allowed the simultaneous RT and PCR amplification of all of the target miRNAs.
87
 The 
sequence-specific cDNAs were then split into six aliquots and quantitation was performed in 
parallel using separate single-plex TaqMan PCR reactions for each target miRNAs. 
Unfortunately, the many PCR cycles needed between the separate amplification and quantitation 
steps compromises the quantitative utility of the approach. 
 In the previous example, multiplexed quantitative PCR (qPCR) cannot be performed 
because there are a limited number of spectrally unique probes that can encode for cDNAs 
derived from each of the target miRNAs. Furthermore, spectral overlap is in general a significant 
challenge in the translation of many single-plex biomolecular techniques/assays multiplexed 
formats. For these reasons, amongst others, there has been a significant effort invested in 
demonstrating spatial rather than spectral multiplexing schemes, and several of these approaches 
will be described in more detail below as they apply to miRNA analysis. 
2.4.4 Microarrays 
Helping to fuel the enormous growth of genomics, and to some extent proteomics, 
microarray analysis technologies are well-suited to massively multiplexed biomolecular 
detection on account of spatial, rather than spectral, multiplexing. Not surprisingly, microarrays 
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have been extensively applied to the high-throughput detection of miRNAs as they are capable of 
simultaneously screening hundreds of target sequences within a single sample volume. 
Moreover, with proper design of capture probes, microarrays can be used to identify both 
precursor and mature miRNAs.  In general, microarrays are not particularly well-suited for 
quantitative detection or copy number determination, but rather are very good tools to examine 
the relative expression of miRNAs between two different biological samples. 
 As with all miRNA analysis methods, specificity is of utmost importance for microarray 
methods as cross hybridization can lead to false positive signals. Similarly to Northern blotting, 
the incorporation of LNA capture probes significantly increases the specificity of a microarray 
towards target miRNAs.
88
 However, even more importantly, is the ability to normalize the 
melting temperature across all of the capture probe-target duplexes through selective integration 
of LNAs, an approach that has been led commercially by Exiqon in their miRCURY line of 
miRNA analysis products. This adjustment allows for uniform stringency rinses to be used with 
the microarray, and helps accounts for differences in binding kinetics normally observed for 
cDNA-only capture probes.  
 In addition to prudent design of capture probes, conventional microarray analysis 
methods require the target miRNAs be labeled, most commonly with a fluorescent tag. This 
labeling is often performed prior to hybridization and can be accomplished via a number of 
methods including the attachment of a pre-labeled oligo via T4 ligase,
89-92
 poly(A) extension 
from the 3′ end via poly(A) polymerase,93 and covalent modification with mono-reactive and 
fluorescently tagged cisplatin derivatives that can complex with guanine nucleotides.
94,95
 
Another popular method for labeling a miRNA-containing sample, prior to microarray 
analysis, involves the incorporation of fluorescent tags (often Cy3 and Cy5) during the process 
of RT-PCR.
65,78,79
 This approach, which borrows from conventional mRNA transcript profiling, 
provides a convenient method of labeling the total cDNA derived from the miRNA targets in a 
sample, but also increases the amount of available target via the PCR amplification. However, 
many of the same challenges faced by stand alone RT-PCR analysis such as sequence bias and 
run-to-run reproducibility are still encountered when analyzing on a microarray platform. 
Furthermore, additional complications can be encountered since the presence of a fluorescent tag 
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can significantly perturb duplex stability, an effect that is particularly significant when 
considering the short lengths of the strands analyzed in miRNA hybridization assays. 
As an alternative to labeling miRNAs prior to hybridization, there have been a number of 
recently developed techniques that focus on introducing labels to the target miRNA after it has 
been bound to the microarray surface. This approach may, in some cases, help to avoid label-
induced perturbations to the duplex hybridization. Liang et al. developed an interesting hybrid 
scheme by which the vicinal diol at the 3′ of a hybridized miRNA was converted to two aldehyde 
groups via oxidation with sodium periodate and subsequently conjugated to biotin in solution.
96
 
The biotinylated miRNAs were then hybridized to the microarray and detected with streptavidin 
coated quantum dots, giving a 0.4 fmol limit of detection. While this method does involve pre-
labeling of the miRNA, it is thought that biotin represents a very small and thus non-disruptive 
tag, compared with larger labels, such as the conventional Cy3 and Cy5 dyes. 
A notable purely post-hybridization strand modification scheme that actually allows read 
out without any covalent modification of the bound miRNA is the RNA-Assisted-Klenow-
Enzyme (RAKE) assay, developed by Nelson and co-workers and illustrated in Figure 2.3.
97
 In 
this methodology, DNA capture probes, which are linked to the surface via its 5′ end, are 
carefully designed to have a spacer sequence presenting three thymidine bases directly adjacent 
to the region complementary to specific miRNA targets. Following hybridization, the entire 
microarray is exposed to DNA exonuclease I, which enzymatically degrades the capture probes 
that are not duplexed with miRNA. The Klenow fragment of DNA polymerase I, an enzyme that 
can act as an RNA-primed DNA polymerase, is then added with biotinylated dATP, which is 
incorporated complementary to the three thymidines in the capture probe template. The amount 
of bound target miRNA can then be determined after incubation with fluorescently labeled 
streptavidin. Because both polymerase I and the Klenow enzyme fragment are sequence 
independent, the assay is not susceptible to any intrinsic signal bias and a detection limit of 10 pg 
was reported. However, one limitation of the technique is that the Klenow enzyme is specific 
only towards the 3′ end of the bound miRNA and thus certain isoforms may elicit unwanted 
cross-hybridization. Nevertheless, similar approaches have been successfully adapted by a 
number of other researchers.
98-100
 
2.5 Emerging methods of miRNA analysis 
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While the previously described techniques were based upon more conventional tools and 
methods in molecular biology, there is increasing interest in developing completely new 
analytical approaches to analyzing miRNA expression. Many of these emerging methods take 
advantage of micro or nanotechnologies and aim to address one or more of the shortcomings 
associated with the previously mentioned techniques including a minimization of sample size, 
increases in measurement sensitivity, precision, and dynamic range, and reduction in sequence 
dependent bias, cost, and time-to-result. Furthermore, a goal of many of these new technologies 
is to allow very high levels of multiplexing, ideally without sacrificing other key performance 
metrics, with cost and assay simplicity being a major driver for clinical diagnostic applications. 
Among the many miRNA analysis methods currently under investigation for miRNA biomarker 
based diagnostics, some of the most promising advances have involved new detection schemes 
based on electronic and optical signal transduction, and many already excel in key performance 
benchmarks. Given their current rapid rate of development, these techniques appear to be 
promising candidates to provide solutions for emerging miRNA analysis applications.  
2.5.1 Electrical Detection 
Electrical detection methods are based on changes in circuit properties that occur upon 
target miRNA hybridization. Signal amplification, often made possible through redox reporters 
and chemical ligation, can confer ultra-high sensitivity to these devices. However, sometimes 
this increase in sensitivity is accompanied by a loss of dynamic range. Here we discuss a 
selection of recently described methodologies, categorized broadly as either direct or indirect 
based according to their reliance on chemical modification of the target miRNA. Indirect 
methods usually involve a chemical ligation step which provides an amplified electrical signal 
following specific target miRNA-DNA hybridization. Though successful, these approaches are 
being challenged by label free technologies which offer equivalent or superior performance with 
a simpler assay, amongst other advantages.
101
 At first glance, direct methods appear to be the 
most attractive owing to a reduced number of error-introducing sample preparation steps and 
thus the potential for faster analysis times, providing that they are able to provide adequate 
sensitivities for the given bioanalytical challenge. 
A good example of a direct miRNA detection method is the use of nanoscale field effect 
transistors to monitor binding in a completely label free assay motif. Peptide nucleic acid (PNA) 
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functionalized silicon nanowires can be incubated with complementary miRNA targets and 
changes in the resistivity of the nanowires is monitored before and after the binding events. 
PNAs are DNA analogues in which the deoxyribose and phosphate backbone is replaced by a 
peptide bonding motif. The resulting oligomer is devoid of charge and displays increased 
specificity and sensitivity for hybridization assays, similarly to LNAs.
102,103
 Using an array of 
PNA-functionalized silicon nanowires, Zhang et. al. demonstrated a 1 fM detection limit and 
single base pair mismatch discrimination capability in the detection of let-7b.
104
 In this scheme, 
the negative charges brought to the surface upon miRNA hybridization (phosphate groups in the 
backbone) act as a gate and locally deplete charge carriers in the semiconducting nanowire, 
resulting in a decrease in conductivity. One of the most promising aspects of this technology is 
the ability to fabricate sensor arrays, as shown in Figure 2.4, via conventional semiconductor 
processing techniques, which might enable multiplexed miRNA detection. However, this 
technology still requires further refinement as field effect transistor based biosensor are 
notoriously prone to variations in sample ionic strength, and cost and fabrication challenges 
might complicate the use of PNAs and silicon nanowires, respectively, for high throughput 
miRNA detection applications. 
Fan and coworkers reported a method for detecting miRNA based upon changes in 
conductance accompanying hybridization to PNA-functionalized gaps between a CMOS-based 
array of microelectrodes.
105
 After hybridization, a solution containing aniline, horseradish 
peroxidase (HRP), and hydrogen peroxide were added, which led to polymerization of the 
aniline that had associated with the phosphate backbone of the miRNAs via electrostatic 
interactions. The amount of conductive polyaniline deposited was proportional to the amount of 
hybridized target and thus the conduction across the microelectrode gap, which drops 
significantly as the target concentration is increased, could be used for quantitation over a 
dynamic range of 20 pM to 10 fM, as shown in Figure 2.5.  
Another scheme utilizes a four-component hybridization for sensitive and specific 
miRNA detection.
106
 A capture probe is designed with a gap complementary to the miRNA 
target of interest. Only upon target binding can a reporter enzyme linked to a further DNA 
complement then hybridize to the end of the probe. This is due to the additional stabilization 
conferred by continuous base pair stacking. A hydrolysable substrate is then added and the 
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resulting current monitored. This method benefits from the amplification inherent to enzyme-
substrate turnover, as well as electrochemical recycling of the substrate product, p-aminophenol. 
This system was shown capable of a 2 attomole detection limit and diagnostic capabilities in 
total RNA extracts from human breast adenocarcinoma MCF-7 cells. Like other direct 
electrochemical approaches this method does not require chemical modification of the target 
miRNA. 
Ultrasensitive detection down to 10 aM concentration of miRNA was recently 
demonstrated by Yang et. al. who utilized a Fe-Ru redox pair as a reporter and amplification 
scheme on a novel nanostructured electrode platform, as shown in Figure 2.6.
107
 Ru
3+
 
accumulates and is reduced at the nanoelectrode surface after miRNA binding to complementary 
PNA capture probes and a ferricyanide solution phase redox couple chemically regenerates Ru
3+
 
from Ru
2+
 leading to incredible signal amplification—hundreds of electrons can be generated 
from a single binding event.
108
 In addition to high sensitivity, the sensor shows specificity for 
mature miRNA over pre-miRNA, and is capable of single base pair mismatch detection. Even 
more significant, the sensor was used to detect the upregulation of miR-21 and miR-205 in total 
RNA samples from three human head and neck cancer cell lines. The high surface area of the 
nanoelectrode is extremely important in this approach as it increases target binding and retention, 
which is essential to reaching the attomolar regime where there may be only hundreds or 
thousands of molecules in a sample. 
A direct approach to miRNA quantitation based on guanine oxidation was demonstrated 
by Lusi and co-workers based upon the oxidation of guanine bases in the hybridized target 
strands.
109
 While this technique does not require any additional reagents and utilizes less 
expensive DNA capture probes, as opposed to PNAs, it does require that all of the guanine bases 
in the capture probe be replaced with inosines. Furthermore, the amount of oxidation current 
observed is proportional to the number of guanines in the target sequence, complicating the 
application of this technique for highly multiplexed analyses.  
A common type of indirect electrical detection method for miRNAs involves the ligation 
of an electrocatalytic tag or other nanoparticle to the target, which upon hybridization provides a 
sequence specific signal.
110-113
 The strength of this amplified chemical ligation strategy is its 
generality, as an extensive number of catalytic or enzymatic moieties can be exploited for 
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improved sensor performance. Several examples of this approach have been reported by Gao and 
coworkers, who have used inorganic nanoparticle catalysts.
111-113
 In one such example, the 3′ 
ends of target miRNAs were first oxidized with sodium periodate and then hybridized to DNA 
capture probes on an electrode surface. Amine modified OsO2 nanoparticles were then attached 
to the 3′ aldehydes of the immobilized miRNA and the current measured from the catalytic 
degradation of hydrazine, which had been added to the solution. This approach allowed detection 
of miRNA over a 0.3 pM to 200 pM dynamic range. Notably, a five-fold difference in signal was 
observed between sequences that had only a single base pair mismatch. 
2.5.2 Optical Detection 
In addition to electrical signals, optical transduction methods have recently been 
successfully applied for miRNA detection. Several different classes of optical biosensors have 
been used to detect miRNAs and here we highlight several innovative examples of fluorescence, 
bioluminescence, spectroscopic, and refractive index based detection platforms. Optical 
fluorescence from labeled oligomers (miRNA or cDNA) is the basis for most of the microarray 
measurements mentioned earlier. However, novel approaches and materials have recently been 
developed that hold promise to significantly improve fluorescence based miRNA analysis 
methods. 
For example, Li et. al. demonstrated a very sensitive method for miRNA analysis using 
hairpin probes, T4 ligase, and the fluorescent detection of Cd
2+
 ions.
114
 Target miRNAs bind to 
carefully designed stem hairpin probes which are then subsequently hybridized with 
complementary CdSe nanoparticle-labeled DNA. T4 ligase is then added to stabilize the 
extended duplex structure before Ag
+
 is added in order to cation exchange the Cd
2+
 ions out of 
the nanocrystals and into solution. The authors state that thousands of Cd
2+
 ions can be liberated 
from each nanocrystal; a mechanism that provides signal amplification when using a fluorescent 
assay for Cd
2+
, allowing miRNA detection down to 35 fM. Sequence specificity is achieved by 
the use of T4 ligase in two ways: 1) the ligation has a much lower yield if the two strands are not 
bound with perfect complementarity, and 2) the resulting long duplex has a higher Tm, which 
allows aggressive stringency washes to be utilized. However, several potential limitations still 
exist, including the use of CdSe nanoparticles that present an unknown toxicity risk, significant 
cross reactivity of the Cd
2+
-sensitive fluorescent dye with Ca
2+
, meaning that the sample must be 
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rigorously purified prior to analysis, and assay complexity, since multiple reagents and 
incubation steps are required. 
Neely et. al. employed a single molecule fluorescence detection method and dual tagged 
miRNA-DNA duplexes to detect down to 500 fM miRNA.
115
 Importantly, this work established 
the robust nature of this technique as the authors impressively demonstrated the expression 
profiling of 45 different miRNA targets in 16 different human tissues, including detection of the 
key cancer biomarkers mir-16, mir-22, mir-145, and mir-191 from as little as 50 ng of total 
RNA. 
Cissell and coworkers developed a hybridization assay for miRNA detection based on the 
displacement of the bioluminescent enzyme, Renilla luciferase (Rluc).
116
 The Rluc enzyme was 
conjugated to a synthetic oligonucleotide with a miR-21 sequence was hybridized to an 
appropriate capture probe and used in a competitive assay. miR-21 in the sample displaced the 
Rluc-conjugated strand resulting in a decrease in fluorescence that was used to achieve a 
detection limit of 40 pM with a greater than 3-order of magnitude dynamic range. An assay time 
of just 90 minutes and potential for integration into a 96 or 384 well plate format makes this an 
attractive technology for high throughput miRNA analyses.  
Surface enhanced Raman spectroscopy (SERS) has been extensively used in the detection 
of biomolecules,
117-119
 but has not generally not achieved widespread use due to poor substrate 
reproducibility. Using the method of oblique angle vapor deposition to generate sufficiently 
reproducible substrates, Driskell et. al. were able to detect and differentiate between miRNAs of 
unrelated sequence based upon the different spectral fingerprints with an incredibly short 
acquisition time of only 10 seconds!
120
 However, due to the subtle differences in peak intensity 
as a function of distinct, but related, sequence composition, identification of specific sequences 
requires extensive multivariate analysis. Furthermore, the chemical specificity of SERS may 
complicate detection in complex samples due to high background signals. Nevertheless, this 
methodology is intriguing for applications in multiplexed miRNA detection. 
Surface plasmon resonance imaging (SPRI) has been shown to be an incredibly versatile 
and effective platform for biomolecule sensing.
121-124
 The technique is based on coupling light to 
the interface of a thin metallic film (typically gold) to excite surface plasmons, which are highly 
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sensitive to changes in the refractive index of the local environment. Properly functionalized 
with an appropriate capture agent, desired biomolecules can be selectively detected by 
monitoring changes in reflectivity. While standard SPRI methods would be highly amenable to 
direct miRNA analysis, an impressive amplification technique incorporating enzymatic strand 
extension and nanoparticle labeling was developed by Fang and coworkers to achieve an 
incredible 5 attomole detection limit, as illustrated in Figure 2.7.
125
 LNA capture probes 
immobilized on a gold SPRi substrate were designed so that they were complementary to a 
targeted miRNA, but left a 6 nucleotide extension of the miRNA beyond the LNA after 
hybridization. This 3′ overhang can be recognized by poly(A) polymerase, which then 
enzymatically grows a poly(A) tail at locations where miRNA is localized. Further amplification 
is achieved by subsequent hybridization of poly(T30) coated Au nanoparticles, which bind to the 
appended poly(A) tails. The presence of the nanoparticle labels greatly enhances the change in 
the SPRI reflectivity image, facilitating extremely low limits of detection and a dynamic range 
from 10-500 fM. Importantly, the dynamic range can be extended to higher concentrations by 
eliminating the nanoparticle amplification step, if required for the application. Given these 
developments, and the existing widespread use of this technology for biomolecular 
measurements, SPRI seems to be a very promising technique for miRNA expression profiling 
based on its sensitivity, scalability, dynamic range, and potential for quantitative detection.  
Recently, our group has developed a label free and modularly multiplexable biomolecular 
detection technology based upon arrays of silicon photonic microring resonators, depicted in 
Figure 2.8.
126-128
 These optical structures, which are fabricated via conventional semiconductor 
processing methods, are incredibly sensitive to binding induced changes in refractive index 
accompanying the binding of a target analyte to the microring surface, observed as a shift in the 
resonance wavelength supported by the microcavity. As a demonstration of the applicability of 
this platform to multiplexed miRNA detection, we recently covalently immobilized DNA capture 
probes onto the surface of an array of microrings and used it to detect four different disease-
relevant miRNAs from a cell line model of brain cancer via a direct hybridization assay.
129
 Using 
this approach we demonstrated a detection limit of 150 fmol after only a 10 minute detection 
period and a linear dynamic range of over 2 orders of magnitude. We also reported an isothermal 
method for the discrimination of single base polymorphisms by including stringency-inducing 
chemical agents directly into the hybridization buffer. 
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We are currently developing mechanisms for further extending detection limits for the 
microring resonator technology, and it is worthwhile to point out that many of the enzymatic 
strand extension or ligation techniques described earlier (poly(A) polymerase, T4 ligase, RAKE, 
etc.) could be integrated onto the platform in a straightforward fashion. While this technology is 
still relatively immature in comparison to well-developed methodologies such as RT-PCR and 
SPRi, the prospects for extremely high level multiplexing and the intrinsic manufacturability of 
the platform make this an promising technique for many emerging miRNA analysis applications, 
particularly those related to clinical diagnostics where metrics such as sample size, time to result, 
and assay cost are of considerable importance. 
2.6 Conclusions and Outlook 
 Over the past 17 years, our understanding of miRNAs has exploded. As the incredible 
importance of these small, non-coding transcripts has become increasingly elucidated, the 
number of tools for their analysis has grown. Still in place today are the original miRNA 
measurement approaches, many of which are based upon the proven tools of molecular biology. 
More recent adaptations of enabling enzymatic processes have greatly improved many aspects of 
these classical techniques and allowed higher throughput measurements to be made using RT-
PCR or microarray techniques. The introduction of alternative capture probes, incorporating 
DNA analogues such as LNA and PNA, has been transformative for many of these methods as it 
in increases the melting temperature for short duplexes. 
In the past five years, physical scientists and engineers have become increasingly 
interested in miRNAs and have intensified efforts to apply emerging detection tools to this 
important bioanalytical challenge. Some of these approaches incorporate novel materials and 
reagents, such as metallic nanoparticles, semiconductor quantum dots, and bioluminescent 
proteins while others utilize the interesting electrical or optical properties of micro- and 
nanostructures. These emerging approaches all strive to offer one or more advantages over 
traditional methods, such as of high sensitivity, assay simplicity and reproducibility, 
multiplexing capability, and device manufacturability.  
In the next decade the appetite for enabling miRNA analysis technologies will certainly 
continue to grow. Recent biological discoveries of correlated expression and action on gene 
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translation have placed impetus on performing global or systems level analyses of miRNAs to 
uncover the full detail of their regulatory function, and therefore methods that offer high levels of 
multiplexing will be of great value to these efforts. Furthermore, recent reports describing the 
value of miRNAs as diagnostic biomarkers for a range of human diseases make the development 
of point-of-care analysis methods incredibly important. In these applications, metrics such as 
time-to-result, sample consumption, and assay cost will be key drivers for technology 
development. As has historically been the demonstrated, transformative biological discoveries 
are often tied to the development of new technological capabilities. The small size of miRNAs 
(and other small RNA molecules) challenges conventional biomolecular analysis methodologies 
and new innovations in miRNA detection will likely play a unique role in enabling future 
biological breakthroughs. 
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2.7 Figures 
 
Figure 2.1. Schematic description of a RT-PCR assay for a target miRNA. Stem-loop primers 
are first hybridized to the miRNA followed by reverse transcription. The resulting transcript is 
then quantitated using conventional real-time PCR via a TaqMan probe.
84
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Figure 2.2. Schematic diagram of the enzymatic ligation-based real-time PCR assay for 
measurement of mature miRNAs. In the presence of the target miRNA, two stem-loop probes, 
each of which is partially complementary to the target, are brought into close proximity via 
hybridization with the miRNA. T4 ligase is then used to attach the probes together, forming an 
extended primer than is amenable to real-time PCR-based quantitation.
86
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Figure 2.3.  Schematic of the RNA-primed, array-based Klenow enzyme (RAKE) assay. 
Hybridized miRNA bound to specially designed capture probes both shields the capture probe 
from enzymatic degradation, but also serves as a primer for strand extension, during which a 
biotinylated nucleotide is introduced. Following extension, the microarray is stained with 
fluorescent streptavidin and imaged to determine the relative amount of miRNA present in the 
original sample.
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Figure 2.4. a) Optical and scanning electron micrograph (inset) showing an array of ten silicon 
nanowire field effect transistors.
103
 b) Schematic showing the interaction between a charged 
nucleic acid and a nanowire field effect transistor. When functionalized with peptide nucleic 
acids (PNAs) the nanowires can be used to sensitively detect miRNAs as the charge 
accompanying miRNA hybridization modulates the current flowing through the nanowire due to 
a gating effect.
130
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Figure 2.5. Fan and co-workers developed a miRNA detection scheme based upon 
polymerization of a conductive polymer across a microscale electrode gap. Aniline selectively 
interacts with the negatively charged backbone of the miRNA hybridized to PNA capture probes, 
which have uncharged backbones. The addition of oxidative reagents then leads to the formation 
of conductive polyaniline and the resistance drop across the electrode gap is proportional to the 
amount of hybridized miRNA.
105
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Figure 2.6. Schematic diagram illustrating the fabrication and operation of arrays of novel 
nanostructured electrodes useful for ultrasensitive miRNA detection. The high surface area of the 
electrode structure allows sensitive detection of miRNAs via a novel redox reporter system that 
provides tremendous gain for each target binding event.
107
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Figure 2.7. Surface plasmon resonance imaging is a promising technique for the detection of 
miRNAs in an array format. High sensitivity was achieved by Fang and coworkers, who used 
poly(A) polymerase and poly(T)-coated gold nanoparticles to greatly amplify the SPR response 
for miRNA binding events.
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Figure 2.8. Arrays of silicon photonic microring resonators can be used to quantitate miRNAs. 
a) Schematic illustration of the hybridization of miRNA onto a modified microring, which leads 
to a shift in the resonance wavelength supported by the integrated microcavity. b) Scanning 
electron micrograph showing an array of microring resonators. A zoomed in view of a single 
sensing element is shown in the inset.
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Chapter 3 
Anti-DNA:RNA Antibodies and Silicon Photonic 
Microring Resonators: Increased Sensitivity for 
Multiplexed microRNA Detection 
 
Notes and Acknowledgements  
This chapter has been adapted from the article ―Anti-DNA:RNA Antibodies and Silicon 
Photonic Microring Resonators: Increased Sensitivity for Multiplexed microRNA Detection‖ 
(Qavi, A.J.; Kindt, J.T.; Gleeson, M.A.; Bailey, R.C. Analytical Chemistry 2011,  83,  5949-
5956). It has been reproduced here with permission from the American Chemical Society. © 
2011. 
A.J.Q and J.T.K contributed equally to this work. The work in this chapter was funded by the 
National Institutes of Health (NIH) Director‘s New Innovator Award Program, part of the NIH 
Roadmap for Medical Research, through grant 1-DP2-OD002190-01; the Center for Advanced 
Study at the University of Illinois at Urbana—Champaign; and the Camille and Henry Dreyfus 
Foundation. J.T.K. was supported by a National Science Foundation Graduate Research 
Fellowship under Grant No. DGE 07-15088-FLW. A.J.Q. was supported by a fellowship from 
the Eastman Chemical Company. I also thank the Immunological Resource Center, part of the 
Roy J. Carver Biotechnology Center at the University of Illinois at Urbana—Champaign, for 
assistance in expressing and purifying the anti-DNA:RNA antibody. I acknowledge the 
contributions of M.A.G. for helpful ideas and suggestions in planning this project. 
This article can be accessed online at http://pubs.acs.org/doi/abs/10.1021/ac201340s. 
  
54 
 
3.1 Abstract 
In this paper, we present a method for the ultrasensitive detection of microRNAs 
(miRNAs) utilizing an antibody that specifically recognizes DNA:RNA heteroduplexes, using a 
silicon photonic microring resonator array transduction platform. Microring resonator arrays are 
covalently functionalized with DNA capture probes that are complementary to solution phase 
miRNA targets. Following hybridization on the sensor, the anti-DNA:RNA antibody is 
introduced and binds selectively to the heteroduplexes, giving a larger signal than the original 
miRNA hybridization due to the increased mass of the antibody, as compared to the 22 
oligoribonucleotide. Furthermore, the secondary recognition step is performed in neat buffer 
solution and at relatively higher antibody concentrations, facilitating the detection of miRNAs of 
interest.  The intrinsic sensitivity of the microring resonator platform coupled with the 
amplification provided by the anti-DNA:RNA antibodies allows for the detection of microRNAs 
at concentrations as low as 10 pM (350 attomoles). The simplicity and sequence generality of 
this amplification method position it as a promising tool for high-throughput, multiplexed 
miRNA analysis, as well as a range of other RNA based detection applications. 
3.2 Introduction 
MicroRNAs (miRNAs) comprise a class of small, noncoding RNAs that are incredibly 
important regulators of gene translation.
1,2
 Although the exact mechanisms of miRNA action are 
still being elucidated, they are known to play an important regulatory role in a number of 
biological functions, including cell differentiation and proliferation,
3-7
 developmental timing,
8-11
 
neural development,
12
 and apoptosis.
13
 Given their importance in such transformative processes, 
it is not surprising that aberrant miRNA levels are found to accompany many diseases, such as 
diabetes,
14
 cancer,
15-17
 and neurodegenerative disorders,
18,19
 and thus these small RNAs have 
been proposed as informative targets for both diagnostic and therapeutic applications.
20
 
Despite their critical role in cellular processes and promise as biomarkers, the short 
sequence lengths, low abundance, and high sequence similarity of miRNAs all conspire to 
complicate detection using conventional RNA analysis techniques, such as Northern blotting, 
reverse transcriptase polymerase chain reaction (RT-PCR), and cDNA microarrays.
21
 Numerous 
approaches have been employed to adapt these methods to the specific challenges of miRNA 
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analysis, and while offering increased measurement performance, many suffer from significant 
complexity. 
22-29
 The analysis of miRNAs is further frustrated by the complex nature by which 
miRNAs affect translation, wherein multiple miRNA sequences can be required to regulate a 
single mRNA and/or a particular miRNA may regulate multiple mRNAs.
30,31
 Given this 
complexity, robust, multiplexed methods of miRNA analysis that feature high target specificity, 
sensitivity and dynamic range will be essential to fully unraveling the biological mechanisms of 
miRNA function, and may also find utility in the development of robust in vitro diagnostic 
platforms. 
Microring optical resonators are an emerging class of sensitive, chip-integrated 
biosensors that have recently been demonstrated for the detection of a wide range of 
biomolecular targets.
32-37
  These optical microcavities support resonant wavelengths that are 
highly sensitive to biomolecule binding-induced changes in the local refractive index. In 
particular, the combined high Q-factor and small footprint of microring resonators make them an 
attractive choice for both sensitive and multiplexed biosensing. Most relevant to this report, we 
recently demonstrated the direct, label-free detection of miRNAs with a limit of detection of 150 
fmol.
33
 While this is sufficient for many miRNA applications, we were interested in developing 
methods to further extend the sensitivity without adding undue complexity or introducing 
sequence-specific bias to the assay, which would compromise the generality and multiplexing 
capabilities of the platform. 
Monoclonal and polyclonal antibodies recognizing RNA:RNA and DNA:RNA duplexes 
have been previously developed and utilized in hybridization based assays for the detection of 
nucleic acid targets including viral nucleic acids and E.coli small RNA.
38-43
 Of particular 
relevance here is an anti-DNA:RNA antibody, named S9.6, which specifically recognizes 
RNA:DNA heteroduplexes and has been utilized to detect RNA in a conventional fluorescence-
based microarray format.
44-47
 
In this paper, we combine the utility of the S9.6 anti-DNA:RNA antibody with the 
appealing detection capabilities of silicon photonic microring resonators to demonstrate the 
sensitive detection of mammalian miRNAs. Importantly, the S9.6 binding response is 
significantly larger than that observed for the miRNA itself, allowing the limit of detection to be 
lowered by ~3 orders of magnitude to 350 attomoles. We apply this approach to the multiplexed 
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quantitation of four miRNA targets both from standard solutions as well as the total RNA extract 
from mouse brain tissue. These results indicate that this strategy is appealing for the multiplexed 
detection of miRNAs in a simple and reasonably rapid assay format that does not require RT-
PCR amplification schemes. 
Importantly, during the preparation of this manuscript, Šípová and co-workers reported a 
similar S9.6 miRNA detection assay on a grating-coupled surface plasmon resonance platform.
48
 
Focusing on the detection of single miRNA, the authors report a similar limit of detection, 
further highlighting the broad utility of the S9.6 antibody in PCR-less assay formats.  
3.3 Experimental Methods 
3.3.1 Materials 
The silane, 3-N-((6-(N'-Isopropylidene-hydrazino))nicotinamide)propyltriethyoxysilane 
(HyNic Silane), and succinimdyl 4-formyl benzoate (S-4FB) were purchased from SoluLink. 
PBS was reconstituted with deionized water from Dulbecco‘s Phosphate Buffered Saline packets 
purchased from Sigma-Aldrich (St. Louis, MO), and the buffer pH adjusted to pH 7.4 (PBS-7.4) 
or pH 6.0 (PBS-6) with sodium hydroxide or hydrochloric acid. A 20X saline-sodium phosphate-
EDTA buffer (SSPE) was purchased from USB Corp. for use in a high stringency hybridization 
buffer. All other reagents were purchased from Fisher, unless otherwise noted, and used as 
received. 
3.3.2 Fabrication of Silicon Photonic Microring Resonators and Measurement 
Instrumentation 
The fabrication of sensor chips and operational principles of the measurement 
instrumentation have been previously reported.
34,49
 Briefly, sensor substrates, each containing 32 
uniquely-addressable microring resonators within a 6x6 mm footprint, were fabricated at a 
commercial-scale silicon foundry on 8‖ silicon-on-insulator wafers using conventional deep-UV 
photolithography and dry etching methods, before being diced into individual chips. After 
immobilization of DNA capture probes (described below), the sensor chips are loaded into a 
biosensor scanner (Genalyte, Inc.), and the wavelengths of optical resonance of the entire array 
57 
 
of microring elements are monitored in near real-time using an external cavity laser, integrated 
control hardware, and data acquisition software. 
3.3.3 Nucleic Acid Sequences 
All synthetic nucleic acids were obtained from Integrated DNA Technologies. DNA 
capture probes were HPLC purified prior to use, while synthetic RNA probes were RNase Free 
HPLC purified. The sequences of all nucleic acid strands used in this work are listed in Table 
3.1. 
3.3.4 Modification of ssDNA Capture Probes 
DNA capture probes, synthesized with amines presented on the 5' end of the sequence, 
were resuspended in PBS-7.4 and then buffer exchanged three times with a new PBS-7.4 
solution utilizing Vivaspin 500 Spin columns (MWCO 5000, Sartorius) to remove residual 
ammonium acetate from the solid phase synthesis. A solution of succinimidyl-4-formyl benzoate 
(S-4FB, Solulink) in N,N-dimethylformamide was added in 4-fold molar excess to the DNA 
capture probe, and allowed to react overnight at room temperature. The 4FB-DNA solution was 
subsequently buffer exchanged three additional times into PBS-6 to remove any unreacted S-
4FB. 
3.3.5 Chemical and Biochemical Modification of Silicon Photonic Microring Resonator 
Surfaces 
Prior to functionalization, sensor chips were cleaned in a freshly-prepared Piranha 
solution (3:1 solution of 16 M H2SO4:30% wt H2O2) for 1 min, and subsequently rinsed with 
copious amounts of water. (Warning: Piranha solutions can react explosively with trace 
organics—use with caution!) Sensor chips were then sonicated for 7 min in isopropanol, dried 
with a stream of N2, and stored until further use. 
To attach DNA capture probes, sensor chips were immersed in a 1 mg/mL solution of 
HyNic Silane in ethanol for 30 min, rinsed and sonicated for 7 min in absolute ethanol, and dried 
with a stream of N2. Small aliquots (1 L) of 4FB-modified-DNA were then carefully deposited 
onto the chips so as to cover only specific sets of microrings, and the solution droplets incubated 
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overnight in a humidity chamber. Prior to hybridization experiments, the substrates were 
sonicated in 8 M urea for 7 min to remove any non-covalently immobilized capture probe. 
3.3.6 Addition of Target miRNA to Sensor Surface 
Target miRNA solutions were suspended in a high stringency hybridization buffer, 
consisting of 30% formamide, 4X SSPE, 2.5X Denhardt‘s solution (USB Corporation), 30 mM 
ethylenediaminetetraacetic acid, and 0.2% sodium dodecyl sulfate. Aliquots (35 µL) of target 
miRNA solutions were recirculated across the sensor surface at a rate of 24 µL/min for 1 hr 
utilizing a P625/10K.133 miniature peristaltic pump (Instech). Solutions were directed across to 
the surface via a 0.007‖ Mylar microfluidic gasket sandwiched between a Teflon cartridge and 
the sensor chip. Gaskets were laser etched by RMS Laser in various configurations to allow for 
multiple flow patterns. 
3.3.7 Surface Blocking and Addition of S9.6 
Following hybridization of the target miRNA to the sensor array, the surface was blocked 
with Starting Block™ (PBS) Blocking Buffer (Thermo Scientific) for 30 min at 10 µL/min, as 
controlled with a 11 Plus syringe pump (Harvard Apparatus) operated in withdraw mode, 
followed by rinsing with PBS-7.4 with 0.05% Tween for 7 min at 30 µL/min. Following surface 
blocking, a 2 µg/mL solution of S9.6 in PBS-7.4 with 0.05% Tween was flowed across the 
sensor surface for 40 min at a rate of 30 µL/min. 
3.3.8 Generation and Purification of the S9.6 Antibody 
The S9.6 antibody was harvested from the medium of cultured HB-8730 cells, a mouse 
hybridoma cell line obtained from the American Type Culture Collection (ATCC). Cells were 
cultured according to manufacturer instructions and the S9.6 antibody was purified using protein 
G by the Immunological Resource Center in the Carver Biotechnology Center at the University 
of Illinois at Urbana-Champaign. The purified antibody was aliquoted at 0.94 mg/mL in PBS-
7.4, and stored at -20
o
C until use. 
3.3.9 Data Analysis 
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To utilize the S9.6 response for quantitative purposes, we used the net sensor response 
after 40 min of exposure to a 2 µg/mL solution of S9.6. Control rings functionalized with a non-
complementary DNA capture probe were employed to monitor non-specific hybridization-
adsorption of the target miRNA as well as the non-specific binding of the S9.6 antibody. The 
signal from temperature reference rings (rings buried underneath a polymer cladding layer on the 
chip) was subtracted from all sensor signals to account for thermal drift. 
Calibration data over a concentration range from 10 pM to 40 nM, with the exception of 
miRNA miR-16 (in which the 40 pM and 10 pM points were not obtained), was fit to the logistic 
function: 
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where A1 is the initial value limit, A2 is the final value limit, and c and p describe the center and 
power of the fit, respectively.  
3.3.10 miRNA Expression Levels in Mouse Tissue 
50 µg of total mouse brain RNA (Clontech) was diluted 1:5 with hybridization buffer and 
recirculated overnight prior to amplification with S9.6. The net sensor response after 40 min 
exposure to 2 µg/mL S9.6 was calibrated to each miRNA to account for variable Tm
 
values and 
any secondary structure that would influence the hybridization kinetics.  
3.4 Results and Discussion 
A schematic of the S9.6 assay is shown in Figure 3.1a. The microrings are initially 
functionalized with ssDNA capture probes complementary to the target miRNAs of interest. A 
solution containing the miRNA is flowed across the sensor surface, after which the surface is 
blocked to prevent non-specific protein adsorption, and subsequently exposed to the S9.6 
antibody. Representative real-time shifts in the resonance wavelength for three DNA-modified 
microrings first to the hybridization of a complementary miRNA and then the S9.6 anti-
DNA:RNA antibody are shown in Figure 3.1b. Notably, we do not observe any significant 
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response when S9.6 is flowed across a surface containing only single-stranded DNA capture 
probes or double stranded DNA duplexes, confirming the specificity of this amplification 
strategy (Figure 3.2). 
Apparent from the data shown in Figure 3.1b is an unusual kinetic binding response for 
the S9.6 antibody binding to the DNA:RNA heteroduplex-presenting surface. Rather than 
display classical Langmuir-type behavior in which the rate of binding is fastest initially, the 
measured response appears sigmoidal, with the rate of binding actually increasing for the first 
10-15 minutes, after which the curves begins to level off. Suspecting either a steric or 
cooperative binding mechanism, we varied the concentration of DNA capture probe immobilized 
onto sensors, incubated complementary miRNA at saturating concentrations, and then performed 
S9.6 enhancement. Since the amount of underlying DNA was varied, the sensors supported 
different saturation levels of miRNA hybridization, but saturation was always reached by 
flowing a very high (40 nM) solution of the target across the surface prior to blocking and 
introducing S9.6. Interestingly, the shape of the S9.6 binding response varied as a function of the 
underlying DNA capture probe loading, as shown in Figure 3.3, transitioning from sigmoidal at 
high relative DNA loadings to the expected logarithmic response at lower concentrations. We 
preliminarily attribute this behavior to some sort of cooperative binding effect, wherein initial 
S9.6 binding is sterically restricted by the high density of capture probes but subsequent binding 
events become increasingly favorable. As described in greater detail below, we have evidence 
that multiple anti-DNA:RNA antibodies can bind to a single heteroduplex and therefore one can 
imagine that the footprint established by the first bound S9.6 allows greater access for 
subsequent interactions at the same DNA:miRNA duplex. Although we do not yet fully 
understand the mechanism of this binding interaction, we do observe that the highest capture 
probe densities result in the largest observed S9.6 responses over all target miRNA 
concentrations measured at a fixed 40 minute time point. Therefore, for the purposes of sensitive 
detection, rather than kinetic analysis, we chose to functionalize our sensors with the highest 
achievable levels of capture probes.  
After the initial verification of S9.6 binding and amplification potential, we sought to 
better understand the applicability and limitations of the antibody. In particular, one interesting 
aspect of the antibody was the large signal amplification we observed upon S9.6 binding to our 
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sensor surfaces, especially under non-saturating conditions. As shown in Figure 3.1b, the net 
sensor shift for the hybridization-adsorption of a 100 nM solution of miR-24-1 (a concentration 
that will saturate binding sites) onto the sensor surface is ~80 pm. The S9.6 response for 
amplification is ~520 pm, limited by steric crowding of the antibody. However this secondary 
amplification becomes even more dramatic at lower miRNA conditions, increasing the response 
over 60-fold (Figure 3.4). Since the miRNA and antibody differ in mass by a factor of 
approximately 21, this suggests that ~3 S9.6 antibodies can bind to a single DNA:miRNA 
duplex.  
To confirm our hypothesis that a single DNA:RNA heteroduplex could be bound by 
multiple S9.6 antibodies, we functionalized a sensor surface with a ssDNA capture probe that 
was complementary to 10- and 20-mer RNA test sequences. As seen in Figure 3.5, the primary 
hybridization response for the 20-mer RNA sequence is almost exactly twice as large as for the 
10-mer. The observed S9.6 binding response is again larger for the 20-mer target, but the 
response is ~2.5 times that of the 10-mer, suggesting that two and sometimes three S9.6 
antibodies can bind to the 20-mer target. Experiments performed with a 40-mer test RNA 
sequence confirm that multiple S9.6 antibodies can bind to single heteroduplexes, and also reveal 
that longer strand responses are accompanied by more complex steric binding considerations. 
These results, while preliminary, suggest that the S9.6 binding epitope is on the order of 6 base 
pairs in size, which is considerably smaller than the 15 nucleotide epitope previously proposed.
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Importantly, the small size of the epitope allows multiple S9.6 antibodies to bind to single 
DNA:miRNA heteroduplexes, which in turn allows for greater signal amplification.  
Another practical consideration of assay development is the ability to regenerate the 
surface by selective removal of the antigen and secondary labels, thereby enabling serial 
interrogation of multiple samples or antigen-containing solutions. This would improve the 
throughput for a given chip as well as reduce error by eliminating chip-to-chip variability. We 
assessed numerous enzymatic and chemical regeneration methods, each with differing 
regeneration mechanisms. Figure 3.6 summarizes the 5 different regeneration methods tested: 
urea, high pH rinses, sodium dodecyl sulfate (SDS) surfactant, and proteinase K (RNase H was 
also tried but showed no regenerative capabilities). A commonly used regeneration chemical is 
urea, a chaotropic agent which destabilizes biomolecular interactions by competing with 
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hydrogen bonds. As seen is Figure 3.6a, its introduction effectively cleanses the surface of all 
S9.6 and most miRNA, evidenced  by the sensor response‘ return to baseline. However, 
subsequent incubation with S9.6 yields a substantial signal, indicating the miRNA hybridized to 
the surface was not completely removed. High pH rinses should also effectively degrade the 
miRNA-S9.6 complex and should function as an efficient surface regeneration tool, however, as 
seen in Figure 3.6b, even a bare chip experiences adverse surface degradation as the high pH 
rinse attacks the silicon oxide surface and fluoropolymer cladding layer, precluding its use in this 
application. Finally, we combined chemical and enzymatic agents by serially introducing SDS 
and proteinase K. Figure 3.6c-d catalog the combined use of SDS and proteinase K, which prove 
to be very effective in their removal of S9.6, however leave the miRNA entirely untouched. 
Without any method for complete removal of both the miRNA and S9.6, all experiments were 
conducted on freshly prepared chips without surface regeneration. However we anticipate that 
the ability to completely remove the S9.6 amplification step with SDS and proteinase K will be a 
useful tool for future assay development.  
Two other important parameters were explored in the process of optimizing the assay: 
miRNA hybridization buffer and capture probe annealing. Buffer composition has a profound 
effect on hybridization efficiency and target specificity, whereby factors such as salt 
concentration, blocking agents, surfactants, and multivalent ions all contribute to modulate 
hybridization efficiency. In Figure 3.7a  we compared the S9.6 response after hybridizing the 
primary miRNA step in 3 different hybridization buffers: ―Hybridization‖, ―Soy‖, and PBS 
buffer. Each buffer is optimized for different nucleic acid applications; our side-by-side 
comparison elucidated the best buffer for our assay to be hybridization buffer. The high salt 
content (0.6 M NaCl) and high stringency (30% formamide) are ideal for high hybridization 
efficiency while simultaneously minimizing any off-target response, respectively. We also 
explored capture probe annealing, a process which removes any physisorbed capture agent as 
well as eliminates any capture probe secondary structure. Each functionalized chip was 
immersed in a 95° C water bath for 3 minutes prior to the assay, and its performance compared 
to our standard assay.  As shown in Figure 3.7b, annealing the chip significant improves the 
miRNA hybridization kinetics, however, the end-point response is lower than that with an 
unannealed surface. Furthermore, it increases the non-specific off-target response. While this 
modified assay would be useful in applications demanding rapid time-to-result, we opted to 
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forgo the faster kinetics for the increased signal response of unannealed chips. Consequently all 
assays were run without annealing.    
To demonstrate the quantitative utility of this signal enhancement scheme, we performed 
S9.6 experiments for sensor arrays exposed to different concentrations of four different perfectly 
complementary target miRNAs. The resulting calibration curves for each of the target miRNAs 
were generated using synthetic miRNAs in buffer on separate chips, and quantitated based on the 
net S9.6 binding response measured after 40 minutes (Figure 3.8). The concentration dependent 
responses were obtained over 3 orders of magnitude down to a concentration of 10 pM; given the 
35 µL sample volume this corresponds to a detection limit of 350 amol. One exception to this is 
miR-16, which only gave consistent measurements down to 160 pM. While the reason for this 
difference is not yet fully understood, we preliminarily attribute it to specific secondary 
structures of the miRNA target and capture probe. A key advantage of S9.6 for miRNA detection 
is the fact that it is a universal recognition element, in contrast to sequence-specific RT-PCR 
primers, and thus the addition of a single reagent can be used to enhance detection for all miRNA 
species being interrogated. This is especially valuable for multiplexed detection platforms, such 
as the arrays of microring resonators used herein. Sensor chips can thus be derivatized to present 
multiple, sequence-specific capture probes specific to multiple miRNAs, exposed to the sample 
of interest, and the signal for each target can be simultaneously enhanced in a single step with the 
addition of S9.6.  
As a proof-of-concept, we functionalized discrete regions of four sensor arrays with 
different ssDNA capture probes that were perfectly complementary towards miR-16, miR-21, 
miR-24, and miR-26a. Sensor chips were then exposed to solutions containing only one of the 
target miRNAs at 40 nM, rinsed, blocked, and exposed to S9.6. This process was repeated for 
each of the four target miRNAs, each on its own chip, and the compiled responses are shown in 
Figure 3.9. Each column in the figure represents a different sensor array incubated with a 
specific target sequence. Taken together, it is clear that the S9.6 antibody does not introduce any 
cross-hybridization even at high target concentrations, and that the specificity of complementary 
probe hybridization, as reinforced through the use of a high stringency buffer, is reflected in the 
enhanced S9.6 assay.  
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To demonstrate the applicability of the S9.6 amplification methodology to the analysis of 
a relevant biological system, we simultaneously examined the relative expression profiles of the 
four aforementioned miRNAs in mouse total brain RNA. We chose to utilize mouse brain RNA 
due to the previously reported relative expression levels of many miRNAs. Two of the sequences 
have been found to be highly overexpressed in the mouse brain relative to other tissues, while the 
others are expressed at lower levels.
22,50-53
 We analyzed the expression of the four miRNAs in 
total mouse brain RNA, and after calibration and accounting for the 5-fold dilution in 
hybridization buffer, original expression levels were determined to be 3.12 ± 1.60 nM, 0.60 ± 
0.39 nM, 0.56 ± 0.25 nM, and 4.87 ± 2.72 nM for miR-16, miR-21, miR-24-1, and miR-26a, 
respectively (Figure 3.10a and 3.11). The overexpression of miR-16 and miR-26a relative to 
miR-21 and miR-24-1 is consistent with previous literature reports across a number of different 
profiling techniques, and is well within the variation observed between those studies, as shown in 
Figure 3.10b.  
We next used our assay to interrogate differential miRNA and siRNA expression in 
various soybean cultivars and tissues. Small interfering RNA and microRNA play important 
roles in the soybean plant system, controlling development of disparate tissue types and 
modulating numerous phenotypic properties. Understanding the relationships between siRNA 
abundance and phenotypic traits is important for further cultivar development and selection of 
breeds with desirable traits.
54
 Furthermore, novel miRNA exist with unknown function, 
promising even more opportunities for the manipulation of cultivar properties.
55
 By applying our 
assay to this system, we hoped to improve upon the current standard in this field, northern blots, 
which are very labor and time intensive. Figure 3.12 shows differential expression profiling of 
miR-156, 167, and a novel miRNA ―miR-192514‖ recently discovered via northern blotting but 
with no record in miRBase. 40 µL of total RNA samples from both seed coat and cotyledon 
tissues was diluted 5-fold in soy hybridization buffer—the rest of the assay was standard. With 
the exception of miR-156 expression in seed coat tissue, all results agree qualitatively with 
siRNA abundance assessed via northern blots, detailed in Table 3.2. We attribute the 
anomalously high response of miR-156 in seed coat to polyphenolic compounds ubiquitous in 
plants which have known deleterious effects on analyte quantitation.
56
 Improved quantitation 
would be possible with further work assembling standard curves, or quantitating via standard 
addition. 
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While slightly beyond the scope of this manuscript, we also investigated the utility of the 
S9.6 signal enhancement strategy for locked-nucleic acid (LNA)-containing DNA:miRNA 
heteroduplexes. LNAs are non-natural nucleotide analogs of DNA that contain a 2'-O, 4'-C-
methylene bridge which confer added rigidity to the resulting duplex.
57
 Importantly, it has been 
previously shown that the incorporation of LNAs into DNA capture probes can increase both the 
selectivity and sensitivity of miRNA hybridization assays.
58
 We found that the S9.6 antibody can 
bind to LNA-containing DNA capture sequences, albeit with a slightly lower efficiency, 
compared to an equally miRNA-saturated ssDNA(only)-modified sensor surface (Figure 3.13). 
Although the bulk of the miRNA detection experiments described herein utilized purely DNA-
based capture probes, we feel as though the demonstrated amenability of the S9.6 signal 
enhancement strategy to LNA-containing capture probes may be of future utility for small RNA 
detection. 
3.5 Conclusion 
The recently understood role of miRNAs in maintaining biological homeostasis and the 
plethora of disease states resulting from their disregulation has heightened the need for sensitive, 
multiplexed, high-throughput technologies for their analysis.  In particular, the ease by which an 
assay can be performed affects its acceptance and utilization by other researchers. We have 
demonstrated a simple, highly sensitive method for the multiplexed detection of miRNAs 
utilizing an anti-DNA:RNA antibody with arrays of silicon photonic microring resonators. The 
simplicity of the assay, the ability to simultaneously read-out multiple miRNAs in a single 
amplification step, and the potential to utilize the antibody in complex media make the 
methodology extremely appealing. 
 Future work will focus on applying this methodology towards deciphering the role of 
miRNAs in a myriad of biological systems. We will also explore ways to further increase the 
amplification provided by S9.6 by conjugating the antibody with tags having advantageous 
dielectric properties, such as nanoparticles, which have previously been used to lower detection 
limits in related sensing applications.
28,59-61
 The ability to utilize S9.6 with LNA capture probes 
also provides the potential for incorporating highly stringent and specific capture probes with 
this assay, possibly improving its performance characteristics in biologically complex samples.  
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3.6 Figures and Tables 
 
 
Figure 3.1. a) Schematic of the S9.6 amplification assay, in which a DNA-modified microring is 
sequentially exposed to complementary miRNA followed by the S9.6 antibody. b) Signal 
responses from 3 separate microrings corresponding to the schematic in a) illustrate the 
heightened sensitivity achieved via the S9.6 antibody. 
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Figure 3.2. Sensor rings were functionalized with cDNA complementary to miR-16, and 
incubated with one of the following: 40nM miR-16, 40 nM DNA analogue of miR-16, or buffer 
only. Real time response of S9.6 amplification towards the resulting single stranded DNA (red), 
a DNA:DNA duplex (blue), and a DNA:RNA heteroduplex (black) illustrate the minimal 
nonspecific adsorption properties of the antibody.  
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Figure 3.3. Capture probe density plot, showing the S9.6 response to varied ssDNA capture 
probe concentrations with a constant miR-24-1 target concentration (40 nM). The binding 
transition from cooperative binding to Langmuir binding kinetics is evident as steric limitations 
are relaxed as the concentration of capture probe deposition solutions is lowered below 125 nM.  
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Figure 3.4. a) A 1 nM solution containing miR-24-1 is flowed across sensor rings functionalized 
with a perfectly complementary DNA capture probe giving a measureable signal, but one that is 
approaching the noise floor of the assay. b)  A solution containing 2 µg/mL of the S9.6 antibody 
is then flowed across the bound heteroduplexes and a much larger and more easily measured 
response. Although the S9.6 response is not yet at equilibrium after 40 minutes of binding, it is 
clear that the amount of amplification is significantly larger than that expected based upon a 1:1 
binding interaction. The bound miRNA (~7 kDa) is approximately 21 times smaller than the S9.6 
antibody (~150 kDa), but the observed amplification factor is at least a factor of 60, suggesting 
that multiple S9.6 antibodies can bind to each surface-bound heteroduplex.   
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Figure 3.5. a) Microrings functionalized with a 40-mer ssDNA capture probe were incubated 
with 100 nM solutions of 10-mer and 20-mer RNA targets complementary to the 3' end of the 
capture probe, revealing a length dependent signal response. As expected, the hybridization of 
the 20-mer results in a signal that is approximately two times larger than for the 10-mer. b) The 
subsequent S9.6 amplification response on the DNA:RNA heteroduplexes consisting of the 20-
mer RNA also shows a larger response than the 10-mer heteroduplex, further supporting the 
notion that multiple (2-3) S9.6 antibodies can bind to a single bound miRNA. Experiments 
performed with a 40-mer test RNA sequence (not shown) confirm that multiple S9.6 antibodies 
can bind to single heteroduplexes, and also reveal that longer strand responses are accompanied 
by more complex steric binding considerations.  
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Figure 3.6 a) Introduction of 8 M urea to the sensor completely removed surface-bound S9.6, 
however, subsequent incubation with S9.6 yielded a significant yet attenuated response relative 
to the initial S9.6 response, indicating incomplete RNA removal. These trends were observed 
across a range of miRNA concentrations ranging from 100 pM to 1 µM. b) Rapid surface 
degradation in the presence of highly basic rinses, evidenced by a continuously decreasing sensor 
response, prevented the use of this regeneration methodology. c) 2% Sodium dodecyl sulfate 
(SDS) proved to be highly effective at removing the S9.6 antibody, especially in combination 
with proteinase K, yielding less than 1 Δpm different between the sensors treated with S9.6 and 
those without. Further investigation d) revealed that a 2% SDS solution alone was sufficient to 
remove the S9.6 antibody.   
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Figure 3.7 a) Three common buffers in nucleic acid applications were compared to maximize 
the miRNA hybridization efficiency and subsequent S9.6 amplification. The hybridization buffer 
gave the highest response with the least off-target response. b) Annealing the sensor chip prior to 
the assay resulted in much faster primary miRNA hybridization kinetics, but at the cost of a 
lower final signal response as well as higher off-target response.   
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Figure 3.8 a) Overlay of the signal responses achieved for each concentration of target miRNA. 
Concentrations utilized were 40 nM (black), 10 nM (red), 2.56 nM (green), 640 pM (blue), 160 
pM (pink), 40 pM (cyan), 10 pM (orange), and a blank (with the exception of miR-16, which did 
not contain the 40 pM and 10 pM calibration points). b) Calibration curves for the S9.6 response 
for miR-16, miR-21, miR-24-1, and miR-26a. Plots were constructed from the relative shifts at 
40 min. The red curves represent the logistic fits to the data points. Error bars represent ±1 
standard deviation for between 4 and 12 independent measurements at each concentration.  
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Figure 3.9. Simultaneous amplification of a panel of 4 miRNA targets (columns) hybridized to 
four complementary capture probes (rows). A panel of 4 chips was functionalized towards all 
four miRNA, and a single 40 nM target solution was introduced to each, followed by 2 µg/mL 
S9.6. Only those channels containing complementary capture probes and target miRNAs elicit an 
S9.6 response, allowing multiplexed miRNA analysis.  
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Figure 3.10. a) Comparison of the concentrations for each of the four target miRNAs in total 
mouse brain RNA. Five-fold sample dilution and individual calibration plots were taken into 
account to calculate the final concentrations. b) Microring resonator-based relative miRNA 
expression profiles, normalized to miR-26a expression levels, correlate well with literature 
results from a variety of detection techniques. Both the technique-to-technique variability and 
incomplete expression profiles of currently accepted techniques highlight the need for highly 
multiplexed and accurate profiling methods.  
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Figure 3.11. Microrings previously functionalized with 4 different capture probes 
complementary to different miRNA of interest were incubated with mouse brain total RNA 
overnight. After a blocking step the microrings are subsequently exposed to S9.6 in buffer. The 
resulting shift is then quantitated via calibration plots for each miRNA.  
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Figure 3.12. A comparison of the expression levels of three miRNA in two different soybean 
tissues, as quantitated via Northern blotting and microring resonators. Expression levels 
correlated highly between the two techniques, with the notable exception of miR-156 abundance 
in soybean seed coat samples, ostensibly due to interference from polyphenolic compounds.  
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Figure 3.13. Sensor rings were functionalized with either cDNA complementary to miR-24-1 or 
an LNA analogue of the DNA capture probe.  A solution of 40 nM miR-24-1 was flowed over 
the entire chip.  The real time response of the S9.6 amplification towards each of the 
heteroduplex pairs is shown above.  While the LNA:RNA heteroduplex (red) elicits a response to 
the S9.6 amplification, the response is lower than seen with an DNA:RNA heteroduplex (black). 
However, the fact that S9.6 can recognize LNA:RNA heteroduplexes should prove to be quite 
useful as LNAs have previously been demonstrated to be  higher affinity capture probes for 
miRNA detection applications, compared to DNA.  
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Table 3.1. Sequences of synthetic nucleic acids in described experiments. Bases in bold 
indicate the substitution of a locked nucleic acid.  
 Sequence 
hsa miR-16 5'-UAGCAGCACGUAAAUAUUGGCG-3' 
hsa miR-21 5'-UAGCUUAUCAGACUGAUGUUGA-3' 
hsa miR-24-1 5'-UGGCUCAGUUCAGCAGGAACAG-3' 
hsa miR-26a 5'-UUCAAGUAAUCCAGGAUAGGCU-3' 
DNA Capture 
Probe  
for hsa miR-16 
5'-NH2 – (CH2)12 – ATC GTC GTG CATTTATAACCGC-3' 
DNA Capture 
Probe  
for hsa miR-21 
5'-NH2 – (CH2)12 – ATCGAATAGTCTGACTACAACT-3' 
DNA Capture 
Probe  
for hsa miR-24-1 
5'-NH2 – (CH2)12 – CTGTTCCTGCTGAACTGAGCCA-3' 
DNA Capture 
Probe  
for hsa miR-26a 
5'-NH2 – (CH2)12 – AAGTTCATTAGGTCCTATCCGA-3' 
10mer RNA 5'-AAAGGUGCGU-3' 
20mer RNA 5'-AAAGGUGCGUUUAUAGAUCU-3' 
40mer DNA 
Modular Capture 
Probe 
5'-NH2–(CH2)12– 
TAGTTGCTGCAACCTAGTCTAGATCTATAAACGCACCTTT-3' 
LNA Capture 
Probe  
for hsa miR-24-1 
5‘-NH2 – (CH2)12 – CTGTTCCTGCTGAACTGAGCCA-3‘ 
gma miR-156 5‘-UUGACAGAAGAGAGAGAGCAC-3‘ 
gma miR-167 5‘-UGAAGCUGCCAGCAUGAUCUU-3‘ 
gma miR-―unk‖ 5‘-UAACUGAACAUUCUUAGAGCAU-3‘ 
DNA Capture 
Probe for gma 
miR-156 
5'-NH2 – (CH2)12 – GTGCTCTCTCTCTTCTGTCAA-3' 
DNA Capture 
Probe for gma 
miR-167 
5'-NH2 – (CH2)12 – AAGATCATGCTGGCAGCTTCA-3' 
DNA Capture 
Probe for gma 
miR-‗unk‘ 
5'-NH2 – (CH2)12 – ATGCTCTAAGAATGTTCAGTTA-3' 
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Table 3.2. Relative abundance of 3 miRNA in Williams 43 soybean cultivar as determined by 
northern blot. Counts denote pixel intensity as measured via phosphor imaging. 
 miR-156 miR-‗unk‘ miR-167 
Seed Coat 6055 192514 182394 
Cotyledon 296023 218 3750 
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Chapter 4 
Label-free, Multiplexed Detection of Bacterial tmRNA 
Using Silicon Photonic Microring Resonators 
 
 
Notes and Acknowledgements  
This chapter has been adapted from the article ―Label-Free, Multiplexed Detection of Bacterial 
tmRNA Using Silicon Photonic Microring Resonators‖ (Scheler, O.; Kindt, J.T.; Qavi, A.J.; 
Kaplinski, L.; Glynn, B.; Barry, T.; Kurg, A.; Bailey, R.C. Biosensors and Bioelectronics 2012,  
36, 1,  56-61). It has been reproduced here with permission from Elsevier © 2012. 
The work in this chapter was funded by the National Institutes of Health (NIH) Director‘s New 
Innovator Award Program, part of the NIH Roadmap for Medical Research, through grant 1-
DP2-OD002190-01; the Center for Advanced Study at the University of Illinois at Urbana—
Champaign; and the Camille and Henry Dreyfus Foundation. Additional support was received 
from the European Social Fund‘s Doctoral Studies and Internationalization Program DoRa and 
targeted financing SF0180026s09 and SF0180027s10 from the Estonian Ministry of Education 
and Research. J.T.K. was supported by a National Science Foundation Graduate Research 
Fellowship under Grant No. DGE 07-15088-FLW. I acknowledge the contributions of O.S., 
A.J.Q., L.K., B.G., T.B., and A.K. 
This article can be accessed online at 
http://www.sciencedirect.com/science/article/pii/S0956566312002072. 
  
86 
 
4.1 Abstract 
A label-free biosensing method for the sensitive detection and identification of bacterial 
transfer-messenger RNA (tmRNA) is presented employing arrays of silicon photonic microring 
resonators. Species specific tmRNA molecules are targeted by complementary DNA capture 
probes that are covalently attached to the sensor surface. Specific hybridization is monitored in 
near real-time by observing the resonance wavelength shift of each individual microring. The 
sensitivity of the biosensing platform allowed for detection down to 53 fmol of Streptococcus 
pneumoniae tmRNA, equivalent to approximately 3.16 x 10
7
 CFU of bacteria. The simplicity 
and scalability of this biosensing approach makes it a promising tool for the rapid, PCR-free 
identification of different bacteria via tmRNA profiling. 
4.2 Introduction 
The ability to rapidly and accurately detect pathogenic bacteria strains is important for 
the screening of infectious diseases as well as for environmental monitoring and food safety. 
Unfortunately, traditional microbiological methods for these purposes typically use slow, labor 
intensive culturing methods. Consequently, numerous biosensing technologies have emerged 
which address the inadequacies of traditional techniques, offering rapid, selective, and sensitive 
bacterial detection.
1-4
 These techniques frequently rely on the analysis of strain-specific 
biomarkers which indicate the presence and abundance of specific bacteria strains. Ideally, these 
biomarkers are present at relatively high copy numbers, while also being sufficiently 
heterologous at the sequence level to allow for differentiation of the pathogen at both the genus 
and species levels.
5
  
An attractive candidate for bacterial biosensing that fulfills the aforementioned criteria is 
transfer-messenger RNA (tmRNA) and its encoding ssrA gene. Specifically, tmRNAs are present 
in all bacterial species 
6,7
 at relatively high copy number 
8-10
  and contains regions of sequence 
sufficiently unique to unequivocally differentiate between species and genus.
11-14
 In addition, the 
presence of intact RNA molecules can also indicate the condition of bacterial population and 
help distinguishing viable bacteria from nonviable.
5,15
 Although the aforementioned properties 
also apply to the widely used biomarker 16S rRNA and its corresponding gene,  several studies 
have shown that 16S rRNA is not always the most suitable biomarker to differentiate between 
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closely related species.
11,16
 In particular, 16S rRNA sequence homogeneity between closely 
related species such as Escherichia coli  and some Salmonella species preclude specific 
identification . Furthermore the discovery of intragenomic heterogeneity between the multiple 
rRNA genes of some organisms (including Streptococci) may further invalidate use of this target 
for diagnostics applications.
17,18
 
Given the clear diagnostic utility of tmRNAs, previous reports have focused on the 
fluorescence in situ hybridization (FISH) based detection of specific bacteria,
11
 food analysis by 
real-time PCR 
12
 or nucleic acid sequence based amplification (NASBA),
13
 and pathogen 
detection using NASBA-microarray combined technology.
14
 However, the combination of 
tmRNA-based species identification and emerging biosensing technologies with key attributes 
(e.g. scalability, time-to-result, sample preparation requirements, etc.) offers the potential for 
rapid, real-time detection and identification of bacterial contaminants and their abundance in 
various sample types.  
Microring resonators are a relatively new class of photonic microcavity device that are 
highly sensitive to changes in the local refractive index, such as those resulting from 
biomolecular binding events. This sensing modality arises from the discrete wavelengths of light 
supported by the circular, interferometric structure that is sensitive to changes in the refractive 
index surrounding the sensor.
19-21
  Since any biomolecular binding event will lead to a 
measurable shift in optical properties, these sensors have been used to detect a broad array of 
targets, including both proteins 
22-24
 and nucleic acids.
25-27
  
Key advantages of this technology include the small footprint and high scalability of the 
microrings afforded by their genesis in semiconductor fabrication. These characteristics position 
the platform advantageously for multiplexed biomarker analysis where diagnostic value 
improves with increasing size of the panel. Additionally, the near real time monitoring capability 
expedites assay development and allows valuable kinetic information to be directly observed, 
which is in contrast to endpoint-based biomarker detection methodologies such as blots or 
ELISAs. 
In this paper we demonstrate the label-free detection and identification of tmRNA 
molecules using arrays of silicon photonic microring resonators. Bacterial analysis via tmRNA 
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detection is a natural application of the platform given the low abundance of tmRNA molecules 
in bacteria, obviating the need for target amplification steps. Additionally, like all nucleic acid 
studies, complementary Watson-Crick base pairing is utilized to specifically and sensitively 
capture tmRNA molecules to the sensor surface for robust bacterial differentiation. Herein, we 
show the ability to distinguish between closely related bacterial species by monitoring 
corresponding tmRNA specific probe hybridization in a single, multiplexed assay. As little as 
52.4 fmol of Streptococcus pneumoniae tmRNA was specifically detected, equivalent to 3.16 x 
10
7
 CFU of corresponding bacteria. Furthermore, the high specificity of this approach is 
demonstrated by the preferential capture of target tmRNAs in the presence of ~ 100-fold excess 
of off-target tmRNA molecules. 
4.3 Experimental Methods 
4.3.1 In vitro tmRNA synthesis 
Streptococcus pneumoniae ATCC 33400 (S.pneumoniae) and Klebsiella pneumoniae 
ATCC 13883 (K.pneumoniae) were obtained  from DSMZ (Braunschweig, Germany). 
Streptococcus agalactiae (S.agalactiae)and Enterococcus faecium (E.faecium) were obtained 
from University College Hospital (Galway, Ireland). ssrA genes of each species were cloned into 
pCR® II-TOPO vectors (Invitrogen, Carlsbad, CA) under the transcriptional control of a T7 
promoter sequence (gene sequences shown in SI). Both vector linearization and RNA synthesis 
were carried out according to the manufacturer‘s suggestions with minor customizations. Briefly, 
the vector was linearized in 1× buffer R using HindIII restriction endonuclease at 37 °C for 120 
min. tmRNA was transcribed in vitro using 250 ng of linearized vector and 40 U of T7 RNA 
polymerase. The final reaction buffer contained 2 mM ATP, 2 mM CTP, 2 mM GTP and 1 mM 
UTP; 40 U RiboLock™ ribonuclease inhibitor was added to prevent possible RNA degradation. 
A final reaction volume of 50 μl was achieved by adding ultrapure H2O. All reagents were 
purchased from (Fermentas-ThermoFischer, Vilnius, Lithuania). The transcription reaction 
continued for 180 min at 37°C prior to purification with a RNeasy MinElute cleanup kit (Qiagen 
Inc., Valencia, CA). Nucleic acids were quantified by UV-Vis measurements (NanoDrop 1000; 
ThermoFischer, Wilmington, DE). 
4.3.2 Microring resonator sensors and instrumentation 
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All sensor chips and read-out instrumentation were purchased from Genaltye, Inc. (La 
Jolla, CA), and have been previously described.
22,28,29
 To summarize, chips containing 32 
individually addressable microring sensors were used for each experiment. The chips were 
functionalized to present ssDNA capture probes using commercially available hydrazone-bond 
linker chemistry (described below).  Functionalized chips were loaded into a microfluidic 
assembly that interfaced to the sensor scanner system. 
4.3.3 Design of specific ssDNA capture probes and chaperones 
Specific capture probes for S.pneumoniae (5‘-
CTTAATCGTATCTCGCTAATAATAAG-3‘) and S.agalactiae (5‘-
TTTTTACAGTAGCCAAACGTAGTTTG-3‘) were designed with SLICSel software as 
described previously.
30
 From the array of designed probes, ―SP_dom 4_24‖ specific for 
S.pneumoniae and ―s_a 4_3‖ specific for S.agalactiae were selected based on their specificity 
and sensitivity in fluorescent microarray hybridization experiments.
14,30
 A poly-T linker was 
added to the S.agalactiae probe to match the surface distance of the other probe. Human miRNA 
24-1 specific DNA capture probe (5‘-CTGTTCCTGCTGAACTGAGCCA-3‘) was used as the 
baseline reference probe. Chaperone oligonucleotides, designed to disrupt tmRNA secondary 
structure, were optimized from previously published data (Chap A-F) and complementary to 
different regions of S.pneumoniae tmRNA. The chaperone sequences were obtained from 
Metabion (Martinsried, Germany). All sequences are listed in full in Table 4.1 & 4.2. 
4.3.4 ssDNA capture probe attachment to the sensor chip surface 
All of the capture probes were obtained with 5‘ amine functionality from Integrated DNA 
Technologies (Coralville, IA) and were HPLC purified prior use. All of the probes were next 
modified with a succinimidyl-4-formylbenzoate  linker (Solulink, San Diego, CA) to introduce 
an aryl aldehyde moiety. In parallel, sensor chips were cleaned and functionalized as described 
previously to introduce reactive hydrazine groups.
25,26
 Small aliquots (1µl) of modified DNA 
probes were deposited onto the chip surface in a spatially controlled manner prior to overnight 
incubation in a humidity chamber; the resulting hydrazone bond linkage afforded covalent 
capture probe immobilization. Both the high DNA probe concentration and overnight incubation 
ensured the surface achieved a high density of DNA probes as monitored in real-time 
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experiments (data not shown) and consistent with literature reports.
31
 A minimum of three rings 
were functionalized with the same capture probe for replicate analysis. Prior to hybridization 
experiments, the substrates were sonicated in 8 M urea for 7 min to remove any non-covalently 
immobilized capture probe. 
4.3.5 Hybridization experiments with tmRNA molecules 
tmRNA hybridization was performed in a buffer consisting of 30% formamide, 30 mM 
ethylenediaminetetracetic acid (EDTA), 4x Saline-Sodium-Phosphate-EDTA (SSPE) Buffer, 
0.2% SDS, and 2.5x Denhardt‘s Solution. All of the hybridization experiments were carried out 
at room temperature by recirculating tmRNA solutions across the sensor surface at a rate of 24 
µl/min for 60 minutes using a P625 peristaltic pump (Instech Labs, Plymouth Meeting, PA). 
Solutions were directed across the surface via a 0.178 mm thick, U-shaped single channel Mylar 
gasket sandwiched between a Teflon cartridge and the sensor chip. To avoid complications with 
hybridization between the capture probes and the secondary structure natively adopted by 
tmRNA molecules, three different sample preparation methods were compared: thermal tmRNA 
denaturation, thermal tmRNA denaturation with a 10-fold excess of chaperones, and chemical 
tmRNA fragmentation. Denaturation consisted of 15 min treatment at 95 °C in 100 µL of 
hybridization buffer. Chaperones are short DNA sequences added to the sample matrix in order 
to disrupt extended secondary structures adopted by full length tmRNAs based upon 
hybridization to specific regions of the tmRNA. Chemical tmRNA fragmentation by metal ion-
catalysis was performed in 100mM ZnCl2 containing Tris (pH 7.0) buffer for 15 min at 70° C 
resulting in a mixture of 80-120 nucleotide long RNA fragments according to agarose gel 
electrophoresis. 
32
 10 µl of fragmented tmRNA solution was added to 90 µl of hybridization 
solution after the fragmentation. All solutions were cooled to room temperature before sample 
introduction and all of the experiments were carried out using 1.66 pmol of S.pneumoniae 
tmRNA (equaling to 1x10
12
 tmRNA molecules or 1x10
9
 CFU of bacteria, respectively), unless 
stated otherwise. 
4.3.6 Data analysis 
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All data for tmRNA specific microrings was corrected for temperature and instrument 
drift by subtracting a series of baseline reference probes. All data was analyzed, fit, and graphed 
using OriginPro8 (OriginLab, Northampton, MA).  
To utilize the curves for quantitative analysis of binding, we fit a 1:1 Langmuir kinetic binding 
isotherm, described by: 
 ( )   (     (    ))    (Eq. 4.1) 
The initial slope of this function was determined by evaluating its derivative at t = t0. At 
concentrations below 1.66 pmol, a linear fit was utilized to determine the initial slope response. 
4.4 Results and Discussion 
In this study, we demonstrate the quantitative detection of specific tmRNA molecules for 
bacterial biosensing using arrays of silicon photonic microring resonators. We decided to 
examine tmRNA from the respiratory tract pathogen S.pneumoniae due to its widespread 
negative impact on human health and also the complications that are linked with current 
detection technologies, including insufficient specificity, rapidness, or robust quantitative 
capability.
33
 Recently published work has established the utility of tmRNA for distinguishing 
between S.pneumoniae and five other closely related respiratory tract pathogens in a highly 
sensitive manner.
14
 In this study, tmRNA molecules from three other pathogens (K.pneumoniae, 
E. faecium and S.agalactiae) are used for comparison purposes. 
  A schematic of the tmRNA hybridization assay is shown in Figure 4.1. In this assay, a 
DNA probe complementary to the target tmRNA of interest is covalently attached to the 
microring surface, after which a solution containing the target tmRNA is flowed across the 
sensor.  The hybridization of tmRNA onto the probe-modified sensor surface results in a change 
in the wavelength of light that is resonantly coupled into the microring, resulting in an easily 
measured shift. 
Unlike small nucleic acids such as siRNAs and miRNAs, tmRNAs frequently possess 
significant secondary and tertiary structures that can complicate simple hybridization based 
detection.
34
 This is of particular concern when making measurements near room temperature, 
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which is convenient from a sensor operation perspective. Early observations reinforced these 
complications as hybridization responses of tmRNA molecules to the sensor surface were 
extraordinarily slow. To address this challenge, three RNA pre-treatment methods were 
investigated to determine the optimal conditions for tmRNA detection at room temperature.  
These methods included: chemical fragmentation of the tmRNAs using ZnCl2, denaturation of 
the target tmRNAs by heating to 95° C before cooling back to room temperature, and thermal 
denaturation of the targets in the presence of chaperone oligonucleotides designed to assist in 
unfolding the tmRNA.  These chaperone sequences were designed and demonstrated to bind to 
predicted secondary structure regions in S.pneumoniae tmRNA, prevent refolding of tmRNA 
after denaturation and therefore enhance tmRNA hybridization in previous work.
30
 
As shown in Figure 4.2, fragmentation of the tmRNA was the most effective method in 
order to enhance both the binding kinetics and overall net response magnitude. We attribute this 
primarily to the reduced secondary structure present in the shorter (80-120 nucleotides) tmRNA 
fragments. Our results agree with the previous report by Wu and co-workers in which RNA 
fragmentation was also found to be the most effective strategy to improve hybridization 
efficiency and sensitivity in a fluorescent microarray analysis.
32
 Consequently, tmRNA 
molecules were fragmented in all subsequent experiments to improve the sensor performance. 
Once fragmentation was established as the most effective pre-treatment for tmRNA 
samples, we sought to optimize fragmentation time. As shown in Figure 4.3, the time in which 
the sample was exposed to the ZnCl2 fragmentation solution was systematically varied from zero 
to 60 minutes, and the resulting hybridization responses measured using identically prepared 
sensors.  These experiments indicated that 10 min of treatment was sufficient for optimal sensor 
performance, and a standard 15 minute fragmentation period was used for all subsequent 
experiments.  Interestingly, we did not observe any significant change in the non-specific sensor 
response as a function of fragmentation time. 
In order for a microbial diagnostic technology to be useful, it must respond quantitatively 
and specifically to low levels of target marker molecules in a high background of non-target 
nucleic acid sequences. This is due to the diversity of bacterial species that may be present in 
clinical or other types of samples. Addressing specificity first, we functionalized a single sensor 
array with ssDNA capture probes targeting bacterial tmRNAs from S.pneumoniae and 
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S.agalactiae.  We subsequently introduced a series of tmRNAs from four bacterial species 
(K.pneumoniae, E. faecium, S.pneumoniae, and S.agalactiae) sequentially across the sensor 
surface. Each tmRNA solution had 1.66 pmoles of target.  As seen in Figure 4.4, K.pneumoniae 
and E.faecium tmRNA did not elicit a response while subsequent hybridization steps with both 
S.agalactiae and S.pneumoniae tmRNA demonstrated strong and specific responses from the 
microrings modified with complementary DNA capture probes.  The different response 
magnitudes from S.pneumoniae- and S.agalactiae-specific microrings can be attributed to 
differences in the probes‘ length and hybridization properties (duplex melting temperatures (Tm), 
binding affinity, nucleotide composition and positioning) of the different DNA capture probe-
RNA target pairs. Additionally, targeting complementary regions in fragmented tmRNA 
molecules can still be unevenly hindered by any remaining secondary structure. In the future, 
probe sequences could be redesigned to normalize for these differences, or higher Tm forming 
locked nucleic acids (LNAs) could be employed. Nonetheless, results at this stage clearly 
demonstrate the potential of the microring resonator platform to directly detect bacterial tmRNAs 
and discriminate between unique strains on the basis of differential hybridization.  
Having demonstrated the high specificity of the method, we then focused on establishing 
the quantitative utility of the platform towards tmRNA detection. DNA-functionalized microring 
sensors were exposed to different quantities of S.pneumoniae  tmRNA, ranging from 52.4 fmol 
to 16.6 pmol. A cocktail of control tmRNAs from three other bacteria (1.66 pmol each of: 
K.pneumoniae, E.faecium and S.agalactiae) were also added to the hybridization mixture as a 
background to mimic the complex matrix in which tmRNA analytes are found naturally. The 
concentration dependent responses, shown in Figure 4.5, gave a limit of detection  of 52.4 fmol 
(or 100 µl of 524 pM tmRNA solution). This limit of detection corresponds to roughly 3.16 x 
10
10
 tmRNA molecules or 3.16 x 10
7
 CFU of S.pneumoniae, with a dynamic range of nearly 
three orders of magnitude. 
The limit of detection reported herein surpasses previous reports on the direct, label-free 
detection of microRNAs and DNA using the same measurement technology.
25-27
 This increased 
sensitivity is due to the larger size of the tmRNA targets. Even after fragmentation, the 
detectable targets are still 80-120 nucleotides in length, compared to the previously investigated 
22 nucleotide microRNA sequences. Furthermore, this detection limit is comparable to that 
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achieved using surface plasmon resonance imaging (SPRi), in which the detection of 2 nM of 
Escherichia coli 16S rRNA was reported in a similar direct hybridization assay.
35
  
Extrapolating beyond this initial report, the potential multiplexing capability of this 
silicon photonic platform is attractive for more informative bacterial diagnostics, whereby the 
presence of a larger number of targeted bacteria can be simultaneously probed using a relatively 
simple and rapid assay protocol. Although the obtained level of sensitivity is far from that 
achieved with regular culture-based methods and molecular methods, the incorporation of signal 
and/or target amplification technologies should allow for sensitivity levels comparable to real-
time NASBA or real-time RT-PCR based detection of tmRNA molecules, albeit with additional 
sample and/or assay manipulation steps.  Recently an antibody specific to DNA-RNA duplexes 
was incorporated onto this microring resonator platform and a ~3 order of magnitude 
improvement in limit of detection was achieved for miRNA analysis.
26
 Also, larger refractive 
index tags can be introduced to dramatically increase limits of detection, as compared to solely 
label-free analyses.
36
 Importantly, both these additional amplification steps could be 
implemented in two hours or less and thus the assay would retain its quick time-to-result as 
compared to traditional microbiology-based analysis schemes. Aside from the sensor platform 
itself, increases in sensitivity can also be accomplished by applying culture enrichment methods 
37,38
  or tmRNA amplification using isothermal NASBA technology prior to hybridization.
39
 
4.5 Conclusions 
In this manuscript we present a promising approach for bacterial diagnostics and 
microbial analysis utilizing arrays of silicon photonic microring resonators.  The capability of 
this analysis platform for multiplexed measurements allowed for the rapid discrimination of 
tmRNA from multiple, distinct  bacterial species.  As little as 53 fmol of Streptococcus 
pneumoniae tmRNA, equivalent to roughly 3.16 x 10
7
 CFU of the corresponding bacteria, was 
easily detected on this platform using a label-free direct hybridization assay.  Using the described 
approach different patient samples, food products, or analyte solutions might be tested and 
quickly screened for multiple pathogenic contaminants in a highly parallel manner.  In particular, 
this methodology holds significant promise in the fields of environmental monitoring, bio-threat 
detection, industrial process monitoring, and clinical microbiology—application areas where 
specificity and time-to-result are of critical importance.  Although this work focused on early 
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stage studies designed to show applicability to in vitro synthesized target tmRNA molecules, this 
platform has been applied to significantly more complex RNA-containing samples and thus the 
assays described herein should be applicable to these samples with only minor modifications to 
hybridization conditions or minor pre-analysis sample preparation.
25,26
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4.6 Figures and Tables 
 
Figure 4.1. Schematic demonstrating the principle of microring optical resonator based detection 
of tmRNA hybridization, including the tmRNA binding curve response of four separate 
microrings. The asterisk (*) denotes the time at which the solution containing 320 ng of 
fragmented target tmRNA is introduced to the sensor chip. 
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Figure 4.2. Comparison of the hybridization-adsorption response of untreated tmRNA with 
different pre-treatment methods. The fragmentation methodology yielded the highest response 
and was used for all experiments.  
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Figure 4.3.  Varied hybridization responses as a function of fragmentation time, ranging from 0 
to 60 minutes. 15 minutes was used in experiments, as it was the minimal time required to 
achieve complete fragmentation. The results of at least three separate identically modified 
microrings are plotted. 
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Figure 4.4. The specific detection of two tmRNA species on a continuous single chip assay. 
Microrings were functionalized with either Streptococcus pneumonia (black) or Streptococcus 
agalactiae (red) tmRNA- specific DNA oligonucleotide capture probes. tmRNA from four 
different bacterial species (Klebsiella pneumoniae, Enterococcus faecium, S.agalactiae, and 
S.pneumoniae) were sequentially introduced into the flow chamber, and a specific response 
observed for each tmRNA. Washing steps with neat buffer solution were carried out between 
hybridization steps.  
100 
 
 
Figure 4.5. a) Concentration dependent responses from the binding of S. pneumonia tmRNA 
(from 16.6 pmol to 0 pmol, decreasing top-to-bottom). b) Calibration plot of tmRNA induced 
sensor response. Quantitation was performed by fitting the initial slope.  
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Table 4.1. DNA capture probes used in experiments. Thermodynamic calculations performed 
using IDT OligoAnalyzer (www.idtdna.com) with default settings. 
 
 
 
Table 4.2. Sequences of ssrA genes. Genes were cloned into plasmid vectors, and degenerate 
ssrA primers were used to prepare and sequence amplicons from target organisms. Sequences 
have been edited to remove ambiguous readings from ends. 
 
Streptococcus pneumoniae ATCC 33400 
TTCGACAGGCATTATGAGGCATATTTTGCGACTCGTGTGGCGACGTAAACGCTCAGT
TAAATATAACTGCAAAAAATAACACTTCTTACGCTCTAGCTGCCTAAAAACCAGCAG
GCGTGACCCGATTTGGATTGCTCGTGTTCAATGACAGGTCTTATTATTAGCGAGATA
CGATTAAGCCTTGTCTAGCGGCTTGATAAGAGATTGATAGACTCGCAGTTTCTAGAC
TTGAGTTATGTGTCGAGGGGCTGTTAAAATAATACATAACCTATGGTTGTAGACAAA
TATGTTGGCAGGTGTTTGGACG 
 
Streptococcus agalactiae 
TTCGACAGGCATTATGAGGTATATTTCGCGACTCATCGGCAGATGTAAAATGCCAGT
TAAATATAACTGCAAAAAATACAAATTCTTACGCATTAGCTGCCTAAAAAACAGCCT
GCGTGATCTTCACAAGATTGTTTGCGTTTTGCTAGAAGGTCTTATTTATCAGCAAACT
ACGTTTGGCTACTGTCTAGTTAGTTAAAAAGAGATTTATAGACTCGCTATGTGAGGG
CTTGAGTTATGTGTCATCACCTAGTTAAATCAATACATAACCTATAGTTGTAGACAA
ATATATTAGCAGATGTTTGGACG 
 sequence GC% Tm° 
S.pneumoniae specific 5‘-CTTAATCGTATCTCGCTAATAATAAG-3‘ 30.8 42.2 
S.agalactiae specific 5‘-TTTTTACAGTAGCCAAACGTAGTTTG-3‘ 42.9 47.2 
Baseline reference 
probe 
5‘-CTGTTCCTGCTGAACTGAGCCA-3‘ 54.5 59.3 
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Table 4.2 (cont.) 
Enterococcus faecium 
GGGGACGTTACGGATTCGACAGGCACAGTCGAGCTTGAATTGCGTTTCGTAGGTTAC
GTCTACGTAAAAACGTTACAGTTAAATATAACTGCTAAAAACGAAAACAACTCTTAC
GCTTTAGCTGCCTAAAAACAGTTAGCGTAGATCCTCTCGGCATCGCCCATGTGCTCG
AGTAAGGGTCCTAACTTTAGTGGGATACGTTTCAACTTTCCGTCTGTAAGTTGAAAA
AGAGAACATCAGACTAGCGATACAGAATGCCTGTCACTCGGCAAGCTGTAAAGTGA
ATCCTTAAATGAGTTGACTATGAACGTAGATTTTTAAGTGGCGATGTGTTTGGACGC
GGGTTCGACTCCCGCCGTCTCCACCA 
 
Klebsiella pneumoniae ATCC 13883 
TTCGACGGGATTTGCGAAACCCAAGGTGCATGCCGAGGGGCGGTTGGCCTCGTAAA
AAGCCGCAAAAAATAGTCGCAAACGACGAAAACTACGCTTTAGCAGCTTAATAACC
TGCTCTGAGCCCTCTCTCCCTAGCTTCCGCTCTTAAGACGGGGATCAAAGAGAGGTC
AAACCCAAAAGAGATCGCGTGGATGCCCTGCCTGGGGTTGAAGCGTTAAATCTAAT
CAGGCTAGTTTGTTAGTGGCGTGTCTGTCCGCAGCTGGCAAGCGAATGTAAAGACTG
ACTAAGCATGTAGTGCCGAGGATGTAGGAATTTCGGACC 
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Chapter 5 
Chaperone Probes and Bead-Based Enhancement 
Improve the Direct Detection of mRNA Using Silicon 
Photonic Sensor Arrays 
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5.1 Abstract  
Herein we describe the utility of chaperone probes and a bead-based signal enhancement 
strategy for the analysis of full length messenger RNA transcripts using arrays of silicon 
photonic microring resonators. Changes in the local refractive index near microring sensors 
associated with biomolecular binding events are transduced as a shift in the resonant wavelength 
supported by the cavity, enabling the sensitive analysis of numerous analytes of interest. We 
employ the sensing platform for both the direct and bead-enhanced detection of three different 
mRNA transcripts, achieving a dynamic range spanning over four orders of magnitude, and 
demonstrating expression profiling capabilities in total RNA extracts from the HL-60 cell line. 
Small, dual-use DNA chaperone molecules were developed and found to both enhance the 
binding kinetics of mRNA transcripts by disrupting complex secondary structure and serve as 
sequence-specific linkers for subsequent bead amplification. Importantly, this approach does not 
require amplification of the mRNA transcript, thereby allowing for simplified analyses that do 
not require expensive enzymatic reagents or temperature ramping capabilities associated with 
RT-PCR-based methods.  
5.2 Introduction 
The concept of personalized medical diagnostics is based upon the premise that panels of 
biomarkers can predict disease progression or otherwise determine an individual patient‘s most 
effective treatment regimen.
1-4
 Advances in laboratory-based, high throughput measurement 
technologies have greatly advanced our understanding of the molecular basis of disease at a 
systems level, revealing a myriad of potential biomarkers at the level of DNA, RNA, proteins, 
and metabolites,
5-7
 through the interrogation of numerous classes of biomarkers; thus, analysis 
techniques which are amenable to studying multiple classes of biomarkers have a distinct 
advantage over those limited to a specific class. Given this, recent biosensor efforts have been 
aimed at creating platforms that are scalable, cost effective, and flexible towards the detection of 
multiple marker classes, as the increase in measured biological information content should 
translate into more molecularly insightful diagnostic capabilities.  
Due to their key position at the intersection between the genome and proteome, 
messenger RNA (mRNA) transcripts are particularly informative biomarkers in research and 
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medical diagnostic applications.
8
 mRNA abundance has been used extensively to study disease 
classification,
9,10
 gene function,
11
 regulatory interactions,
12
 and therapeutic efficacy,
13-16
 among 
other applications. However, the naturally low abundance of mRNA, as well as challenges 
associated with their size and extensive secondary structure, present complications to many 
hybridization-based detection methodologies.
17
 
Since the original extension of polymerase chain reaction (PCR) to RNA in the form of 
reverse transcription polymerase chain reaction (RT-PCR),
18
 numerous transduction methods 
have been developed to identify and quantitate the resultant amplicons including microarrays,
19
 
fluorescent reporters,
20
 and sequencing.
21
 More recently other optical
22,23
 and electrochemical
24-
27
 techniques have been successfully applied to the analysis of in vitro transcribed mRNA and 
mRNA isolated from cell lines. While these approaches to mRNA analysis provide robust 
analytical capabilities and high sensitivity, further improvements, particularly in multiplexing 
capability, time-to-result, and potential amenability to the simultaneous analysis of multiple 
classes of biomarkers, would be of potential value to the clinical diagnostic community.  
Silicon photonic microring resonators have emerged as a promising technology for 
biomolecular analysis. These sensors are sensitive to binding-induced changes in the local 
refractive index and, after functionalization with appropriate capture agents, have been used to 
quantitate a range of biomolecular analytes including DNA,
28
 miRNA,
29,30
 proteins,
31-40
 
bacteria,
41
 and whole virus particles.
42
 In this work, we apply this technology to the detection of 
three full length mRNA transcripts—c-myc, β-actin, and IL-8. These mRNAs serve as 
potentially useful diagnostic or theragnostic markers based on their involvement and abnormal 
expression in numerous oncological processes.
43-46
 mRNA analysis was performed in a 
multiplexed format to profile expression changes in HL-60 cells upon differentiation. 
Importantly, we utilized an signal enhancement approach combining short DNA chaperones and 
sub-micron beads that dramatically increased the assay sensitivity by removing the secondary 
structure of the mRNA and also increasing the refractive index change associated with the each 
target strand bound to the sensor. The end result is a quantitative, multiplexed, and PCR-free 
assay to analyze full length mRNA with a limit of detection of 512 amol.  
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5.3 Experimental Methods  
5.3.1 Materials 
PBS buffer was reconstituted with deionized water from Dulbecco‘s Phosphate Buffered 
Saline packets purchased from Sigma-Aldrich (St. Louis, MO), and the pH adjusted to 7.4 (PBS-
7.4) or 6.0 (PBS-6). A PBS + 0.5% Tween buffer (PBST) was created by the addition of Tween-
20 to PBS-7.4. A high stringency hybridization buffer consisting of 30% formamide, 0.2% 
sodium dodecyl sulfate, 4X saline-sodium phosphate-EDTA buffer (SSPE, USB Corp.), and 3X 
Denhardt‘s Solution (Invitrogen) was used for all hybridization steps. Bio-Streptavidin Plus 114 
nm magnetic beads were obtained from Ademtech and buffer exchanged in PBST in 3 kDA 
MWCO Vivaspin columns (Sartorius) prior to use to remove free streptavidin from solution. 
Starting Block was obtained from Thermo-Scientific and used to prevent nonspecific fouling of 
streptavidin-coated beads. The silane 3-N-((6-(N‘-Isopropylidene-
hydrazino))nicotinamide)propyltriethyoxysilane (HyNic Silane)  and succinimidyl-4-
formylbenzamide (S-4FB) were purchased from Solulink. All other reagents were purchased 
from Fisher, unless otherwise noted, and used as received. 
5.3.2 Sensor Arrays, Read-Out Mechanism, and Instrumentation 
Sensor chips and read-out instrumentation were obtained from Genalyte, Inc (San Diego, 
CA), and have been described previously.
40,47
 Sensor chips were fabricated at a silicon foundry 
on 8‖ silicon-on-insulator wafers using deep UV photolithography and dry etch methods, spin-
coated with a fluoropolymer cladding layer, and diced into individual 6 x 6 mm chips, each 
having an array of 32 individually addressable microrings. The fluoropolymer cladding is 
selectively removed from 24 of the rings leaving these exposed to the solution and responsive to 
binding events. The eight occluded rings serve as control elements for subtracting thermal drift. 
Chips were fitted with a laser etched Mylar gasket, which defined flow chambers when 
sandwiched with a Teflon lid, and loaded into the read-out instrumentation. All experiments 
were performed at a flow rate of 20 µL/min unless noted otherwise. 
As reported previously,
47
 resonant wavelengths for each microring were determined by 
coupling a tunable laser source (centered at 1550 nm) into an adjacent linear waveguide via on-
chip grating couplers. The laser output was then swept through and appropriate spectral window 
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and the light intensity in the linear waveguide past the microring was used to determine the 
resonance wavelength. This process was then serially repeated for each ring in the array and the 
resultant shifts in resonance as a function of time are recorded. 
The resonance condition is given by: 
              (Eq. 5.1) 
where m equals a nonzero integer, λ is the wavelength of propagating light, r is the microring 
radius, and neff is the effective refractive index of the local microring environment. Therefore, the 
binding of higher refractive index biomolecules and accompanying displacement of water results 
in a resonance shift to longer wavelengths—a positive shift that is listed in units of  picometers 
(pm). 
5.3.3 Nucleic Acid Sequences 
All synthetic nucleic acid sequences were obtained from Integrated DNA Technologies 
(Coralville, IA). Three kinds of synthetic oligonucleotides were used in this work. Single 
stranded DNA (ssDNA) capture probes, 5‘ amine terminated for covalent surface 
immobilization, were designed to target specific mRNA target regions having minimal secondary 
structure so that hybridization would link the molecule to the biosensor surface. To enable 
conjugation to the sensor surface, capture probes were reacted with a 10-fold molar excess of S-
4FB in a 1:1 solution of DMSO:H2O for two hours, followed by buffer exchange in 3kDa 
MWCO Vivaspin columns (Sartorius) to remove unreacted S-4FB. DNA chaperones were 
designed with two functional regions: the first complementary to regions immediately adjacent to 
capture probe binding epitopes to disrupt target mRNA secondary structure, and a second polyA 
region to serve as a linker for subsequent bead recognition. Thirdly, poly(T) linkers with a biotin 
moiety were employed to link the chaperone-primed, surface immobilized mRNA targets with 
streptavidin coated beads. For clarity, this sequential molecular linkage is illustrated in Figure 
5.9a. All DNA was resuspended in PBST and buffer exchanged prior to use. 
mRNA was synthesized via in vitro transcription using a Promega T7 RiboMAX Express 
Large Scale RNA Production System and Origene TrueClone cDNA clones following the 
manufacturers recommended procedures. A Qiagen RNeasy MinElute cleanup kit was used for 
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subsequent mRNA purification and final mRNA quality was assessed via 1% agarose gels. A 
sample gel of transcription products is shown in Figure 5.1. The sequences of all synthetic 
nucleic acids used in this work are listed in Tables 5.2-5.5; additional primary mRNA sequence 
information can be found online at the National Center for Biotechnology Information.
48
 Atomic 
force microscopy images of C-myc plasmid and full length C-myc mRNA are shown in Figure 
5.2a and Figure 5.2b, respectively. 
5.3.4 Biochemical Modification of the Silicon Photonic Microring Resonator Surface 
Prior to chemical modification, sensor chips were first immersed in a piranha solution 
(3:1 H2SO4:30% H2O2) for 30 seconds to clean the surface (Caution! Piranha solutions are 
extremely dangerous and react explosively with trace amounts of organics). Subsequently a 1 
mg/mL solution of HyNic Silane in ethanol was applied to the surface for 20 minutes to activate 
the surface towards S-4FB modified DNA capture probes. Following a 7 minute sonication rinse 
in ethanol, chips were dried under a stream of N2 and manually spotted in a spatially controlled 
manner with ~10 µM solution of 4FB modified DNA capture probes in PBS and incubated 
overnight to covalently modify the surface. Immediately prior to an experiment, chips were 
sonicated in 8 M Urea for 7 minutes and rinsed in deionized water to remove physisorbed DNA 
capture probes. 
5.3.5 mRNA Analysis and Nanoparticle Amplification 
In vitro transcribed mRNA was first incubated with a 5-fold excess of polyadenylated 
DNA chaperones in hybridization buffer at 95 °C for 3 minutes, followed by 30 minutes at room 
temperature.  The 200 µL mRNA sample was then introduced to the sensor chip and recirculated 
for 60 minutes and the binding response was monitored as a shift in microring resonance 
wavelength. Following a 5 minute PBST rinse, a 2 µM biotinylated T30 linker solution in PBST 
was hybridized to the polyA sequence on the surface immobilized chaperone-mRNA complex in 
preparation for binding of streptavidin coated beads. After surface blocking for 10 minutes in 
Starting Block to prevent non-specific bead binding, a 50 µg/mL bead solution in PBST was 
introduced at 10 µL/min and the binding response arising from the streptavidin-biotin interaction 
was monitored. Importantly, beads were buffer exchanged twice immediately prior to use to 
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remove free streptavidin from solution, as this can out-compete bead immobilized streptavidin 
for surface binding sites due to its more rapid diffusion rate. 
5.3.6 Data Analysis 
All data was analyzed in Origin Pro 8. Direct mRNA hybridization was quantitated by 
recording the resonance shift after 60 minutes; the bead-amplified signal was recorded at 45 
minutes. Both of these times reflect pseudo-equilibrium points and were chosen with respect to 
overall assay time and quantitation considerations. Control rings functionalized with non-
complementary DNA were subtracted from direct mRNA hybridization signals to account for 
temperature fluctuations during the experiment. Calibration data was fit to a logistic function,  
 ( )  
     
  (
 
  
)
        (Eq. 5.2) 
where A1 is the initial value limit, A2 is the final value limit, c is the center of the fit, and p is the 
power of the fit. 
5.3.7 Cell Culture and Total RNA Analysis 
The promyelocytic HL-60 cell line was purchased from ATCC (CCL-240) and 
propagated in accordance with ATCC recommended protocols. Cells were cultured in RPMI 
media + 10% heat inactivated FBS + Penicillin and Streptomycin and passaged every 2-3 days to 
maintain the cell density between 0.13-1x10
7
 cells/mL. Cells were differentiated by the addition 
of DMSO to a final concentration of 1.3%, and subsequently incubated for 7 days in these 
conditions prior to RNA extraction. Total RNA extracted with Qiagen RNeasy Mini kits was 
assessed for purity and quantity using a Thermo-Fisher Nanodrop UV-Vis spectrometer, and 
stored at -80 C until further use. Total RNA samples were analyzed identically to in vitro mRNA 
studies, excepting the addition of total RNA extracts instead of in vitro transcribed mRNA. 
5.4 Results and Discussion 
Full length mRNA transcripts average 2200 ribonucleotides in length and can pose 
several significant challenges with respect to their analysis when compared to smaller molecules 
(ex. miRNA). Specifically, full length mRNA transcripts often feature extensive secondary 
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structure that can hinder hybridization to surface immobilized capture probes. That is to say that 
targeted binding regions of the molecule can be effectively screened from interacting with 
surface bound capture probes by ‗spectator‘ regions of the transcript.49 Diffusion  of mRNA is 
also considerably slower than for smaller RNA molecules, necessitating longer assay times to 
achieve comparable sensor response.
50
  Finally, the larger size of the mRNA molecule increases 
the probability that its orientation, with respect to a given surface immobilized capture probe, 
will not be optimal for hybridization. Combined, these effects conspire to reduce mRNA 
detection efficiency and kinetics. Figure 5.3a illustrates this point by comparing the 
hybridization binding curves of a 22 nt miRNA to a full-length, 1820 nt mRNA at the identical 
concentration. As shown, the mRNA hybridization response is dramatically slower even though 
the concentration of target is identical to that of the miRNA. 
To address this challenge, several methods were investigated to enhance the sensor 
response from primary mRNA binding events. In all cases, mRNA targets were annealed at 95° 
C for 3 minutes prior to other treatment or detection methodologies to denature secondary 
structure. To improve the accessibility of capture agents to complementary epitopes on the 
mRNA target, small DNA helper strands, or ‗chaperones‘, were introduced to unravel portions of 
the secondary structure and enhance binding kinetics. These 20-nucleotide long chaperones were 
designed to hybridize starting immediately adjacent to the mRNA epitope targeted by capture 
agents, and extending with each successive chaperone away from the binding epitope. This 
creates a localized duplex region with reduced secondary structure, and thus hopefully improving 
target accessibility. A total of 6, 12, or 24 unique chaperone sequences were designed to be  
adjacent to the three regions targeted by the myc DNA capture probes. These chaperone 
sequences were incubated all together with the full length mRNA and their resultant 
hybridization therefore resulted in 20, 40, or 80 base pair double stranded regions flanking both 
sides of the binding epitope, effectively linearizing the regions required for binding to the surface 
immobilized capture probes.  
Figure 5.3b shows that an enhanced response is observed with increasing chaperone 
number up to 12 chaperones added simultaneously, at which point additional chaperones have a 
minimal effect on binding kinetics. Given the close surface proximity and 3‘ to 5‘ orientation of 
the final surface immobilized mRNA, additional experiments were performed containing 
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chaperones on only the 3‘ or 5‘ side of the epitope to confirm that the formation of a rigid, 
double stranded region immediately adjacent to the surface did not produce unfavorable steric 
conditions for mRNA binding. No difference in sensor response was observed for either 
configuration (data not shown). Consequently, all analyses were run using 12 mRNA-specific 
chaperones targeting both flanking regions directly adjacent to mRNA epitope targeted by the 
capture probe.  
To improve the likelihood that an encounter with the surface would result in 
hybridization, we increased the number of capture probes targeting each mRNA in hopes of 
enhancing the probability of a hybridization event occurring upon every target-surface 
interaction. Capture probes were selected to target unique identifier regions of the primary 
sequence as determined by BLAST searches to successfully eliminate cross-reactivity amongst 
other mRNA species. Figure 5.4 demonstrates the efficacy of this approach, as very little off-
target response is observed. Additionally, regions with conserved regions of minimal secondary 
structure based on Mfold calculations were preferentially targeted to improve hybridization 
efficiency.
51
 An example of the most thermodynamically stable folding structure of myc mRNA 
is shown in Figure 5.5. Screening of this and similarly stable conformations revealed conserved 
regions of the RNA which remained single stranded, and thus attractive targets towards which 
capture probes were targeted. As shown in Figure 5.6a for myc mRNA, using three ssDNA 
capture probes (myc1-3), as opposed to only one (myc1), enhanced the signal by a factor of two 
after 60 minutes as compared to a single capture agent.  
This finding was expected given the higher probability of accessing and hybridizing to 
the target region using multiple capture agents. Additionally, the possibility exists for multiple 
binding interactions with a single target, resulting in an increase in binding strength over time as 
initial capture with a single capture probe can transition to a multivalent interaction. A 
concomitant reduction in the overall desorption constant would also enhance signal response. 
Given these improvements, three capture agents were used for all further experimentation. 
Further ‗support‘ for multivalent interactions was found as we evaluated the optimal flow 
rate for mRNA hybridization experiments on both myc1 and myc1-3 functionalized sensors. As 
shown in Figure 5.6b, enhanced target binding was observed up to flow rates of 20 µL/min for 
both single and multiple capture probe-modified sensors. However, at higher flow rates the 
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hybridization response, which was recorded at a defined time point of 60 minutes of 
hybridization, was negligible for the myc1 sensors, while the myc1-3 microrings still showed 
significant hybridization response. In general, faster flow rates are useful in biosensor systems, 
as mass transport is less of a limitation under this scenario, up until the point that the target dwell 
time competes with the period needed to form a stable interaction with the capture agent. In this 
case, the reduced rate of target desorption achieved by multivalent surface interactions help to 
preserve a significant hybridization response. Nonetheless, the hybridization response was still 
found to be maximized at 20 µL/min and this flow rate was used subsequently for all detection 
experiments. 
Another challenge associated with mRNA analysis is the naturally low abundance of 
many transcripts, which can be over 1000 times less abundant than miRNAs, for example.  This 
necessitates further sensitivity enhancements to enable comprehensive mRNA expression 
profiling in relevant samples and biological systems. As no further binding efficiency 
optimization could circumvent the limitations of direct, label-free detection, we decided to 
pursue two signal-enhancement methodologies. The first methodology relies on a hairpin chain 
reaction, in which short DNA hairpins are engineered to unfold upon hybridization to a 
complementary target. The stored energy released when unpaired nucleotides in the hairpin loop 
become double stranded after hybridization then drives the reaction to hybridize to a secondary 
hairpin, which subsequently unfolds and is available to hybridize another hairpin. This chain 
reaction continues until the two types of monomeric hairpins are depleted from solution, leaving 
a long, double-stranded DNA segment on the original initiation site. This methodology has been 
used previously for the quantitation of cytokine-secreting peripheral mononuclear cells to great 
effect,
52
  and we theorized would also improve our assay detection limit. By engineering the 
hairpin construct to be triggered by the capture of an mRNA analyte to the surface, we could 
specifically initiate a cascade of surface bound mass and subsequent increase in signal response. 
Prior to using the more complex mRNA, we initially investigated three structurally diverse 
hairpin sets on a simple surface scaffold with short DNA segments, as shown in Figure 5.7 and 
listed in Table 5.5. The three structures chosen had long, intermediate, and short hairpins 
corresponding to high, intermediate, and low potential energy storage, respectively. After initial 
optimization, it became apparent that while the chain reaction worked quite well (gel analysis, 
data not shown), it did not translate to the microring resonator platform. Figure 5.8 demonstrates 
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the typical response observed, characterized by a rapidly diminishing incremental signal with 
each successive layer. We attribute this to the relatively rigid nature of double stranded DNA 
(persistence length 50 nm),
53
 and the surface-sensitive nature of the evanescent field (1/e at 63 
nm),
54
 whereby the additional mass bound with successive layers grew appreciably distant from 
the sensor surface, and beyond the effective sensing range of the device.  
Consequently we decided to abandon this approach and instead modify the DNA 
chaperones to accommodate subsequent recognition by a large refractive index label (~114 nm 
magnetic bead, Ademtech). Importantly, this approach does not require PCR, thereby eliminating 
the need for enzymatic reagents, variable temperature control, and avoiding potential sequence 
biases during amplification. Finally, the lack of reliance upon PCR leaves this approach 
potentially amenable to multi-class biomarker analysis (RNA and proteins). 
Based upon the previously optimized conditions for disrupting mRNA secondary 
structure and improving surface hybridization, we developed an assay to detect full length 
mRNAs from both buffer and isolated total RNA from cell lysate. This multi-step assay is 
schematically illustrated in Figure 5.9a, with representative sensor responses in Figure 5.9b.  
An initial thermal denaturation step is performed to allow polyadenylated DNA 
chaperones to hybridize to the messenger RNA target, thus reducing secondary structure, while 
also incorporating recognition motifs for subsequent bead binding. The mRNA sample is then 
flowed across a sensor array presenting microring sensors previously modified with ssDNA 
capture probes and hybridization is monitored as a function of time as a shift in the resonant 
wavelength of the microring resonators. To further increase the signal resulting from mRNA 
hybridization, a biotinylated T30 linker and protein blocking solution are sequentially introduced, 
followed by exposure to streptavidin-coated beads. Bead binding greatly increases the refractive 
index change near the sensor surface and therefore offers a further method of signal 
enhancement.  
Using the chaperone-assisted detection methodology described above, we were able to 
quantitate three mRNA targets over a 2- to 3-order of magnitude concentration range and achieve 
a 32 fmol detection limit. Pursuing the bead-based amplification strategy detailed in the latter 
part of Figure 5.9, we demonstrated a 16- to 64-fold increase in sensitivity over direct, label-free 
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detection with the total dynamic range exceeding 4 orders of magnitude. Figure 5.10 
summarizes the quantitative capabilities afforded by this joint methodology utilizing both direct 
and bead-enhanced detection. All assays were performed followed the procedures described 
previously in the Experimental section. A single mRNA concentration was assayed on each chip, 
with chips subsequently regenerated and re-functionalized for the next measurement. 
Consequently calibration plots were made across multiple chips, demonstrating high 
reproducibility and minimal chip-to-chip variability. 
To demonstrate the amenability of this assay to a more challenging matrix, we performed 
expression profiling of the three mRNA transcripts in total RNA extracted from HL-60 cells 
using the same procedures optimized for studies in buffer. Following standard protocols, we 
differentiated HL-60 cells with 1.3% DMSO and harvested total RNA after 7 days, in tandem 
with RNA extraction from undifferentiated cells.
55
 Twenty micrograms of total RNA was 
analyzed on a sensor chip functionalized towards all three mRNAs of interest. As shown in 
Figure 5.11, myc expression decreases upon differentiation, while β-actin abundance increased 
by a factor of ~3 accompanying visual changes in the cellular morphology associated with the 
differentiation process. Literature reports corroborate these changes in the expression levels of 
both myc and β-actin mRNA upon differentiation,56,57 albeit in a qualitative manner. We attribute 
any remaining discrepancies in expression levels not to the measurement process, but rather to 
the incomplete cellular differentiation achieved in this study, determined by flow cytometry data 
and detailed in Figure 5.12 and Table 5.1  
We were unable to accurately quantitate IL-8 mRNA transcripts due to their lower 
abundance, demonstrating the need for further sensitivity increases in future work. Further 
improvements in assay performance are still required before this assay is competitive with 
conventional PCR-based assays in terms of sensitivity; however we feel that the insights 
communicated herein may be important to related surface hybridization-based detection methods 
such as surface plasmon resonance or microcantilevers, and establish this platform‘s potential for 
full-length mRNA detection. Additionally, numerous enzymatic signal amplification 
methodologies could be readily modified to augment the methods developed in this work, 
including horseradish peroxidase,
58
 duplex specific nuclease,
59
 and RNA-assisted Klenow 
enzyme.
60
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In this work we have shown the quantitation of whole mRNA in a multiplexed format, 
achieving a dynamic range over four orders of magnitude and detecting as little as 512 amol of 
mRNA. This demonstration is significant because it enables analysis of whole mRNA 
transcripts, without requiring either fragmentation of mRNA or PCR. The lack of reliance upon 
PCR, or any other class-specific detection strategy, seems particularly compelling as the 
microring resonator platform has been previously applied to the separate detection of DNA, 
miRNA, and proteins. Although admittedly a long term vision still requiring many advances in 
terms of enhanced sensitivity and sample handling, we feel that the realization of an integrated 
platform for simultaneously profiling biomarkers from multiple, distinct classes of biomolecules 
is a compelling aspiration.  
5.5 Conclusion 
mRNAs represent an important class of potential biomarkers for understanding disease 
onset and progression, but their analysis using surface hybridization-based biosensors can be 
complicated by the size and secondary structure of the full length transcript. In this work we 
have developed methodologies to enable multiplexed mRNA profiling using arrays of silicon 
photonic microring resonators, and demonstrated mRNA expression profiling capabilities in total 
RNA samples. Importantly, we found that the addition of short, secondary structure-disrupting 
chaperones and the use of multiple, co-localized capture probes significantly improved the 
hybridization kinetics of full length mRNA molecules. Furthermore, we showed that these 
chaperones can be designed so that a subsequent bead recognition step significantly enhances the 
observed resonance shift allows quantitation over a broad dynamic range. Future efforts will 
focus on further improving methodological measurement sensitivity, enabling the analysis of 
lower abundance transcripts and simultaneously reducing the amount of sample input required. 
These capabilities, in conjunction with previous demonstrations of the detection of DNA, 
miRNA, and protein biomarkers suggest that chip-integrated, multi-class biomarker analysis 
might eventually be achievable using this scalable analytical platform. 
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5.6 Figures and Tables 
 
Figure 5.1.  Agarose gel showing C-myc in vitro transcription products in lanes 1 and 2. 
Comparison to the ladder in lane 4 confirms they are the proper length of ~2400 nucleotides.  
  
1          2          3        4  
119 
 
 
Figure 5.2.  Atomic force microscopy images of a) C-myc plasmid, as well as b) full length 
mRNA transcripts after in vitro transcription. Images obtained on an Asylum Research MFP-3D 
instrument. 
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Figure 5.3.  a) Real-time shifts in microring resonances accompanying target hybridization 
highlight that despite over an 80-fold increase in size, full length mRNA elicits a much lower 
sensor response than smaller miRNA molecules based on steric inhibition and diffusion 
limitations.  b) Small DNA chaperones were pre-hybridized to a 2.56 nM concentration of myc 
mRNA before being flowed across an array of ssDNA-presenting microring resonators. The 
chaperone/mRNA mixture was introduced to the sensor array at t=0 minutes, and the resultant 
responses demonstrate the enhanced rate of target binding in the presence of chaperones.  
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Figure 5.4. Array of sensor responses to 10 nM complementary and noncomplementary targets. 
Sensors functionalized towards a specific mRNA only illicit a response when incubated with the 
complementary mRNA target, as shown by the high responses diagonally across the array, 
confirming the specificity of the capture DNA probes. 
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Figure 5.5. One of the most thermodynamically stable conformations of myc mRNA, with 
conserved regions of minimal secondary structure highlighted. Capture agents targeted these 
regions to improve the probability of mRNA capture.  
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Figure 5.6.  a) Increasing the number of DNA capture agents from one to three probes 
significantly enhanced the kinetics of mRNA capture. Shown here is 2.56 nM myc mRNA 
hybridizing to either myc1 capture probe or an equimolar mixture of three myc capture probes 
(myc1-3). b) Flow rates ranging from 5 to 160 µL/min were tested and the net response was 
quantitated at 60 minutes. The signals increased for both the single and multi-capture probe 
sensors up until the maximum response at 20 µL/min. Further increases in flow rate led to the 
complete loss of hybridization for the single probe-functionalized rings while the multi-probe 
rings retained binding capabilities. Note the non-linear x-axis. 
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Figure 5.7.  The three sets of hairpins used in hybridization chain reactions. HCR 1 and 2 have 
the shortest hairpin and lowest energy storage, HCR 3 and 4 are essentially entirely single-
stranded, while HCR 5 and 6 are of intermediate length and energy. The energy potential 
correlates to the number of single stranded nucleotides in each sequence. 
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Figure 5.8.  Net and incremental response for HCR-3 and HCR-4 hairpins after sequential 
introduction to the sensor surface. The rapid loss in incremental signal with successive cycles is 
readily apparent, likely a result of increasing distance from the sensor surface and the associated 
decrease in evanescent field strength. 
  
126 
 
 
Figure 5.9.  a) Schematic of the mRNA assay, in which target mRNA is first annealed and 
hybridized to short ‗chaperone‘ DNA molecules prior to hybridization to surface immobilized 
DNA capture probes (i). Following the binding of biotinylated T30 linker strands (ii) and a 
blocking step, streptavidin coated beads are introduced and bind to the biotin activated mRNA 
(iii), resulting in significant signal enhancement. b) Response curves for three microring 
resonators illustrate each step of the previous schematic, demonstrating the significant signal 
enhancement capabilities conferred by bead based amplification. Note the protein blocking step 
at ~76 minutes, as well as the bulk refractive index shift due to changing buffers between direct 
and bead-based detection, is omitted for clarity.  
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Figure 5.10.  The concentration-dependent sensor response for direct a-c) and bead-enhanced d-
f) mRNA detection. In each trace sample or beads was injected at t=0 minutes. Direct 
hybridization responses (a-c) were quantitated at 60 minutes and bead-enhanced responses (d-f) 
at 45 minutes. These pseudo-equilibrium time points were chosen as a balance between 
minimizing total assay time while still maintaining quantitation capabilities. Calibration plots g-
i) demonstrate the full 3-4 order of magnitude dynamic range achieved combining direct and 
bead-based detection.  
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Figure 5.11.  Microring resonators addressed with 20 µg of total RNA harvested from either a) 
proliferating or b) differentiated HL-60 cells show differing responses reflective of the molecular 
changes accompanying the phenotypic change. c) Using the concentration calibrations to 
quantitate these responses, we observed the expected increase in β-actin production upon cell 
differentiation, and a marginal decrease in myc expression upon differentiation. This residual 
myc response is explained by the incomplete differentiation of HL-60 cells.   
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Figure 5.12. a) Flow Cytometry Analysis of native HL-60 cells and b) seven days after 
differentiation. Cells are gated as undifferentiated (red), differentiated (blue), or nonviable 
(green).   
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Table 5.1: Sharp changes in relative population abundances for HL-60 cells with and without 
1.3% DMSO treatment indicate the efficacy of differentiation treatment.  
 Untreated DMSO Treated 
Undifferentiated 75.94 % 18.98 % 
Differentiated 7.00 % 53.64 % 
Nonviable 17.05 % 27.37 % 
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Table 5.2: C-myc. C-myc DNA capture probe, chaperone, and primary transcript sequences. 
Epitopes targeted by DNA capture probes are bolded and underlined 
 Capture Probe Sequences Length Nucleotide 
position from 5‘ 
End 
Myc1 5'-/5AmMC12/TTC GTG GAT GCG GCA AGG GT-3' 20 340-359 
Myc2 5'-/5AmMC12/GAG TTC CGT AGC TGT TCA AGT 
TTG TGT T-3' 
28 1853-1880 
Myc3 5'-/5AmMC12/ACC ACC GAG GGG TCG ATG CA-3' 20 1132-1151 
  
 Chaperone Sequences 
1 TGC GGA CCG CTG GCT GGG GG (A)30 
2 (A)30 ACC GCT GCT ATG GGC AAA GT 
3 CTC TGA GGC GGC GGC GCT CA (A)30 
4 (A)30 CGT TGA GAG GGT AGG GGA AG 
5 TCA ACT GTT CTC GTC GTT TC (A)30 
6 (A)30 TTA CTT TTC CTT ACG CAC AA 
7 AAA ACA ATT CTT AAA TAC AA (A)30 
8 (A)30 ATT GAA ATT CTG TGT AAC TG 
9 (A)30 CTC CTC TGG CGC TCC AAG AC 
10 (A)30 TCC AGA CTC TGA CCT TTT GC 
11 (A)30 CCT GTT GGT GAA GCT AAC GT 
12 GGC GGC CGC GAG CAG CAC AG (A)30 
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Table 5.2 (cont.) 
1 GACCCCCGAG CTGTGCTGCT CGCGGCCGCC ACCGCCGGGC CCCGGCCGTC CCTGGCTCCC 
61 CTCCTGCCTC GAGAAGGGCA GGGCTTCTCA GAGGCTTGGC GGGAAAAGA ACGGAGGGAG 
121 GGATCGCGCT GAGTATAAA GCCGGTTTTC GGGGCTTTAT CTAACTCGCT GTAGTAATTC 
181 CAGCGAGAGG CAGAGGGAGC GAGCGGGCGG CCGGCTAGGG TGGAAGAGCC GGGCGAGCAG 
241 AGCTGCGCTG CGGGCGTCCT GGGAAGGGAG ATCCGGAGCG AATAGGGGGC TTCGCCTCTG 
301 GCCCAGCCCT CCCGCTGATC CCCCAGCCAG CGGTCCGCAA CCCTTGCCGC ATCCACGAAA 
361 CTTTGCCCAT AGCAGCGGGC GGGCACTTTG CACTGGAACT TACAACACCC GAGCAAGGAC 
421 GCGACTCTCC CGACGCGGGG AGGCTATTCT GCCCATTTGG GGACACTTCC CCGCCGCTGC 
481 CAGGACCCGC TTCTCTGAAA GGCTCTCCTT GCAGCTGCTT AGACGCTGGA TTTTTTTCGG 
541 GTAGTGGAAA ACCAGCAGCC TCCCGCGACG ATGCCCCTCA ACGTTAGCTT CACCAACAGG 
601 AACTATGACC TCGACTACGA CTCGGTGCAG CCGTATTTCT ACTGCGACGA GGAGGAGAAC 
661 TTCTACCAGC AGCAGCAGCA GAGCGAGCTG CAGCCCCCGG CGCCCAGCGA GGATATCTGG 
721 AAGAAATTCG AGCTGCTGCC CACCCCGCCC CTGTCCCCTA GCCGCCGCTC CGGGCTCTGC 
781 TCGCCCTCCT ACGTTGCGGT CACACCCTTC TCCCTTCGGG GAGACAACGA CGGCGGTGGC 
841 GGGAGCTTCT CCACGGCCGA CCAGCTGGAG ATGGTGACCG AGCTGCTGGG AGGAGGACATG 
901 GTGAACCAGA GTTTCATCTG CGACCCGGAC GACGAGACCT TCATCAAAAA CATCATCATC 
961 CAGGACTGTA TGTGGAGCGG CTTCTCGGCC GCCGCCAAGC TCGTCTCAGA GAAGCTGGCC 
1021 TCCTACCAGG CTGCGCGCAA AGACAGCGGC AGCCCGAACC CCGCCCGCGG CCACAGCGTC 
1081 TGCTCCACCT CCAGCTTGTA CCTGCAGGAT CTGAGCGCCG CCGCCTCAGA GTGCATCGAC 
1141 CCCTCGGTGG TCTTCCCCTA CCCTCTCAAC GACAGCAGCT CGCCCAAGTC CTGCGCCTCG 
1201 CAAGACTCCA GCGCCTTCTC TCCGTCCTCG GATTCTCTGC TCTCCTCGAC GGAGTCCTCC 
1261 CCGCAGGGCA GCCCCGAGCC CCTGGTGCTC CATGAGGAGA CACCGCCCAC CACCAGCAGC 
1321 GACTCTGAGG AGGAACAAGA AGATGAGGAA GAAATCGATG TTGTTTCTGT GGAAAAGAGG 
1381 CAGGCTCCTG GCAAAAGGTC AGAGTCTGGA TCACCTTCTG CTGGAGGCCAA CAGCAAACCT 
1441 CCTCACAGCC CACTGGTCCT CAAGAGGTGC CACGTCTCCA CACATCAGCA CAACTACGCA 
1501 GCGCCTCCCT CCACTCGGAA GGACTATCCT GCTGCCAAGA GGTCAAGTT GGACAGTGTC 
1561 AGAGTCCTGA GACAGATCAG CAACAACCGA AAATGCACCA GCCCCAGGTC CTCGGACACC 
1621 GAGGAGAATG TCAAGAGGCG AACACACAAC GTCTTGGAGC GCCAGAGGAG GAACGAGCTA 
1681 AAACGGAGCT TTTTTGCCCT GCGTGACCAG ATCCCGGAGT TGGAAAACAA TGAAAAGGCC 
1741 CCCAAGGTAG TTATCCTTAA AAAAGCCACA GCATACATCC TGTCCGTCCA AGCAGAGGAG 
1801 CAAAAGCTCA TTTCTGAAGA GGACTTGTTG CGGAAACGAC GAGAACAGTT GAAACACAAA 
1861 CTTGAACAGC TACGGAACTC TTGTGCGTAA GGAAAAGTAA GGAAAACGAT TCCTTCTAAC 
1921 AGAAATGTCC TGAGCAATCA CCTATGAACT TGTTTCAAAT GCATGATCAA ATGCAACCTC 
1981 ACAACCTTGG CTGAGTCTTG AGACTGAAAG ATTTAGCCAT AATGTAAACT GCCTCAAATT 
2041 GGACTTTGGG CATAAAAGAA CTTTTTTATG CTTACCATCT TTTTTTTTTC TTTAACAGAT 
2101 TTGTATTTAAGAATTGTTTT TAAAAAATTTT TAAGATTTAC ACAATGTTTC TCTGTAAATA 
2161 TTGCCATTAA ATGTAAATAA CTTTAATAAA ACGTTTATAG CAGTTACACA GAATTTCAAT 
2221 CCTAGTATAT AGTACCTAGT ATTATAGGTA CTATAAACCC TAATTTTTTT TATTTAAGTA 
2281 CATTTTGCTT TTTAAAGTTG ATTTTTTTCT ATTGTTTTTA GAAAAAATAA AATAACTGGC 
2341 AAATATATCA TTGAGCCAAA TCTTAAAAAA AAAAAAAAAA 
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Table 5.3: β-actin.  β-actin DNA capture probe, chaperone, and primary transcript sequences. 
Epitopes targeted by DNA capture probes are bolded and underlined 
 Capture Probe Sequence Lengt
h 
Nucleotide position 
from 5‘ End 
Act1 5'-/5AmMC12/GCGGTTGGCCTTGGGGTTCA 20 413-432 
Act2 5'-/5AmMC12/TAGCCGCGCTCGGTGAGGAT 20 658-677 
Act3 5'-/5AmMC12/TGATCTCCTTCTGCATCCTGTCGGCAA 27 1010-1036 
  
 Chaperones 
1 CGG CAA AGG CGA GGC TCT GT (A)30 
2 GAG GAT GCC TCT CTT GCT CT (A)30 
3 GGC CTC GGT CAG CAG CAC GG (A)30 
4 (A)30 ATG ATC TGG GTC ATC TTC TC 
5 CTT CAT GAG GTA GTC AGT CA (A)30 
6 (A)30 CGG CCG TGG TGG TGA AGC TG 
7 TGC CAG GGT ACA TGG TGG TG (A)30 
8 (A)30 TGT GCT GGG TGC CAG GGC AG 
9 GTG TAA CGC AAC TAA GTC AT (A)30 
10 CAT CTC ATA TTT GGA ATG AC (A)30 
11 (A)30 AAG TGG GGT GGC TTT TAG GA 
12 CCT TCA TAC ATC TCA AGT TG (A)30 
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Table 5.3 (cont.) 
1 ACCGCGUCCG CCCCGCGAGC ACAGAGCCUC GCCUUUGCCG AUCCGCCGCC CGUCCACACC 
61 CGCCGCCAGC UCACCAUGGA UGAUGAUAUC GCCGCGCUCG UCGUCGACAA CGGCUCCGGC 
121 AUGUGCAAGG CCGGCUUCGC GGGCGACGAU GCCCCCCGGG CCGUCUUCCC CUCCAUCGUG 
181 GGGCGCCCCA GGCACCAGGG CGUGAUGGUG GGCAUGGGUC AGAAGGAUUC CUAUGUGGGC 
241 GACGAGGCCC AGAGCAAGAG AGGCAUCCUC ACCCUGAAGU ACCCCAUCGA GCACGGCAUC 
301 GUCACCAACU GGGACGACAU GGAGAAAAUC UGGCACCACA CCUUCUACAA UGAGCUGCGU 
361 GUGGCUCCCG AGGAGCACCC CGUGCUGCUG ACCGAGGCCC CCCUGAACCC CAAGGCCAAC 
421 CGCGAGAAGA UGACCCAGAU CAUGUUUGAG ACCUUCAACA CCCCAGCCAU GUACGUUGCU 
481 AUCCAGGCUG UGCUAUCCCU GUACGCCUCU GGCCGUACCA CUGGCAUCGU GAUGGACUCC 
541 GGUGACGGGG UCACCCACAC UGUGCCCAUC UACGAGGGGU AUGCCCUCCC CCAUGCCAUC 
601 CUGCGUCUGG ACCUGGCUGG CCGGGACCUG ACUGACUACC UCAUGAAGAU CCUCACCGAG 
661 CGCGGCUACA GCUUCACCAC CACGGCCGAG CGGGAAAUCG UGCGUGACAU UAAGGAGAAG 
721 CUGUGCUACG UCGCCCUGGA CUUCGAGCAA GAGAUGGCCA CGGCUGCUUC CAGCUCCUCC 
781 CUGGAGAAGA GCUACGAGCU GCCUGACGGC CAGGUCAUCA CCAUUGGCAA UGAGCGGUUC 
841 CGCUGCCCUG AGGCACUCUU CCAGCCUUCC UUCCUGGGCA UGGAGUCCUG UGGCAUCCAC 
901 GAAACUACCU UCAACUCCAU CAUGAAGUGU GACGUGGACA UCCGCAAAGA CCUGUACGCC 
961 AACACAGUGC UGUCUGGCGG CACCACCAUG UACCCUGGCA UUGCCGACAG GAUGCAGAAG 
1021 GAGAUCACUG CCCUGGCACC CAGCACAAUG AAGAUCAAGA UCAUUGCUCC UCCUGAGCGC 
1081 AAGUACUCCG UGUGGAUCGG CGGCUCCAUC CUGGCCUCGC UGUCCACCUU CCAGCAGAUG 
1141 UGGAUCAGCA AGCAGGAGUA UGACGAGUCC GGCCCCUCCA UCGUCCACCG CAAAUGCUUC 
1201 UAGGCGGACU AUGACUUAGU UGCGUUACAC CCUUUCUUGA CAAAACCUAA CUUGCGCAGA 
1261 AAACAAGAUG AGAUUGGCAU GGCUUUAUUU GUUUUUUUUG UUUUGUUUUG GUUUUUUUUU 
1321 UUUUUUUUGG CUUGACUCAG GAUUUAAAAA CUGGAACGGU GAAGGUGACA GCAGUCGGUU 
1381 GGAGCGAGCA UCCCCCAAAG UUCACAAUGU GGCCGAGGAC UUUGAUUGCA CAUUGUUGUU 
1441 UUUUUAAUAG UCAUUCCAAA UAUGAGAUGC GUUGUUACAG GAAGUCCCUU GCCAUCCUAA 
1501 AAGCCACCCC ACUUCUCUCU AAGGAGAAUG GCCCAGUCCU CUCCCAAGUC CACACAGGGG 
1561 AGGUGAUAGC AUUGCUUUCG UGUAAAUUAU GUAAUGCAAA AUUUUUUUAA UCUUCGCCUU 
1621 AAUACUUUUU UAUUUUGUUU UAUUUUGAAU GAUGAGCCUU CGUGCCCCCC CUUCCCCCUU 
1681 UUUUGUCCCC CAACUUGAGA UGUAUGAAGG CUUUUGGUCU CCCUGGGAGU GGGUGGAGGC 
1741 AGCCAGGGCU UACCUGUACA CUGACUUGAG ACCAGUUGAA UAAAAGUGCA CACCUUAAAA 
1801 AAAAAAAAAA AAAAAAAAAA 
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Table 5.4: IL-8. IL-8 DNA capture probe, chaperone, and primary transcript sequences. 
Epitopes targeted by DNA capture probes are bolded and underlined 
 Capture Probe Sequence Length Nucleotide position 
from 5‘ End 
IL1 TTCTGTGTTGGCGCAGTGTGGT 22 327-348 
IL2 TGGCCCTTGGCCTCAATTTTGCT 23 747-769 
IL3 ACTGTGAGGTAAGATGGTGGCTAAT 25 999-1023 
  
 Chaperone Sequences 
1 (A)30 TGG AAG TCA TGT TTA CAC AC 
2 CCA CTC TCA ATC ACT CTC AGA (A)30 
3 (A)30 TCA GAA AGC TTT ACA ATA AT 
4 (A)30 CCA GGA ATC TTG TAT TGC AT 
5 ATT TGT ATA TTC TCC CGT GC (A)30 
6 (A)30 TTA AAG TTC GGA TAT TCT CT 
7 (A)30 AGG ATT TCC AGC TAA ATT TG 
8 ACT TTT TCC ACT TAG AAA TA (A)30 
9 (A)30 CCA CAT GTC CTC ACA ACA TC 
10 ATA ATG TAC TTA TAC TAA AA (A)30 
11 (A)30 TGG GAG TAT CAA ACT AGG AT 
12 GAA TCT ATT TGT ACA TAA TA (A)30 
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Table 5.4 (cont.) 
1 GAAUUCGGCA CGAGGCAGCA GAGCACACAA GCUUCUAGGA CAAGAGCCAG GAAGAAACCA 
61 CCGGAAGGAA CCAUCUCACU GUGUGUAAAC AUGACUUCCA AGCUGGCCGU GGCUCUCUUG 
121 GCAGCCUUCC UGAUUUCUGC AGCUCUGUGU GAAGGUGCAG UUUUGCCAAG GAGUGCUAAA 
181 GAACUUAGAU GUCAGUGCAU AAAGACAUAC UCCAAACCUU UCCACCCCAA AUUUAUCAAA 
241 GAACUGAGAG UGAUUGAGAG UGGACCACAC UGCGCCAACA CAGAAAUUAU UGUAAAGCUU 
301 UCUGAUGGAA GAGAGCUCUG UCUGGACCCC AAGGAAAACU GGGUGCAGAG GGUUGUGGAG 
361 AAGUUUUUGA AGAGGGCUGA GAAUUCAUAA AAAAAUUCAU UCUCUGUGGU AUCCAAGAAU 
421 CAGUGAAGAU GCCAGUGAAA CUUCAAGCAA AUCUACUUCA ACACUUCAUG UAUUGUGUGG 
481 GUCUGUUGUA GGGUUGCCAG AUGCAAUACA AGAUUCCUGG UUAAAUUUGA AUUUCAGUAA 
541 ACAAUGAAUA GUUUUUCAUU GUACCAUGAA AUAUCCAGAA CAUACUUAUA UGUAAAGUAU 
601 UAUUUAUUUG AAUCUACAAA AAACAACAAA UAAUUUUUAA AUAUAAGGAU UUUCCUAGAU 
661 AUUGCACGGG AGAAUAUACA AAUAGCAAAA UUGAGGCCAA GGGCCAAGAG AAUAUCCGAA 
721 CUUUAAUUUC AGGAAUUGAA UGGGUUUGCU AGAAUGUGAU AUUUGAAGCA UCACAUAAAA 
781 AUGAUGGGAC AAUAAAUUUU GCCAUAAAGU CAAAUUUAGC UGGAAAUCCU GGAUUUUUUU 
841 CUGUUAAAUC UGGCAACCCU AGUCUGCUAG CCAGGAUCCA CAAGUCCUUG UUCCACUGUG 
901 CCUUGGUUUC UCCUUUAUUU CUAAGUGGAA AAAGUAUUAG CCACCAUCUU ACCUCACAGU 
961 GAUGUUGUGA GGACAUGUGG AAGCACUUUA AGUUUUUUCA UCAUAACAUA AAUUAUUUUC 
1021 AAGUGUAACU UAUUAACCUA UUUAUUAUUU AUGUAUUUAU UUAAGCAUCA AAUAUUUGUG 
1081 CAAGAAUUUG GAAAAAUAGA AGAUGAAUCA UUGAUUGAAU AGUUAUAAAG AUGUUAUAGU 
1141 AAAUUUAUUU UAUUUUAGAU AUUAAAUGAU GUUUUAUUAG AUAAAUUUCA AUCAGGGUUU 
1201 UUAGAUUAAA CAAACAAACA AUUGGGUACC CAGUUAAAUU UUCAUUUCAG AUAUACAACA 
1261 AAUAAUUUUU UAGUAUAAGU ACAUUAUUGU UUAUCUGAAA UUUUAAUUGA ACUAACAAUC 
1321 CUAGUUUGAU ACUCCCAGUC UUGUCAUUGC CAGCUGUGUU GGUAGUGCUG UGUUGAAUUA 
1381 CGGAAUAAUG AGUUAGAACU AUUAAAACAG CCAAAACUCC ACAGUCAAUA UUAGUAAUUU 
1441 CUUGCUGGUU GAAACUUGUU UAUUAUGUAC AAAUAGAUUC UUAUAAUAUU AUUUAAAUGA 
1501 CUGCAUUUUU AAAUACAAGG CUUUAUAUUU UUAACUUUAA GAUGUUUUUA UGUGCUCUCC 
1561 AAAUUUUUUU UACUGUUUCU GAUUGUAUGG AAAUAUAAAA GUAAAUAUGA AACAUUUAAA 
1621 AUAUAAUUUG UUGUCAAAGC AAAAAAAAAA AAAAAAAACU CGAC 
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Table 5.5: HCR Sequences  
HCR- 1 GTG GCA CTA GTC TAC GGC TGC GGT CGT GCA GCC GTA GAC 
TAG TGC GCG AAT 
HCR- 2 ACG ACC GCA GCC GTA GAC TAG TGC ATT CGC GCA CTA GTC 
TAC GGC TGC AAC 
HCR- 3 TAT CAG GGT ACA TGG GCA GCC GTA GAC TAG  
HCR- 4 CCA TGT ACC CTG ATA CTA GTC TAC GGC TGC 
HCR- 5 GAG ACC TGT TGA GCC ATG ACG GGC TTT TTT ACA GTA TAT GGC 
TCA ACT TCT GGA 
HCR- 6 GCC CGT CAT GGC TCA ACA GGT CTC TTT TTT GCC AGA AGT TGA 
GCC ATA TAC TGT 
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Chapter 6 
In vitro Recapitulation of RNA Induced Silencing 
Complex for Biomolecular Interaction Screening using 
Silicon Photonic Microring Resonators 
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6.1 Abstract 
 Herein we describe the use of microring resonators to characterize fundamental 
interactions of the RNA Induced Silencing Complex (RISC). To do so we reconstitute the 
complex by assembling recombinant Ago2, miRNA, and mRNA, which correspond to the 
catalytic engine of RISC, the guide strand conferring target specificity, and the target itself, 
respectively. We observed Ago2-miRNA complex binding to mRNA, followed by cleavage of 
the target. This cleavage was performed in an Ago2 concentration-dependent manner, and the 
extent of cleavage was found to scale directly with the degree of target strand-guide strand 
complementarity. Importantly, the assay orientation is flexible, whereby either the target RNA or 
Ago2 protein can be surface immobilized while the other component is fluidically introduced. 
Importantly, this assay does not require radiolabelling or other time- and labor-intensive 
preparation steps, and is well suited to the application of biomolecular interaction screening 
based on its high throughput, real-time, label free analysis capabilities.  
6.2 Introduction 
Biological systems are built on a seemingly endless number of biomolecular interactions, 
the scale and diversity of which when taken together give rise to organism-scale stability and 
homeostatis.
1
 These interactions constitute processes such as development, metabolism, immune 
response, regulatory control, and cell signalling, and are the frequent target of numerous analysis 
methods.
2-5
 An improved understanding of the interactions which constitute these processess 
would be valuable both for the advancement of fundamental scientific knowledge, as well as 
have practical significance in drug development, medical treatment, and healthcare.  Important 
applications include discovering novel interactions, screening for inhibitors of specific protein 
signalling pathways, and epitope mapping. Unfortunately the complex nature of these 
interactions, the number of players involved, and the frequently subtle and transient nature of 
their associations conspire to frustrate thorough system-wide characterization, and sometimes 
even focused studies.
6
 Reductionist approaches hazard missing key interactions which leads to 
inevitable oversimplification, while in vivo studies struggle to unambiguously infer causal 
relationships. Furthermore, the sensitivity of many systems is such that the simple act of 
measurement, unless performed carefully, will perturb the system significantly. 
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A classic example of such a highly complex biomolecular interacting system is the RNA 
Induced Silencing Complex, or RISC. This ribonucleoprotein complex, the importance of which 
has only recently been fully appreciated, is being very actively studied for its role in regulating 
gene transcripts. Variations exist in the exact mechanism of gene expression modulation, 
however two factors are universal across all RISC action. First, an Argonaute family protein is at 
the core of the complex, and exerts the primary effect upon the target RNA. Secondly, there 
always exists a ‗guide‘ strand, a short RNA molecule which guides the entire assembly to the 
gene of interest via complementary base pairing.
7
 There exist 4 different argonaute proteins in 
humans, however only Argonaute 2 (Ago2) is capable of catalytic cleavage of the target RNA, 
and this only under certain conditions. The outcome of RISC‘ interaction with a target RNA is 
also highly dependent on the guide strand sequence—perfect complementarity tends to lead 
towards target cleavage, whereas imperfect base-pairing simply results in RNA binding. 
Additionally, specific regions of the guide strand are more sensitive to perfect base-pairing—the 
‗seed‘ region, nucleotides 2-8 from the 5‘ end, must be nearly completely complementary, while 
nucleotides near the 3‘ end are less important. In addition to nucleic acid dependencies, a host of 
other proteins—some studies show over 50— have been show to associate with the RISC 
complex via immunoprecipitation experiments, including Dicer, GW182, and helicases, among 
others.
8,9
 The role of many of these proteins remains nebulous, and in some cases such as the 
protein HuR, reports conflict as to whether the protein inhibits or aids RISC action.
10,11
 While 
much is known about this important regulatory complex, even more remains unknown—a 
complete list of interacting proteins, the exact mechanism of translation repression, degradation 
of mRNA transcript, etc.  
Argonaute 2 has drawn considerable attention for its important role as the catalytically 
active component of RISC. An important study by Rivas et al. demonstrated that Ago2 and an 
siRNA alone were sufficient to form recombinant RISC capable of sequence-specific RNA target 
cleavage.
12
 Further work by MacRae et al. expanded on this rudamentary in vitro model, 
incorporating not just the cleavage components, but also the RISC loading complex (RLC), by 
which proteins Ago2, Dicer, and TRBP work in concert to load a guide RNA strand into Ago2. 
The authors demonstrated the dicing, slicing, guide-strand selection, and Ago2 loading process 
all in an in vitro model.
13
 A third important work by Gu et al. focused on the RNA sequences 
which serve as guide strands when loaded into Ago2. The authors determined the RNA loading 
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process to proceed in a two step fashion and depend on the thermodynamic stability of the RNA 
hairpins.
14
 These studies and others like them characterizing the structure and function of the 
RISC assembly
15-18
 elucidated some of the fundamental processes of Ago2 and RISC 
interactions, but also raised many questions for further studies. Additionally, these studies relied 
primarily on gel-based radiolabelling tools for analysis, a reliable but also time intensive and 
labor intensive process. Consequently more recent work has been performed utilizing improved 
sensing methodologies such as electrochemical reporters or FRET to characterize the simplified 
RISC as a stand-in for its endogenous and more complex counterpart.
19,20
  
Silicon photonic microring resonators are a refractive index-based biosensing technology 
well suited to characterization of biomolecular interactions, including the RISC complex. The 
existence of numerous robust functionalization chemistries compatible with silicon enables a 
great degree of freedom in surface functionalization. Additionally since the sensors are sensitive 
to minute changes in the refractive index at the sensor surface, biomolecular interrogation could 
be performed label free, a huge benefit given the adverse affect of using labels in these systems. 
Finally, we have previously demonstrated the detection of numerous classes of biomolecules 
with our platform, including DNA,
21
 miRNA,
22
 mRNA,
23
 and proteins.
24
 These studies have laid 
the groundwork for the analysis of ribonucleoprotein complexes like Ago2 and the RISC 
complex on our sensing platform.  
6.3 Experimental Methods  
6.3.1 Materials 
PBS buffer was reconstituted with deionized water and Dulbecco‘s Phosphate Buffered 
Saline packets purchased from Sigma-Aldrich (St. Louis, MO), and the pH adjusted to 7.4 (PBS-
7.4) or 6.0 (PBS-6). A PBS + 0.5% Tween buffer (PBST) was created by the addition of Tween-
20 to PBS-7.4. A high stringency hybridization buffer consisting of 30% formamide, 0.2% 
sodium dodecyl sulfate, 4X saline-sodium phosphate-EDTA buffer (SSPE, USB Corp.), and 3X 
Denhardt‘s Solution (Invitrogen) was used for all hybridization steps. RISC buffer consists of 20 
mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, pH 7.40. Starting Block was obtained from Thermo-
Scientific and used to prevent nonspecific fouling. The silane 3-N-((6-(N‘-Isopropylidene-
hydrazino))nicotinamide)propyltriethyoxysilane (HyNic Silane)  and succinimidyl-4-
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formylbenzamide (S-4FB) were purchased from Solulink. Adenosine triphosphate gamma P
32
 
was obtained from Perkin Elmer and stored in a 1 cm thick plexiglass container. FLAG-tagged 
Ago2 proteins produced in Sf-9 cells were a gift from Ian MacRae at Scripps Institute. All other 
reagents were purchased from Fisher, unless otherwise noted, and used as received. 
6.3.2 Sensors and Instrumentation 
 Both the sensor chips and optical scanning instrumentation have been described 
previously in detail.
25
 Briefly, deep UV photolithography and dry etching processes were utilized 
to create all chip features. Subsequently a fluoropolymer cladding layer was spin coated on the 
chip surface, and annular openings around the sensor rings created to enable sample access. Two 
different generations of chips were used, differing only in the number of rings and ring layout. 
The first design consisted of 24 sensor rings and 8 thermal control rings, the latter still coated in 
a fluoropolymer layer. The second and more evolved design contains 128 sensor rings, 4 thermal 
control rings, and 4 leak sensors. Similarly, two different variants of optical scanning 
instrumentation accompanied each sensor type; however the fundamental principles and 
execution are similar. An external cavity diode laser centered at 1550 nm is manipulated via 
mirrors to scan across an array of grating couplers along one side of the sensor chip. The light is 
coupled through free space into on-chip linear waveguides through these grating couplers, where 
it interfaces with a sensor microring. As the electromagnetic energy propagates via total internal 
reflection, a non-zero EM field exists at the waveguide edge, resulting in an evanescent field 
extending into the local environment. The circular waveguides, or microrings, are positions 
within 200 nm of the linear waveguide, such that under certain resonant conditions light couples 
into the resonator, resulting in attenuation on the distal end of the linear waveguide. This drop in 
intensity is measured by a photodiode after light is coupled back out of the sensor chip and into 
the scanning instrumentation through another grating coupler. The resonance condition is given 
by equation 1,              
                                                                             (Eq. 6.1) 
where an integer (m) multiple of the wavelength ( ) equals the circumference times the effective 
refractive index (neff). 
6.3.3 Biochemical Modification of Sensor Surface and Capture Agents 
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Sensor chips were first cleaned in Piranha solution consisting of 3:1 H2SO4:30% H2O2. 
(Caution: Piranha solution is extremely caustic and should be handled with care and appropriate 
personal protective equipment!) 10 mL of Piranha solution was brought to a slow boil, and 
sensor chips immersed for 30 seconds, followed by a brief water rinse. Chips were then 
sonicated in ethanol for 3 minutes, followed by the application of 1 mg/mL Hynic silane in 
ethanol for 20 minutes. Chips were once again sonicated in ethanol for 3 minutes to remove 
excess Hynic silane, and dried under an N2 stream. For assays requiring surface immobilization 
of nucleic acids, SFB-modified nucleic acids were spotted in 0.5 to 1.0 µL droplets onto the chip 
surface, and left in a humidity chamber overnight. Chips were then rinse briefly in 8 M urea prior 
to the assay. For assays utilizing antibody capture agents, immediately after Hynic silane 
functionalization chips were introduced into the sensing instrumentation, and SFB-modified 
antibodies flowed across the chip surface at between 2 to 10 µL/min for ~20 minutes. Chips were 
then stored in a blocking protein cocktail overnight prior to use the following day.  
Capture agents, either nucleic acid or protein in nature, were modified in a similar 
fashion. Nucleic acids were put through Vivaspin 3k molecular weight cutoff columns to remove 
synthesis salts, and subsequently incubated with a 10-fold excess of S-4FB dissolved in DMF. 
After incubation the sample was again put through a Vivaspin 3k MWCO column to remove 
unreacted S-4FB.  Antibodies were functionalized identically, except using Zebaspin desalting 
columns to remove excess salts and unreacted S-4FB. Note, it is important to dilute stock S-4FB 
DMF solutions into PBS buffer, else the high final DMF concentration (~2% vs 0.2%) will 
adversely affect antibody activity. Protein and nucleic acid concentrations were assessed with the 
NanoDrop 1000 spectrometer (Thermo Scientific).  
6.3.4 Nucleic Acid Sequences 
 All nucleic acids were purchased form Integrated DNA Technologies (IDT), and stored at 
200 µM in PBS at -20° C. A complete list of nucleic acids used in this project are given in Table 
6.1 – 6.2. 
6.3.5 Protein Production Systems 
 Numerous commercial sources and production methods were explored in the process of 
obtaining catalytically competent Ago2. Recombinantly expressed Ago2 was initially obtained 
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from Sino Biological, however, no cleavage or binding capabilities were observed despite 
significant experimental optimization, and we conclude that the Ago2 from this source was 
denatured or inactivated. We next pursued a recombinant protein expression in a bacterial 
system—BL21-RIPL-NT9 cells containing a plasmid for Ago2, generously provided by Leemor 
Joshua-Tor at Cold Spring Harbor. Frozen bacterial stocks were thawed, streaked onto a LB-
Amp/Kan agar plate, and one colony selected for further inoculation. Subsequently bacteria were 
grown, induced, and lysed, followed by cell lysate purification on Pierce glutathione spin 
columns. GST column elutions were filtered and run on a Superdex 200 10/300 size exclusion 
column on a FPLC in the lab of T.J. Ha in the Institute for Genomic Biology. GST-Ago2 elutions 
were combined, concentrated, and flash frozen with 10% glycerol. Unfortunately Ago2-
containing fractions showed no sign of RNA cleavage capabilities. In our next approach, protein 
was produced in HeLa cells by the transient transfection of an FLAG-Ago2 plasmid produced in 
the lab of Thomas Tuschl. The Ago2 plasmid was first heat-shock transformed into DH5αa E. 
Coli, selected for and grown on ampicillin agar, and purified via a Qiagen MiniPrep kit to 
produce sufficient plasmid. This plasmid was the transfected into HeLa cells obtained from 
Jessie Peh in the lab of Paul J. Hergenrother using jetPrime transfection reagent. After sufficient 
growth, cells were harvested and the protein purified using a Sigma FLAG M protein 
purification kit; however, subsequent cleavage assays revealed no Ago2 activity. In our last 
unsuccessful attempt, we received stably expressing FLAG-Ago2 HEK293 cells from Ian 
MacRae at Scripps Institute. Following protein purification with the Sigma FLAG M protein 
purification kit, Coomassie staining revealed no protein in the FLAG elutions. Coomassie 
comparisons to native HEK293 cells did not demonstrate any unique bands indicative of 
differential Ago2 expression. Western blots revealed that of all the approaches employed, only 
the Sino biological source contained any protein, and this inactive. Control experiments using 
FLAG-tagged bacterial alkaline phosphatase demonstrated the purification kit was functioning 
properly, and the problem lay somewhere upstream with the various cell lines.  
 Catalytically active Ago2 was finally obtained from FLAG-Ago2 expressing Sf-9 cells 
sent by Ian MacRae. In brief, this protein expression system hijacks a plant virus, baculovirus, by 
substituting a native polyhedron protein with the gene of interest in the viral DNA. This 
recombinant ‗bacmid‘ is then introduced to a cell line, in our case Sf-9 insect cells, and viral 
production begins. This proceeds for 8-10 hours until most cells are infected, followed by a 
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protein production phase, in which the cells, now hostage to the viral bacmid, produce copious 
quantities of the Ago2 protein. We received these frozen cells, which only required cell 
harvesting and purification on the FLAG M kit. Each frozen cell aliquot, 100x10
6
 cells, was 
thawed on ice and resuspended in 10 mL ice-cold lysis buffer (300 mM NaCl, 10 mM Imidazole, 
0.5% Triton X-100, 5% glycerol, 0.5 mM tris (2-carboxyethyl)phosphine (TCEP) 50 mM sodium 
phosphate pH 8.0, and 1% protease inhibitor cocktail (Sigma). Resuspended cells were lysed in a 
Kontes Dounce tissue grinder (Fisher) with 10 strokes of pestle B. Insoluble material was 
pelleted by centrifugation (16,873 x g for 15 min), and the supernatant solution incubated with 1 
mL of Anti-FLAG M2 Affinity Gel (Sigma) in a 15 mL conical tube for 1.5 hrs at 4° C with 
gentle rocking. The resin was subsequently gently pelleted (750 x g for 5 min), and washed with 
15 mL of wash buffer 5x (150 mM NaCl, 20 mM Tris pH 8.0, 2 mM MgCl2, 0.5 mM TCEP). 
The resin was then packed in a propylene column and Ago2 protein eluted with 150 µg/mL 
FLAG peptide. Cleavage-competent Ago2 production was confirmed via Coomassie staining, 
Western blot, and radiolabeled RNA cleavage assays. Protein abundance was quantitated via 
bicinchoninic acid (BCA) assay and Coomassie staining against BSA standards. 
6.3.6 Radiolabeling Assays 
 Select nucleic acid sequences were radiolabeled with P
32
 labeled adenosine triphosphate 
(ATP). P
32
 is a radioactive phosphorus isotope with a short half life (14.29 days) which decays 
via beta emission to S
32
 (Caution! Proper precautions and training must be taken when working 
with radioactive isotopes to prevent bodily harm, and it is highly recommended to work in a 
dedicated radiation room to prevent contamination).  
 After calculating the activity of the P
32
 ATP, the RNA to be labeled was incubated for 30 
minutes at 37° C in a lead capsule in a mixture similar to the following: 15.5 µL H2O, 2 µL 10x 
PNK buffer, 2 µL 5 µM RNA, 0.5 µL 25 µM ATP, 0.5 µL Polynucleotide Kinase enzyme. The 
reaction mixture is vortexed prior to enzyme addition. The reaction is stopped by the addition of 
20 µL of 80% stop solution: 80% formamide, 1x TBE, 50 mM EDTA, 0.025% bromphenol blue. 
The sample was then loaded onto a homemade 20% acrylamide gel, and run at 30 W (1,000 V) 
for 90 minutes. After completion, the gel was removed from its casing, wrapped in plastic wrap, 
and imaged on a clean phosphor screen for 30 seconds (Caution! Running buffer will likely be 
radioactive and proper precautions should be taken). Exact imaging time is dependent on ATP 
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age. After confirmation of successful RNA labeling, the RNA band is excised  and placed in a 
microcentrifuge tube. It is incubated with 330 µL of Tris + 300 mM NaCl buffer for 90 minutes 
at 37 °C, with vortexing every 30 minutes. TEN-based RNA extraction is repeated again, and 
900 µL ethanol is added to each aliquot of 300 µL extract. Both samples are then frozen in dry 
ice at -80 °C until frozen. Samples are then centrifuged for 30 minutes at 16,100 g at 4 °C. 
Supernatant is pipetted out, being sure not to disturb the RNA pellet. 75 µL ethanol is added and 
spun at 16,100 g for 5 minutes, still at 4 °C. The ethanol is pipette out, and the remaining 
solution removed via speed-vac. Radiolabelled RNA is resuspended in H2O.  
 Radiolabeled cleavage assays with Ago2 were performed under varying conditions, 
however generally followed an initial incubation of Ago2 with a guide strand, subsequent 
incubation with a P
32
 labeled target strand, and finally denaturation in a loading buffer followed 
by gel loading. A standard assay recipe consists of 200 nM Ago2, 20 nM p-let-7a, 10 nM RNA 
target, 1 unit/µL RNasin, 20 mM Tris, 50 mM KCl, 5% glycerol, 1.5 mM MgCl2. In recipe 
format: 12.5 µL 2x RISC buffer, 0.5 µL RNasin, 5 µL Ago2, 5 µL p-let-7a, 0.5 µL P
32
 labeled 
RNA target, 1.5 µL H2O. After completion, gels were imaged for ~60 minutes on a phosphor 
screen to achieve sufficiently clear images.  
6.3.7 Microring Resonator Assay Design 
 Assay designs varied considerably with the evolution of the project, but all relied upon 
the optical scanning instrumentation and standard fluidic and chip-holder devices. Assays 
performed on the Norris instrument were coupled to syringe pumps (Harvard), whereas the 
Maverick instrument generation includes fully automated fluidics. Assays generally fell into one 
of two categories: nucleic acid immobilization followed by Ago2 protein introduction, or the 
reverse—Ago2 immobilization to the surface, with the subsequent introduction of nucleic acid 
sequences. Where myc mRNA was utilized, established protocols were followed including the 
use of DNA chaperones to remove secondary structure, as well as the use of three capture agents 
to improve surface immobilization.  
6.3.8 Data Analysis 
 Origin 9.0 was used for most data analysis, including all curve fitting and data 
normalization. Images were analyzed with ImageJ vs. 1.47a.  
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6.4 Results and Discussion  
 To properly perform experiments characterizing the complexities of interacting 
biomolecule species, one must first understand any perturbations or biases introduced by the 
measurement apparatus, as well as ways to minimize this interference. In our case, the surface 
may introduce steric affects which limit the accessibility of RNA-Ago2 interactions. 
Consequently we considered the orientation of the Ago2 protein in our assay design—whether it 
should it be surface immobilized while appropriate RNA were fluidically introduced, or the 
opposite whereby RNA molecules are decorated on the sensor surface and Ago2 is introduced 
via the fluidic system. While we observed successful RNA cleavage events in both orientations, 
the latter methodology is preferred for several reasons. First, the mass-sensitive nature of the 
sensors means capturing a large protein (~100 kDa) on the sensor surface would result in a 
significantly higher response than miRNA capture (~7 kDa), lending this approach improved 
signal response and thus greater sensitivity. Additionally, this format would afford the ability for 
high-throughput screening of RNA sequence and structure variations against Ago2 catalytic 
activity, as RNA could be arrayed in a high density format across the sensor arrays, followed by 
a single Ago2 binding and cleavage step. Finally, nucleic acids are readily modified with spacers 
to minimize the steric effects of close proximity to the surface.   
Figure 6.1 confirms the presence and cleavage competency of Sf-9 derived Ago2 based 
on Coomassie staining, Western blotting and radiolabeled cleavage assays.  Ago2 abundance in 
the first three column elutions was 15, 70, and 30 μg/mL respectively, as determined by BSA 
standards and BCA assays (data not shown). Through improved planning and protocol, 
subsequent protein purifications resulted in even higher Ago2 concentrations up to 500 μg/mL. 
Interestingly, endogenous endonucleases in the cell lysate, cell pellet, and flow-through fractions 
(lanes 1-4) completely and nonspecifically degrade the P
32
-labeled target RNA, resulting in a 
broad band which migrates rapidly. In contrast, Ago2 elution fractions (lanes 5-7) demonstrate 
more focused bands of larger size, corresponding to specific and Ago2 mediated target cleavage. 
As expected, the intensity of these bands is inversely correlated to the amount of unreacted single 
stranded and double stranded RNA, and directly correlated to the Ago2 abundance in the 
Coomassie gel.  
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Prior to using Ago2 in microring resonator experiments, we performed two rounds of 
optimization using our radiolabeled system to optimize and characterize the cleavage activity and 
suitability of our Ago2 and nucleic acid sequences. In Figure 6.2a, the generality of Ago2 is 
demonstrated via cleavage of 3 different target strands using the same complementary guide 
strand (lanes 1-3), resulting in P
32
 labeled fragments of various sizes as expected. The ratio of 
Ago2, phosphorylated let-7 miRNA guide strand, and target strand ―B‖ were varied in lanes 3-7 
to determine the optimal combination. Additionally, the assay was run at 37° C once to see if the 
performance was improved, but no notable difference was observed.  Figure 6.2b details the 
next stage of optimization, in which the assay time was shortened (lane 4), the incubation of the 
guide and target strand was performed simultaneously rather than sequentially (lane 5), RNasin 
was omitted (lane 6), and the reagent quantities were reduced (lane 7-8). We were able to draw 
several conclusions from this data to optimize future assays. Firstly, Ago2 is capable of cleaving 
numerous different targets when loaded with the perfectly complementary guide strand, 
however, this cleavage capability is untested with imperfectly matched guide strands. Various 
ratios of the protein, guide strand, and target strand all resulted in cleavage, however it is best to 
maintain the guide strand in excess of the target strand, and Ago2 in excess of the guide strand. 
Temperature appears to have a minimal effect on the assay. Simultaneous incubation of all three 
components prevents target cleavage. This is likely due to the rapid formation of an RNA 
duplex, precluding the guide strand from loading into Ago2. To confirm this, we repeated the 
assay but introduced fully duplexed RNA, and saw no cleavage (data not shown). Finally, the 
presence of RNasin in the reaction is imperative to prevent nonspecific degradation of the RNA 
by adventitious endonucleases.  
With sufficient methodology optimization completed, we transferred our assay to the 
microring resonator sensor arrays. Figure 6.3 illustrates the most straightforward assay design 
schematically along with accompanying data. Myc mRNA was immobilized to the sensor 
surface following the protocol optimized previously: three capture agents targeting different 
portions of the transcript, while the mRNA itself was incubated beforehand with 12 chaperones 
to reduce secondary structure and thus promote surface hybridization. After the mRNA is surface 
bound, evidenced by ~120 pm shift, a protein blocking solution is briefly introduced to prevent 
nonspecific fouling of the surface by the Ago2 protein. Omitting this step results in significant 
nonspecific Ago2 fouling (data not shown). Finally, a 70 nM Ago2 solution loaded with a 140 
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nM concentration of 3 anti-myc guide RNA strands is introduced, resulting in cleavage of the 
surface bound mRNA and an accompanying negative resonance shift. The wavelength shift of 85 
pm corresponds to 65% of the original mRNA loading signal response. Given the 3 different 
guide strands loaded into Ago2, each targeting a different region of the mRNA, a 65% loss in 
surface bound mRNA seems reasonable. Importantly, we simultaneously introduced Ago2 sans 
any guide strand, to confirm the RNA-conferred specificity necessary for Ago2 cleavage. As 
expected, this off-target response is essentially zero, with no wavelength shift or loss of mRNA. 
To demonstrate the flexibility of the assay, we flipped the orientation of the protein and 
RNA, immobilizing Ago2 to the surface via anti-Ago2 antibodies prior to introducing target 
RNA. This assay format is more nuanced than the previous approach, as the observed signal 
response will result from both mRNA capture by the guide strand, as well as mRNA cleavage by 
Ago2. These two processes will yield opposite signal responses—mRNA capture redshifts the 
resonant wavelength, while the cleavage process moves the resonance dip to shorter 
wavelengths. However, the time scales of these two processes may differ slightly, enabling 
temporally resolved measurements of binding and cleavage processes. Additionally, we 
anticipate the resultant response will be an increase in resonant wavelength, given the partial 
cleavage of surface bound mRNA demonstrated in Figure 6.3.  After appropriate antibody 
functionalization shown in Figure 6.4a, Ago2 is introduced to the sensor surface and rapidly 
captured by the anti-Ago2 antibodies (Figure 6.4b). Note that Ago2 pre-loaded with guide 
strand RNA was introduced, as well as bare Ago2 without any guide strand. In the latter case, a 2 
µM guide strand solution was introduced post Ago2 capture for on-line Ago2 loading. We 
anticipate the preloaded-Ago2 will have better target mRNA capture properties given the more 
complete loading afforded by solution phase kinetics. This is indeed the case, as the subsequent 
introduction of 10 nM myc mRNA results in ~20 pm response for pre-loaded Ago2, and only 10 
pm response for Ago2 loaded online. Similar experiments were performed with a 
noncomplementary guide strand, and no guide strand at all. The averaged mRNA capture 
responses are compiled in Figure 6.4c. Clearly, a noncomplementary or absent guide strand 
results in no RNA target capture or cleavage.  
Having demonstrated a guide strand to be essential for Ago2 induced RNA cleavage, we 
explored the capability of a partially complementary guide strand to induce cleavage. Let-7a is 
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one of the earliest discovered miRNA, and has been implicated in numerous important biological 
roles.
26
 Importantly, it is in an autoregulatory loop with myc messenger RNA, wherein it 
downregulates this powerful promoter of gene transcription.
27
 Thus, an increase in let-7 
abundance reduces myc mRNA abundance, and thus globally decreases gene transcription. Since 
myc itself promotes let-7 production, these form an autoregulatory loop.
28
 Let-7 binds at the 114 
nucleotide in the 3‘ UTR of the myc mRNA transcript and demonstrates partially complementary 
base-pairing. Mismatches, stated in reference to the 5‘ miRNA, exist at the 3rd and 5th position, 
positions 10-15, and position 19. Significant mismatch freedom exists for the middle region, 
however, we anticipate the two mismatches in the important ‗seed region‘ from nucleotides 1 to 
8 will significantly affect Ago2 cleavage capabilities. We chose to load phosphorylated let-7a 
into Ago2 as a guide strand, targeting myc mRNA. Figure 6.5 compares the resultant mRNA 
cleavage relative to a perfect complementary guide strand, as well as in the absence of a guide 
strand entirely. The partially complementary let-7 only results in a 24 pm signal drop, 
approximately ¼ the signal loss associated with a fully complementary guide strand. This finding 
is surprising given the standard model for Ago2 cleavage and binding. Generally perfectly 
complementary guide-target pairing results in Ago2 induced target cleavage, whereas partially 
complementary RNA interactions results in Ago2 binding, but not cleavage. The attenuated 
cleavage response we observed is thus curious, and would suggest limited Ago2 cleavage 
capabilities even when loaded with partially complementary guide strands. In addition to 
sequence dependencies, we observed a direct correlation between Ago2 concentration and degree 
of cleavage. This would indicate the Ago2-guide strand complex was not at saturating 
concentrations.  
6.5 Future Directions 
This recapitulation of minimal RISC on microring resonators demonstrates the valuable 
contributions of this platform towards improving in vitro biomolecular screening assays. 
However, this is only the first step in what we anticipate to be a long and beneficial field of 
study. The described assay could be expanded from the interaction of 3 components to the 
interactions of 30, and still not have captured the full complexity of RISC interactions. 
Numerous important and interesting interactions exist which have not been fully characterized 
which could be readily explored with the developed assay. For example, the HuR protein has 
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been shown to bind to the 5‘ UTR of mRNA transcripts, resulting in competitive inhibition of 
RISC.
11,29
 Numerous questions concerning the extent of inhibition, the conditions under which it 
occurs, and the exact mechanism of steric interactions could be readily interrogated with our 
assay.  Proteins besides Ago2 also are valuable targets of study, and lead to important questions. 
Are all 4 human Argonaute proteins equally effective at stopping mRNA translation, or does the 
cleavage capabilities of Ago2 confer special inhibitory capabilities? Are there specific conditions 
which preferentially recruit certain Ago proteins? Since Ago2-facilitated RNA cleavage is 
observed sans other modulating proteins, what exactly is their role in RISC-based regulatory 
control? Even more questions remain when considering the RNA which guide RISC activity, and 
upon which RISC acts. How does miRNA guide strand sequence affect RISC loading 
efficiencies? How does the lengthy mRNA 5‘ UTR scaffold affect its accessibility to RISC 
action? Does mRNA 5‘ UTR sequence, and thus secondary structure, play a role in mRNA 
accessibility to RISC endonuclease activity? Finally, the kinetics of many RISC interactions are 
poorly understood, and the real time nature of the microring resonator platform is ideally suited 
to answer this genre of questions.  
Beyond RISC, there are numerous other protein-nucleic acid, and even protein-protein 
interactions which can build on the developments described in this study. The strengths of 
microring resonators as an analytical sensing platform are well suited to the requirements of 
screening biological interactions: real-time data collection, minimal modification of biological 
players, and high throughput formats for highly multiplexed assays. We anticipate future studies 
will explore applications such as drug-target screens, epitope mapping, and regulatory protein 
networks, among others.  
6.6 Conclusions 
We have successfully demonstrated an in vitro model of minimal RISC action—
Argonaute 2, loaded with various guide strands,  binding and cleaving full length mRNA. We 
have further demonstrated the dependence of Ago2 activity on the guide strand sequence. The 
developed assay can be performed with either RNA or Ago2 immobilized on the sensor surface, 
providing a flexible platform for high throughput screening of other RISC associated proteins, as 
well as nucleic acid dependent processes. We anticipate this assay will provide an attractive 
alternative to traditional radiolabelling methodologies to interrogate RISC interactions. RISC 
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associated RNA and proteins can be used directly in the assay with minimal preparation, a 
significant advantage given the growing appreciation of the number of interacting biomolecules 
in RISC-mRNA interactions. Additionally, mating high density spotting technologies with the 
sensor array will allow full utilization of the 128 sensor rings, providing the quantity and quality 
of data necessary to fully characterize this important ribonucleoprotein complex.   
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6.7 Figures and Tables  
 
Figure 6.1. a) A Coomassie stained gel demonstrates the protein content in various stages of the 
protein purification process. Ago2, which is expected to migrate at ~90 kDa, is observed in the 
first 3 column elutions (Lanes 5-7). b) A radiograph of various protein purification fractions, 
after incubation with a P
32
 labelled target RNA and complementary guide strand RNA, only 
shows specific cleavage products in the Ago2-bearing Lanes 5-7.  c) Western blotting confirmed 
the presence of Ago2 in the first three column elutions.  
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Figure 6.2. Radiographs were used to optimize the Ago2-dependent RNA cleavage assay. a) 
Ago2 was shown to demonstrate activity across three different RNA targets (lanes 1-3), under 
various stoichiometric ratios of Ago2, let-7a guide miRNA, and RNA ―B― target (lanes 3-7), and 
temperatures (lane 8).  b) Further optimization demonstrated the capability to reduce assay time 
(lane 4), the necessity of sequential guide strand and target strand incubation (lane 5), the 
necessity of RNasin in the reaction (lane 6), and the ability to reduce reagent quantities (lane 7-
8).  
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Figure 6.3. a) Schematic illustrating Ago2 induced cleavage of surface bound mRNA. mRNA is 
first hybridized to capture DNA probes decorating the sensor surface. Subsequent introduction of 
Ago2, previously loaded with a guide RNA strand complementary to the mRNA, results in rapid 
mRNA cleavage and removal from the surface. b) Concomitant data illustrates the 85 pm loss in 
signal associated with Ago2 induced mRNA cleavage. This corresponds to 65% loss in signal. 
Note a brief blocking step directly before Ago2 introduction is omitted for clarity. 
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Figure 6.4. a) Sensor functionalization with anti-Ago2 and anti-IL-4 control antibodies. b) Both 
unloaded and loaded Ago2 are readily immobilized to the surface. Unloaded Ago2 is loaded 
online by the introduction of 2 uM guide strand. Differential mRNA capture is subsequently 
observed, dependent on guide strand loading methodology. c) mRNA capture responses to Ago2 
loaded with a noncomplementary guide strand, as well as when the guide strand is entirely 
absent, are compared to the average responses from figure b). 
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Figure 6.5. a) Comparative normalized responses are shown for Ago2 cleavage assays with 
various RNA guide strands and various Ago2 concentrations.  Perfectly complementary guide 
strands result in the most cleavage followed by partially complementary let-7a. In the absence of 
a guide strand no cleavage is observed. b) The same data as panel a) displayed in a bar graph 
clearly demonstrates the dependency of cleavage on a complementary pairing between the guide 
and target RNA strands. Additionally, increasing the Ago2 concentration 2-fold results in 
increased cleavage.   
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Table 6.1. Nucleic acid sequences. 
RISC_1 Cap Probe 5'-/5AmMC12/TTT TTG CTG GAC AAG TAC CCT GAT A-3' 
RISC_1 Target 5'-rArArC rUrArU rArCrA rArCrC rUrArC rUrArC rCrUrC rATT TTA 
TCA GGG TAC TTG TCC AGC-3' 
RISC_2 Cap Probe 
w Spacer 
5'-/5AmMC12//iSp18//iSp18/TTT TTG CTG GAC AAG TAC CCT 
GAT A  
RISC_2 Target 5'- /5Biosg/TTT CAG TCrA rArCrU rArUrA rCrArA rCrCrU rArCrU 
rArCrC rUrCrA TTT TAT CAG GGT ACT TGT 
let-7a 5'-rUrGrA rGrGrU rArGrU rArGrG rUrUrG rUrArU rArGrU rU-3' 
phosphorylated let-
7a 
5'- /5Phos/rUrGrA rGrGrU rArGrU rArGrG rUrUrG rUrArU rArGrU rU  
3' Amine let-7 + 
spacer 
5'-
/5Phos/rUrGrArGrGrUrArGrUrArGrGrUrUrGrUrArUrArGrUrUTTTTT
TTTTT/3AmMO/-3' 
hot ladder 9 nt AAC TAT ACA 
hot ladder 12 nt AAC TAT ACA ACC 
hot ladder 15 nt AAC TAT ACA ACC TAC 
hot ladder 18 nt AAC TAT ACA ACC TAC TAC 
hot ladder 24 nt CCA ACA TAT CAA ACT TTC AAG TGC 
hot ladder 27 nt ATC CAA CAT ATC AAA CTT TCA AGT GCT 
hot ladder 30 nt CAT ATC CAA CAT ATC AAA CTT TCA AGT GCT 
let-7a DNA comp 
target 
AAC TAT ACA ACC TAC TAC CTC A 
42mer let-7a comp 
RNA target 
rArUrG rArCrC rArUrC rArArA rCrUrA rUrArC rArArC rCrUrA 
rCrUrA rCrCU rCrArG rArCrA rUrUrC rGrArU 
MacRae A UGA GGU AGU AGG UUG UAU AGU UUG AAA GUU CAC GAU 
U 
MacRae B UCG UGA ACU UUC AAA CUA UAC AAC CUA CUA CCU CAU U 
Anti-myc-1 5'-/5Phos/rUrGrG rGrCrG rArGrC rUrGrC rUrGrU rCrGrU rUrGrA rG -
3' 
Anti-myc-2 5'-/5Phos/rCrGrU rCrGrU rCrCrG rGrGrU rCrGrC rArGrA rUrGrA rA-
3' 
Anti-myc-3 5'-/5Phos/rCrGrC rGrUrC rCrUrU rGrCrU rCrGrG rGrUrG rUrUrG rU-
3' 
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Table 6.2: C-myc. C-myc DNA capture probe, chaperone, and primary transcript sequences. 
Epitopes targeted by DNA capture probes are bolded and underlined 
 Capture Probe Sequences Length Nucleotide 
position from 5‘ 
End 
Myc1 5'-/5AmMC12/TTC GTG GAT GCG GCA AGG GT-3' 20 340-359 
Myc2 5'-/5AmMC12/GAG TTC CGT AGC TGT TCA AGT 
TTG TGT T-3' 
28 1853-1880 
Myc3 5'-/5AmMC12/ACC ACC GAG GGG TCG ATG CA-3' 20 1132-1151 
  
 Chaperone Sequences 
1 TGC GGA CCG CTG GCT GGG GG (A)30 
2 (A)30 ACC GCT GCT ATG GGC AAA GT 
3 CTC TGA GGC GGC GGC GCT CA (A)30 
4 (A)30 CGT TGA GAG GGT AGG GGA AG 
5 TCA ACT GTT CTC GTC GTT TC (A)30 
6 (A)30 TTA CTT TTC CTT ACG CAC AA 
7 AAA ACA ATT CTT AAA TAC AA (A)30 
8 (A)30 ATT GAA ATT CTG TGT AAC TG 
9 (A)30 CTC CTC TGG CGC TCC AAG AC 
10 (A)30 TCC AGA CTC TGA CCT TTT GC 
11 (A)30 CCT GTT GGT GAA GCT AAC GT 
12 GGC GGC CGC GAG CAG CAC AG (A)30 
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Table 6.2 (cont.) 
1 GACCCCCGAG CTGTGCTGCT CGCGGCCGCC ACCGCCGGGC CCCGGCCGTC CCTGGCTCCC 
61 CTCCTGCCTC GAGAAGGGCA GGGCTTCTCA GAGGCTTGGC GGGAAAAGA ACGGAGGGAG 
121 GGATCGCGCT GAGTATAAA GCCGGTTTTC GGGGCTTTAT CTAACTCGCT GTAGTAATTC 
181 CAGCGAGAGG CAGAGGGAGC GAGCGGGCGG CCGGCTAGGG TGGAAGAGCC GGGCGAGCAG 
241 AGCTGCGCTG CGGGCGTCCT GGGAAGGGAG ATCCGGAGCG AATAGGGGGC TTCGCCTCTG 
301 GCCCAGCCCT CCCGCTGATC CCCCAGCCAG CGGTCCGCAA CCCTTGCCGC ATCCACGAAA 
361 CTTTGCCCAT AGCAGCGGGC GGGCACTTTG CACTGGAACT TACAACACCC GAGCAAGGAC 
421 GCGACTCTCC CGACGCGGGG AGGCTATTCT GCCCATTTGG GGACACTTCC CCGCCGCTGC 
481 CAGGACCCGC TTCTCTGAAA GGCTCTCCTT GCAGCTGCTT AGACGCTGGA TTTTTTTCGG 
541 GTAGTGGAAA ACCAGCAGCC TCCCGCGACG ATGCCCCTCA ACGTTAGCTT CACCAACAGG 
601 AACTATGACC TCGACTACGA CTCGGTGCAG CCGTATTTCT ACTGCGACGA GGAGGAGAAC 
661 TTCTACCAGC AGCAGCAGCA GAGCGAGCTG CAGCCCCCGG CGCCCAGCGA GGATATCTGG 
721 AAGAAATTCG AGCTGCTGCC CACCCCGCCC CTGTCCCCTA GCCGCCGCTC CGGGCTCTGC 
781 TCGCCCTCCT ACGTTGCGGT CACACCCTTC TCCCTTCGGG GAGACAACGA CGGCGGTGGC 
841 GGGAGCTTCT CCACGGCCGA CCAGCTGGAG ATGGTGACCG AGCTGCTGGG AGGAGGACATG 
901 GTGAACCAGA GTTTCATCTG CGACCCGGAC GACGAGACCT TCATCAAAAA CATCATCATC 
961 CAGGACTGTA TGTGGAGCGG CTTCTCGGCC GCCGCCAAGC TCGTCTCAGA GAAGCTGGCC 
1021 TCCTACCAGG CTGCGCGCAA AGACAGCGGC AGCCCGAACC CCGCCCGCGG CCACAGCGTC 
1081 TGCTCCACCT CCAGCTTGTA CCTGCAGGAT CTGAGCGCCG CCGCCTCAGA GTGCATCGAC 
1141 CCCTCGGTGG TCTTCCCCTA CCCTCTCAAC GACAGCAGCT CGCCCAAGTC CTGCGCCTCG 
1201 CAAGACTCCA GCGCCTTCTC TCCGTCCTCG GATTCTCTGC TCTCCTCGAC GGAGTCCTCC 
1261 CCGCAGGGCA GCCCCGAGCC CCTGGTGCTC CATGAGGAGA CACCGCCCAC CACCAGCAGC 
1321 GACTCTGAGG AGGAACAAGA AGATGAGGAA GAAATCGATG TTGTTTCTGT GGAAAAGAGG 
1381 CAGGCTCCTG GCAAAAGGTC AGAGTCTGGA TCACCTTCTG CTGGAGGCCAA CAGCAAACCT 
1441 CCTCACAGCC CACTGGTCCT CAAGAGGTGC CACGTCTCCA CACATCAGCA CAACTACGCA 
1501 GCGCCTCCCT CCACTCGGAA GGACTATCCT GCTGCCAAGA GGTCAAGTT GGACAGTGTC 
1561 AGAGTCCTGA GACAGATCAG CAACAACCGA AAATGCACCA GCCCCAGGTC CTCGGACACC 
1621 GAGGAGAATG TCAAGAGGCG AACACACAAC GTCTTGGAGC GCCAGAGGAG GAACGAGCTA 
1681 AAACGGAGCT TTTTTGCCCT GCGTGACCAG ATCCCGGAGT TGGAAAACAA TGAAAAGGCC 
1741 CCCAAGGTAG TTATCCTTAA AAAAGCCACA GCATACATCC TGTCCGTCCA AGCAGAGGAG 
1801 CAAAAGCTCA TTTCTGAAGA GGACTTGTTG CGGAAACGAC GAGAACAGTT GAAACACAAA 
1861 CTTGAACAGC TACGGAACTC TTGTGCGTAA GGAAAAGTAA GGAAAACGAT TCCTTCTAAC 
1921 AGAAATGTCC TGAGCAATCA CCTATGAACT TGTTTCAAAT GCATGATCAA ATGCAACCTC 
1981 ACAACCTTGG CTGAGTCTTG AGACTGAAAG ATTTAGCCAT AATGTAAACT GCCTCAAATT 
2041 GGACTTTGGG CATAAAAGAA CTTTTTTATG CTTACCATCT TTTTTTTTTC TTTAACAGAT 
2101 TTGTATTTAAGAATTGTTTT TAAAAAATTTT TAAGATTTAC ACAATGTTTC TCTGTAAATA 
2161 TTGCCATTAA ATGTAAATAA CTTTAATAAA ACGTTTATAG CAGTTACACA GAATTTCAAT 
2221 CCTAGTATAT AGTACCTAGT ATTATAGGTA CTATAAACCC TAATTTTTTT TATTTAAGTA 
2281 CATTTTGCTT TTTAAAGTTG ATTTTTTTCT ATTGTTTTTA GAAAAAATAA AATAACTGGC 
2341 AAATATATCA TTGAGCCAAA TCTTAAAAAA AAAAAAAAAA 
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7.1 Abstract 
Herein we combine two important technologies, silicon photon microring resonators and 
the horseradish peroxidase enzyme, to develop a sensitive and rapid assay for the multiplexed 
detection of interleukins in both buffer and cerebral spinal fluid. The unprecedented signal 
enhancement of this enzymatic approach enables a faster, simpler, and more sensitive alternative 
to previous mass-label signal amplification schemes. Importantly, the high gain of the enzymatic 
approach enables the quantitation of very low abundance (<1 pg/mL) biomarkers in spite of 
Langmuir limitations stipulating a near-stochastic number of bound analytes. The assay was 
successfully used to quantitate three interleukins in numerous cerebral spinal fluid samples to 
demonstrate the preservation of quantitative capabilities in complex sample matrices. We 
achieve a dynamic range extending over 3 orders of magnitude, which when coupled with 
primary- and secondary-based quantitation, should enable an 8-decade dynamic range.  
7.2 Introduction 
Robust biomolecule quantitation is central to biomarker-based clinical diagnostics, 
driving the development of high throughput, low cost medical diagnostic devices based on a 
myriad of biosensing technologies. Chief among the many relevant performance metrics of these 
devices is the ability to quantitate extremely low abundance analytes in the complex matrices of 
clinical samples in a multiplexed format.
1
 Regardless of the specific architecture and strategy 
employed towards this end, all biosensors dependent on capture agents are at the mercy of the 
Langmuir binding isotherm, which relates the ratio of solution-phase analyte to surface-bound 
analyte. At low concentrations the amount of bound analyte is directly proportional to the 
solution sample concentration, as shown in Equation 1 where θ is the surface coverage, kads is the 
equilibrium binding constant, and [C] is the solution-phase analyte concentration. Low analyte 
abundance and the limited binding affinities of capture agents, compounded by the miniaturized 
footprints of modern sensors, conspire to result in only a few individual molecules being bound 
to the surface, as illustrated in Figure 7.1 (an example empirical determination of capture 
antibody affinity is given in Figure 7.2). 
       
       
         
      (Eq. 7.1) 
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Efforts to circumvent this fundamental limitation include both the development of highly 
nanostructured morphologies with vastly increased surface areas, as well as the integration of 
numerous signal enhancement schemes to augment intrinsic biosensor sensitivity and improve 
detection limits.
2,3
 Desirable characteristics include high signal gain, cross-platform modularity, 
resistance to matrix effects, and linear signal response. Common signal amplification strategies 
employ enzymatic,
3
 nucleic acid,
4
 electrochemical,
5
 or particle-based labels;
6,7
 however 
enzymatic-based methods are particularly attractive due to the high gain possible from multiple 
turnovers. Horseradish peroxidase (HRP) has found widespread usage in biochemical 
applications for possessing many of these desirable characteristics; in particular high substrate 
turnover (400 s
-1
) and extended stability which result in an extremely high theoretical signal 
amplification (10
7
).
8-10
 Numerous commercially available HRP kits with a wide range of 
biomolecular HRP-conjugates ensure low cost and broad applicability of HRP-based signal 
enhancement strategies. 
Herein we utilize silicon photonic microring resonators coupled with horseradish 
peroxidase to demonstrate the efficacy of coupling a promising, high-throughput in vitro 
diagnostic device with an enzymatic-based signal enhancement strategy. To showcase the pairing 
of these two technologies, we analyze a panel of three interleukins, which pose significant 
quantitation challenges due to their small size and naturally low abundance, and are thus prime 
candidates for an enzymatic amplification scheme.
11
 Interleukins are small (~10 kDa) signaling 
cytokines primarily involved in the immune response, and have been implicated in the 
development and progression of numerous diseases including Alzheimer‘s,12,13 dementia,14 and 
cancer.
15
 While enzyme linked immunosorbent assays (ELISAs) remain the standard method for 
interleukin quantitation, the method's labor intensive nature and inability to multiplex have 
motivated the development of alternate quantitation methods.
3,16-18
  Our lab has utilized silicon 
photonic microring resonators for the detection of DNA,
19
 RNA,
20
 and proteins,
21
 employing 
various signal enhancement strategies to boost assay performance.
6,22
 This study builds on these 
efforts with an improved enzymatic signal enhancement step which should be broadly useful due 
to its modular nature.  
7.3 Experimental Methods 
7.3.1 Materials 
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PBS buffer was reconstituted from Dulbecco‘s phosphate buffered saline packets 
purchased from Sigma-Aldrich (St. Louis, MO) into two formulations: PBS buffer for antibody 
functionalization was reconstituted at 10x concentration with the addition of 50 mM aniline and 
pH balanced to 6.0 (PBS 6); a PBS running buffer was reconstituted at 1x concentration with the 
addition of 0.1 mg/mL BSA at pH 7.4 (PBS 7.4). Starting block was purchased from Thermo-
Scientific and used as a blocking agent to prevent nonspecific fouling. The silane 3-N-((6-(N‘-
isopropylidene-hydroazino))nicotinamide)propyltriethyoxysilane (HyNic Silane) and 
succinimidyl-4-formylbenzamide (S-4FB) were purchased from Solulink. Protein desalting 
columns were purchased from Thermo-Scientific. Recombinant interleukin proteins, antibodies, 
and ELISA kits were obtained from various commercial vendors listed in Table 7.1. 
Streptavidin-conjugated horseradish peroxidase (SA-HRP) was purchased from Thermo-
Scientific. When necessary, detection antibodies were biotinylated using a Thermo-Scientific 
EZ-Link NHS-PEG4-Biotin conjugation kit. 4-chloro-1-naphthol (4-CN) solution was purchased 
from Sigma-Aldrich. All other reagents were purchased from Fisher, unless otherwise noted, and 
used as received. 
7.3.2 Instrumentation 
Sensor chips and instrumentation were obtained from Genalyte (San Diego, CA), and 
their use has been described previously.
23
 Briefly, UV photolithography and reactive ion etching 
were used to fabricate chip features on 8‖ silicon wafers, prior to dicing into individual 6 x 6 mm 
chips. Each chip contains 32 individually addressable microring resonators. A fluoropolymer 
cladding layer is spin coated over the entire chip surface, and annular openings are 
photolithographically opened over 24 rings, yielding 24 active sensor rings and 8 covered 
thermal control rings. The sensor chip is sandwiched between an aluminum cartridge holder, 
0.007‖ Mylar flow gasket, and Teflon cartridge top to enable µL-scale 4-plexed fluidic delivery.   
Silicon photonic resonators confine discrete frequencies of light via total internal 
reflection, and achieve constructive interference when light circumnavigates the structure an 
integer multiple of its wavelength, as shown in Equation 7.2, where m is a non-zero integer, r is 
the microring radius, λ is the resonant wavelength, and neff is the effective refractive index.  
                   (Eq. 7.2) 
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Boundary conditions of this propagating light dictate a non-zero electric field at the reflecting 
boundary, resulting in an evanescent field extending into the local environment of the sensor. 
Interactions between this evanescent field and the local environment perturb the resonant 
wavelength of the structure, which is monitored with sub-picometer precision by the optical 
scanning instrumentation. A tunable external cavity diode laser centered at 1550 nm is coupled 
into the sensor via microring-specific grating couplers, and scanned across an appropriate 
spectral window to determine transmission dips associated with resonant coupling. The laser is 
then rastered across each microring in the array to provide near real-time (~8 seconds) 
interrogation of analyte binding events.  
7.3.3 Biochemical Modification of Sensor Surface and Capture Agents 
Sensor chips are initially cleaned in a piranha solution (3:1 H2SO4/ 30% H2O2) for 30 
seconds. (Caution! Piranha solutions are extremely dangerous and react explosively with 
organics.) Following a 3 minute sonication in ethanol, chips are dried under N2 and spotted with 
a 1 mg/mL HyNic silane solution for 20 minutes, followed by another 3 minute sonication in 
ethanol and drying with N2. Chips are promptly loaded into the cartridge assembly and a stable 
baseline in PBS 6 buffer is obtained. 10 µg/mL antibody solutions are introduced at 10 µL/min 
for 5 minutes, then the flow rate is slowed to 2 µL/min for another 25 minutes. Following a 5 
minute buffer rinse, chips are rapidly transferred to blocking solution and stored overnight at 4° 
C. Representative antibody functionalization is shown in the Figure 7.3.  
Prior to covalent modification with S-4FB, antibodies are buffer exchanged into 100 mM, 
pH 7.4 PBS using protein desalting columns, followed by a 2 hour incubation with a 10-fold 
molar excess of S-4FB. Unreacted S-4FB is subsequently removed using another desalting 
column. 
7.3.4 Interleukin Assay 
After antibody functionalization and overnight blocking, sensor chips are briefly rinsed in 
PBS 7.4 prior to loading into the instrument. All assay steps are performed at a relatively rapid 
flow rate of 30 µL/min to avoid diffusion-limited kinetics, and are separated by 3 minute buffer 
rinses. An initial 3 minute low-pH rinse is performed to remove any unstable blocking protein, 
followed by a return to a stable baseline in PBS 7.4. The interleukin sample is then introduced 
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for 20 minutes, followed by a 5 minute buffer rinse. Subsequently, serial introduction of 
biotinylated secondary antibodies (each 1 µg/mL) and streptavidin-linked horseradish peroxidase 
(2 µg/mL) completes the surface bioconjugation. A freshly prepared 4-CN solution (0.48 mM 4-
CN; 0.0003% H2O2; 17% methanol) is introduced to the sensor for 25 minutes, and the HRP 
catalyzed oxidation of 4-chloro-1-naphthol to 4-chloro-1-naphthon (4-CNP) results in deposition 
of this insoluble precipitate, which is monitored as an increase in the resonant wavelength of the 
sensor. Sensor responses are quantitated following a final 5 minute PBS 7.4 buffer rinse. 
7.3.5 Cerebral Spinal Fluid Analysis 
Human pooled, mixed gender CSF was obtained from Chemed Services, Lot Number 
BCC062613PMG1, and stored at -80° C immediately upon receiving. Samples were thawed at 
room temperature for 30 minutes prior to use, and introduced undiluted to the sensor surface. To 
reduce sample consumption, the flow rate was reduced to 15 µL/min for this step only. 
7.3.6 Data Analysis 
All data analysis was performed in Origin Pro 9.0. Signal response was quantitated after a 
5 minute buffer rinse following the 4-CN step. Control rings functionalized with an IgG isotype 
control were subtracted from the on-target rings to account for the bulk refractive index shift 
associated with the 4-CN solution. Calibration data was fit to a logistic function,  
      ( )  
     
  (
 
  
)
        (Eq.7.3)  
where A1 is the initial value limit, A2 is the final value limit, c is the center of the fit, and p is the 
power of the fit. Equilibrium dissociation constant determination is discussed in Figure 7.2, 
followed by the fitting parameters for the calibration plots in Table 7.2. 
7.4 Results and Discussion: 
7.4.1 Assay Development 
Prior to attempting interleukin quantitation in a multiplexed format or in complex 
matrices, we performed an exhaustive optimization of assay parameters to maximize the sensor 
response, minimize assay time and eliminate off-target response. All components of the 4-CN 
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precipitation solution were varied over a wide range to determine the optimal concentrations of 
methanol, 4-CN, and H2O2, as shown in Figure 7.4.  As the optimal methanol and 4-CN 
concentration were identical to those of a commercially available product, we chose to use this 
commercial product, but spike in the appropriate amount of H2O2 immediately before use as it 
was found that the H2O2 must be added immediately prior to use or its activity was insufficient to 
facilitate efficient substrate oxidation. After an initial screen to find the optimal antibody 
sandwich pairs, it was discovered that using a second detection antibody improved the signal 
response. Subsequently, two detection antibodies were used for each interleukin. Both the 
streptavidin-HRP (SA-HRP) conjugate and the two detection antibodies were introduced at 2 
µg/mL final concentration. To minimize nonspecific fouling, sensor chips were incubated in a 
protein blocking solution overnight after capture agent functionalization but prior to interleukin 
quantitation. Additionally, 0.1 mg/mL BSA was included in the PBST 7.4 running buffer to 
maintain a blocked surface. 
This optimized 90 minute assay enables a remarkable amplification in signal response 
relative to the primary interleukin binding event, as shown in Figure 7.5. While the primary 
binding of 3125 pg/mL IL-6 cannot be observed directly, subsequent detection antibody and SA-
HRP conjugation steps clearly result in an increased signal due to their larger size relative to the 
interleukin. However even these responses are dwarfed by the subsequent 4-CN precipitation 
step, in which surface conjugated HRP catalyzes the oxidation of 4-chloro-1-naphthol into an 
insoluble precipitate, 4-chloro-1-naphthon, which rapidly deposits on the sensor surface. This 
reaction is allowed to proceed for 25 minutes until a pseudo-equilibrium point is achieved, at 
which point PBS pH 7.4 is reintroduced to account for the bulk refractive index shift associated 
with the higher refractive index of the 4-CN solution.  
The advantages of enzymatic signal amplification is readily seen when compared to 
linear signal enhancement strategies previously used on the microring resonator platform. For 
comparison, a detection antibody enhances the signal relative to the primary antigen by a factor 
of ~3,
17
 and a bead-based approach yields an even higher gain in signal of ~50.
24
 In contrast, 
Figure 7.5 illustrates a HRP-derived signal gain of 10
4
. Furthermore, this response is under 
nearly saturating concentrations; at lower antigen abundance this amplification would be even 
higher. We attribute the magnitude of this response to both the high turnover of HRP, as well as 
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the dense packing of the 4-chloro-1-naphthon precipitate relative to biomolecules. Figure 7.6 
shows representative scanning electron microscopy images of microrings after varying amounts 
of 4-chloro-1-naphthon deposition. Interestingly, the 4-CN deposition process appeared far from 
homogenous, favoring the formation of precipitation clusters.  This unexpected morphology gave 
credence to the idea of highly localized 4-CN precipitation around the enzyme, and the 
opportunity for further signal amplification should the precipitation length-scale be increased. 
Attempts to shorten the assay by pre-incubating the primary and secondary, or secondary 
and HRP into a single step were largely unsuccessful, and at best only matched the performance 
of the sequential assay described above. While this abbreviated approach should benefit from 
faster solution-phase kinetics, we imagine it suffered from unfavorable sterics and suboptimal 
HRP orientation on the sensor surface. Similarly, efforts to conjugate additional HRP molecules 
through multivalent biotin-HRP conjugates and free streptavidin were unsuccessful for similar 
reasons. Subsequently, all assays were performed identical to the optimized methodology 
illustrated in Figure 7.5.     
7.4.2 Assay Quantitation 
To enable subsequent quantitation in clinical samples, the concentration dependent 
responses of IL-2, IL-6, and IL-8 were assayed from 1 pg/mL up to 3125 pg/mL. Overlays of 
these assays, shown in Figure 7.7, illustrate the remarkably wide range of signal responses 
relative to previous non-enzymatic assays. In the case of IL-8, an exceptionally robust capture 
antibody enabled quantitation down to 500 fg/mL. The linear response was found to extend over 
3 concentration decades, illustrated in Figure 7.7d-f. This dynamic range can be readily 
extended to higher concentrations via either sample dilution, else quantitation based on 
secondary and even primary responses, as demonstrated previously.
6
 Combined, this approach 
would enable quantitation across 8 decades from 500 fg/mL to 50 µg/mL.  
7.4.3 Application of Interleukin Assay to Cerebral Spinal Fluid Samples 
Having demonstrated multiplexed interleukin quantitation in a buffer system, we applied 
our assay to cerebral spinal fluid (CSF) samples to showcase its robust nature and clinical utility. 
CSF is a promising medium for biomarker-based diagnostics as it has significantly reduced 
protein content relative to serum, is in direct contact with the extracellular space in the brain, and 
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contains important putative diagnostic markers.
25
 Furthermore, in some cases CSF has been 
shown to have more disease diagnostic value than plasma-based analysis for brain-related 
disease.
13
  
We performed several different studies in CSF samples to demonstrate that interferents 
did not degrade the quantitative nature of the assay, shown in Figure 7.8. We began by 
performing IL-6 quantitation in undiluted, 10-fold, and 100-fold dilutions of the same CSF 
sample. While the concentration of IL-6 in the sample was unknown, precise 10-fold dilutions 
should result in a commensurate 10-fold decrease in the measured IL-6 abundance. As shown in 
Figure 7.8a, after converting the raw signal response to a concentration with calibration plots, a 
very linear concentration-dependent response was obtained for all three CSF concentrations. 
Next, we quantitated the abundance of IL-2, IL-6, and IL-8 in several individual patient CSF 
samples to measure the patient to patient variability, shown in Figure 7.8b. Finally, a 125 pg/mL 
internal standard was added to the CSF sample, and compared to a 125 pg/mL external standard 
in buffer only. As shown in Figure 7.8c, after subtracting the CSF-only response to determine 
the response due solely to the 125 pg/mL internal standard, we observe a very similar response to 
the 125 pg/mL external standard. 
Aware that matrix effects could potentially interfere with quantitation in undiluted CSF, 
we employed both external standard and standard addition calibration methods and correlated the 
results with well-based ELISA assays. We anticipated that while standard addition should better 
compensate for matrix effects to give more accurate measurements, the extrapolation 
necessitated in this method might lead to reduced precision.
26
 Figure 7.9a shows good 
agreement between both the ELISA and microring-based quantitation of IL-8, IL-6, and IL-2 in 
pooled human CSF samples when using external standard calibration. In all cases the precision is 
comparable between the two technologies and the microring measurements gave somewhat 
lower concentration for IL-6 and IL-8. These discrepancies are likely due to complex matrix 
effects, which are known to differentially affect dissimilar detection technologies.
27
 Importantly 
though, while variability between CSF samples and processing methods prohibits a directly 
quantitative comparison,
28
 the qualitative  order of abundance, IL-8 > IL-6 > IL-2, agrees with 
literature reports.
13
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To further probe the accuracy of our enzymatically-enhanced microring resonator 
measurements, we performed a focused study on IL-6 using the method of standard additions to 
better compensate for matrix effects. As shown in Figure 7.9b, the implementation of the 
standard addition method brings the measured concentrations into excellent agreement. Not 
surprisingly, the precision of the standard addition microring quantitation is reduced compared to 
the external standard calibration; however, an equivalent reduction in precision is noted for the 
ELISA measurement when subjected to an identical standard addition extrapolation. Data from 
standard additions are shown in Figure 7.10. 
While the challenging quantitative properties of interleukins position them as an excellent 
benchmark of assay robustness and quantitative capabilities, numerous other biomarkers exist 
with more utility in disease diagnostics, and we anticipate this assay will be applied to these 
markers in the near future. Notable examples include aβ40, aβ42, phosphorylated tau, and tau in 
Alzheimer‘s disease.25  
7.5 Conclusions 
We have integrated an enzymatic amplification strategy into a multiplexed interleukin 
assay using silicon photonic microring resonators for sensitive quantitation in cerebral spinal 
fluid. HRP-induced oxidation of 4-CN results in precipitation of the insoluble product onto the 
sensor surface, transduced as a mass-binding event. The high gain of this modular signal 
amplification strategy enables us to bypass limitations of the Langmuir binding isotherm, 
theoretically detecting the binding of 10s of biomolecules to the sensor surface. We demonstrate 
<1 pg/mL limit of detection, and a 3 decade linear dynamic range which can be readily extended 
to higher concentrations. We anticipate the modular nature of the assay will allow further studies 
of protein and nucleic acid biomarkers with improved clinical utility.  
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7.6 Figures and Tables 
 
 
Figure 7.1. Calculations based on the Langmuir Binding Isotherm (Equation 1) demonstrate the 
profound effect of capture agent affinity and analyte concentration on the number of molecules 
bound to a sensor surface. Measurements in the fM concentration range require high gain 
amplification strategies to permit quantitation due to the minimal number of binding events. 
Assumptions include a sensor surface area of 85 µm
2
 and 6x10
11
 capture agents /cm
2
, parameters 
taken from a typical microring resonator assay. 
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Figure 7.2. a) Kinetic fitting parameters ka, kd, and KD were determined by fitting both the 
association and dissociation phases of interleukin binding to a surface-immobilized capture 
antibody with Equations 4 and 5, respectively,  
      ( )           (   )   (Eq. 4) 
      ( )           (   )   (Eq. 5) 
where A is the y offset, kobs is the observed binding constant, t is the time, and U is the time 
offset. The dissociation constant, kd, is directly obtained from the dissociation phase as kd = kobs. 
b) ka, the association constant, is obtained from the association phase by determining the slope of 
kobs plotted against analyte concentration, as shown in Equation 6.  
                          (Eq. 6) 
Data shown is for IL-6; calculated kinetic values listed in Table 7.2. 
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Figure 7.3. A typical antibody functionalization, showing the functionalization of single chip 
with 4 separate antibodies. It was determined that a minimum of 100 pm antibody loading is 
required to sufficiently cover the sensors in capture agent and ensure reproducible performance. 
Interestingly, antibody loading above 100 pm did not improve the sensor performance any 
further.   
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Figure 7.4. The concentration of methanol and 4-CN were varied from 0.25x to 4x the 
recommended concentrations of 17% and 0.48 mM, respectively. As expected, the 1x 
concentrations proved to give the highest response and were used for all subsequent experiments. 
Data shown is for 125 pg/mL IL-6 standard.   
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Figure 7.5. a) Schematic representation of the interleukin assay using HRP as an enzymatic 
reporter, illustrating the stepwise surface immobilization of primary antigen, detection antibody, 
and SA-HRP, followed by precipitation of 4-chloro-1-naphthon onto the sensor surface. b) 
Representative data corresponding to the cartoon above illustrates the large signal gain obtained 
via 4-chloro-1-naphthon deposition using an IL-6 concentration of 3125 pg/mL. 
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Figure 7.6. SEM images of 3 different microrings with various IL-6 concentrations: a) 3125 
pg/mL, b) 625 pg/mL, c) 25 pg/mL, d) magnification of 625 pg/mL. The heterogeneity of the 
precipitation process is readily observed, likely corresponding to localized deposition around 
surface-immobilized HRP enzymes. Images captured on a JEOL 6060LV general purpose SEM 
at 15 kV.  
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Figure 7.7. The concentration dependent response of 4-CN deposition a-c) is observed to span 
>3 orders of magnitude dynamic range for all three interleukins studied. The associated 
calibration plots d-f) illustrate a detection limit of 1 pg/mL for all three interleukins, and 500 
fg/mL for IL-8. Calibration plots are fit with logistic functions.  
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Figure 7.8. The application of the optimized interleukin assay to various CSF samples. a) 10 
fold dilutions of CSF result in a strong linear concentration dependent response for IL-6. b) 
Profiling of the panel of 3 interleukins in 5 individual patient CSF samples, as well as one pooled 
control. While qualitative in nature, the order of signal response (IL-8>IL-6>IL-2) correlates 
well with literature precedent. c) The differential response between CSF with a 125 pg/mL IL-6 
standard added, and neat CSF with no exogenous IL-6 added results in a very similar to a 125 
pg/mL IL-6 standard in buffer only, demonstrating minimal matrix effects on quantitation. 
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Figure 7.9. a) Using an external standard method, good agreement was observed between 
ELISA and microring resonator-based measurements of interleukin levels in CSF samples. 
Additionally, he two assay showed comparable precision. Error bars represent the standard 
deviation of n=3-4 individual sensors for microring measurements and n=3 for ELISA. b) A 
focused study on IL-6 levels showed even better agreement with ELISA measurements when 
using a standard addition calibration method; however, as expected, the precision for both 
ELISA and microring measurements is reduced when using the standard addition method.  
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Figure 7.10. A comparison of IL-6 quantitation by the method of standard additions for both 
ELISA and microring resonators. 
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Table 7.1. Clone numbers and vendors of all interleukins, antibodies, and ELISA kits. 
Clone #/Vendor IL-2 IL-4 IL-6 IL-8 
Antigen 
14-8029/ 
eBioscience 
34-8049/ 
eBioscience 
14-8069/ 
eBioscience 
208-IL/ 
R&D Systems 
Capture Antibody 
555051/ 
BD Biosciences 
8-D4-8/ 
eBioscience 
MQ2-13A5/ 
eBioscience 
554716/ 
BD Biosciences 
Detection Antibody 
#1 
555040/ 
BD Biosciences 
 
MQ2-31C3/ 
eBioscience 
554718/ 
BD Biosciences 
Detection Antibody 
#2 
MQ1-17H12/ 
eBioscience 
 
BAF206/ 
R&D Systems 
BAF208/ 
R&D Systems 
ELISA Kit BD Biosciences  Abcam BD Biosciences 
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Table 7.2. Kinetics constants of anti-IL-6 MQ2-13A5 capture antibody. 
 
 
 
  
Constants Value 
Ka 2.8x10
6
 
Kd 1.3x10
-2
 
K 2x10
8
 M
-1
 
KD 4.8x10
-9
 M 
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 Chapter 8 
Future Directions 
8.1 Introduction 
A variety of exciting opportunities exist for the application of microring resonator 
technology, however due to space considerations I will focus on projects which are natural 
extensions of those discussed previously. The primary performance metrics derived from 
microring based measurements are the multiplexing capabilities, high sensitivity, and real-time 
data collection. The former two attributes are particularly valuable for biomarker-based 
diagnostics applications, where predictive capabilities frequently correlate with marker panel 
size, and the biomarkers themselves are often found at low abundances (<1 pg/mL). Conversely, 
the real-time data collection and high temporal resolution are enabling attributes for interrogating 
biomolecular interactions. Consequently, future work can be broadly categorized as either 
applications-focused, whereby enzymatic amplification steps and analyte preconcentration 
methodologies are developed for biomarker panel assays, or fundamental in nature, in which 
novel understanding of biological systems is attained through screening biomolecular 
interactions. 
8.2 Enzyme-based Signal Enhancement 
Enzymatic enhancement strategies have a number of desirable attributes which make 
them an attractive method for high gain signal enhancement. Standard mass labels are 
fundamentally limited in their ability to improve sensor response, as they provide linear signal 
enhancement proportional to their size. Additionally, highly surface-sensitive sensors such as 
microring resonators cannot take full advantage of large labels since the majority of the particle 
extends beyond the detection region. In pursuing various signal enhancement strategies, we have 
determined that not just the refractive index, but the packing density of an amplification material 
is equally important. Put another way, while the effective refractive index of many biomolecules 
is the same, their unique physico-chemical properties results in widely varied packing densities. 
Figure 8.1 showcases the differences in signal enhancement potential of four different building 
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blocks: nucleic acids, proteins, polymers, and small molecules. Note those substrates with the 
tightest packing capacities result in the greatest signal response. Thus, unsurprisingly the 
precipitation of 4-CN, a small organic molecule capable of dense surface packing, results in the 
greatest signal response. Remarkably, this particular process is believed to occur quite locally 
around the HRP enzyme and doesn‘t coat nearly the entire ring surface, yet still results in the 
greatest signal enhancement. In fact, the current limitation on signal response at high 
concentrations is not the HRP-enabled substrate precipitation, but rather the ability of the optical 
scanning instrumentation to track such a large wavelength shift (>15 nm).   
Several promising avenues exist for further improvement of enzymatic enhancement 
strategies, including alternate substrates, varying substrate solubility, and multi-enzyme 
conjugation. All enzymatic enhancement studies to date have utilized 4-chloro-1-napthol as a 
HRP substrate, however an additional substrate, 3,3‘-Diaminobenzidine (DAB), offers several 
promising advantages over 4-CN.  Whereas it was not possible to increase the solubility of 4-CN 
further, as increasing the organic component of the buffer any further eliminates the activity of 
the surface bound HRP enzyme, DAB precipitates in standard PBS 7.4 buffer. Consequently, the 
organic content of the buffer can be increased significantly before inducing any deleterious 
effects on enzyme activity, to a point of improving the precipitation range of the substrate. This 
is significant, as the proposed limitation of enzyme-mediated signal enhancement is a buildup of 
precipitate around the enzymatic site, resulting in steric hindrances to substrate-enzyme 
interactions, enzyme instability, and coating of precipitate. A second advantage of the low or 
zero amount of organic solvents in the DAB running buffer is this step will cause minimal 
perturbations to biologically functionalized surfaces. Finally, preliminary experiments shown in 
Figure 8.2 confirm significantly faster kinetics for the DAB substrate, enabling even more rapid 
time-to-result for this assay. Numerous other substrates such as 3,3‘,5,5‘-Tetramethylbenzidine 
(TMB) and 2,2‘-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS), among others, may 
have even better performance properties.  
Another proven method for improving signal response is the conjugation of a multitude 
of enzymes to an individual nanoparticle or other scaffold, or even the conjugation of clusters of 
nanoparticles functionalized with enzymes. Mani et al. demonstrate the former, conjugating 
~7500 HRP molecules per gold nanoparticle, and using this label to improved their detection 
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limit of prostate specific antigen (PSA) by 3 orders of magnitude.
1
 Similarly, Munge et al. 
evolved this concept further, combining together multiple HRP-coated nanoparticles into an even 
larger cluster with a total of ~500,000 HRP molecules.
2
 This supercluster results in 500,000 HRP 
molecules for a single target molecule, not to mention the high turnover and robust catalytic 
performance of the HRP enzyme. Combined, the authors demonstrated an improvement in their 
detection limit of IL-8 by 3 orders of magnitude, detecting 1 fg/mL IL-8 in serum. In a final 
application, Joensson and colleagues quantitated the abundance of cell surface proteins on 
individual cells by integrating digital microfluidics and enzyme-based, single cell analysis.
3
 We 
anticipate applying the nanoparticle-clustering methodology to our microring resonator assay 
should result a similar improvement in our limit of detetection—3 orders of magnitude. 
Preliminary work in this area demonstrated the successful creation of bead superclusters as 
shown in Figure 8.3. 
8.3 Analyte Preconcentration 
Regardless of the gain achieved through various signal amplification schemes, a 
fundamental limitation arises when interrogating extremely low abundance analytes. As detailed 
in Figure 7.1, at ultralow analyte concentrations finite sensor size and capture agent binding 
affinities conspire to result in only a few target analytes bound to the surface, or even none at all. 
Less than one analyte bound per sensor results in a stochastic sensing regime, in which analyte 
abundance can theoretically be quantitated based on the near-Boolean sensor response arising 
from ‗on‘ or ‗off‘ sensors with either 1 or 0 analytes bound, respectively.4 Practical 
considerations make this approach challenging, particularly in complex media environment 
where some amount of nonspecific binding always occurs and tends to mask the binding of a 
single analyte, even with signal amplification. A promising alternative is preconcentration, 
wherein an analyte-containing sample is treated with a reagent capable of concentrating the 
analyte of interest into a much smaller volume or onto a scaffold, thereby increasing the effective 
concentration and sidestepping Langmuir limitations. Numerous preconcentration strategies 
exist, most frequently dependent on microfluidic
5,6
 or nanoparticle-based preconcentration and 
separation.
7-10
 Nanoparticle preconcentration is particularly well suited to microring resonator 
assays, as nanoparticles can be functionalized with both capture antibodies and reporter enzymes 
to become a dual-purpose concentrator-reporter tool. We anticipate with further assay 
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optimization, particularly improvements in enzymatic reporter systems, pre-concentration steps 
will be mandatory. In fact, the sub-pg/mL interleukin detection already demonstrated is in the 
stochastic sensing regime. 
8.4 RISC Interaction Screening 
 With the development of a robust in vitro RISC model, the groundwork has been laid for 
combinatorial, high throughput interrogation of interacting RISC components. Since the minimal 
RISC used previously contains only the most basic elements of the complex—Ago2, miRNA 
guide strand, and mRNA target strand—significant experimental space remains to be probed to 
more fully characterize this complex. One particular promising line of inquiry lies with the 
sequence-dependent interactions of Argonaute proteins with their putative guide strands. While 
many of the fundamental properties governing the interaction between the two have been 
characterized, a high throughput screen of systematically mutated guide strands should reveal 
much more nuanced interactions, as well as possible biases in RISC-induced regulatory control. 
Several such interactions are shown in Figure 8.4. Many applications would benefit from this 
improved understanding, including miRNA prediction algorithms and RNAi designs. Systematic 
interrogation of RISC-associated proteins would be an equally fruitful pursuit, albeit more 
fundamental in nature. Dozens of proteins have been implicated in RISC activity with varying 
degrees of certainty through co-immunoprecipitation experiments, and the microring resonator 
platform serves as an excellent platform to obtain real-time data for more thorough 
characterization of these interactions.
11,12
 One representative interaction is that between Ago2, 
HuR, and the mRNA transcript, made particularly interesting for its controversial role in RISC 
mediated regulation. Initial results suggested HuR inhibited myc expression through an 
interdependent mechanism with let-7-loaded RISC.
13
 However, subsequent studies found HuR 
acts as a RISC inhibitor, preventing RISC-mediated gene repression by promoting the 
dissociation of RISC from the target mRNA transcript.
14
 While these studies appear to show 
conflicting results, the possibility also exists for some undiscovered actor which modulates the 
activity of HuR under different circumstances. While a microring resonator based assay is ill 
suited to discovery of such an unknown player in an endogenous environment, it would be 
excellent at combinatorial interrogation of known RISC-associated proteins to identify 
previously unknown interactions.   
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 Several other promising opportunities exist for microring resonator based interaction 
screens. Antibody screens are an important time saving measure when developing a new 
biomarker based assays, a particular concern given the wide range of quality and activities of 
commercially sourced biologicals. This problem is exacerbated when designing highly 
multiplexed assays and the number of antibodies involved grows rapidly. Such antibody 
performance screening depends on real-time data collection to determine on and off rates, which 
subsequently inform the selection of capture and detection antibodies. Drug screening remains an 
important and largely unexploited assay type for microring resonator sensor arrays. With an 
expanding understanding of compatible immobilization chemistries, it should be possible to 
interrogate an extensive library of potential drug candidates against surface immobilized drug 
targets. Finally, epitope mapping remains an important field amenable to microring resonator 
assays. Sensor arrays are first decorated with spatially separated peptide fragments, prior to 
introducing various antibodies and screening their interactions. One important application of this 
assay would be the screening of Troponin auto-antibodies. Troponin protein fragments, which 
are released during acute myocardial infarction, serve as potent biomarkers of myocardial 
damage.
15
 However, the presence of anti-troponin autoantibodies in many populations 
significantly hampers accurate quantitation, resulting in false negatives.
16
 A troponin microring 
resonator assay, coupled with an appropriate peptide array, could both quantitate the troponin 
abundance as well as map the epitopes of various anti-troponin autoantibodies, enabling proper 
normalization and more accurate quantitation.  
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8.5 Figures 
 
Figure 8.1. Various signal enhancement strategies each have unique packing density, and hence 
signal enhancement potential. In all cases except for 4-CN, the signal is believed to be limited by 
extension beyond the evanescent field, thus enabling an equitable comparison between relative 
‗packing densities‘ of the different amplification strategies.  Note the different time scale for the 
polymer and protein layer by layer deposition. 
196 
 
 
Figure 8.2. A side-by-side comparison of 4-CN and DAB substrates under identical conditions 
illustrate the rapid kinetics of DAB oxidation and subsequent precipitation. The similar signal 
response, regardless of kinetics, indicates a common termination mechanism which prevents 
further substrate turnover. Increasing the solubility of the DAB substrate slightly should sidestep 
this ‗signal ceiling‘, allowing for substrate precipitation over a much larger region and improving 
catalytic longevity.   
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Figure 8.3. SEM images of microrings decorated with clusters of magnetic beads. a) Individual 
100 nm beads are crosslinked via biotinylated antibodies to form clusters covering large portions 
of the ring surface. b-d) Successive close-ups of a bead cluster, as well as individual beads 
decorated on the microring surface. e-f) 1 µm beads display different aggregation properties than 
their smaller counterparts. f) Individual beads binding to the sensor surface. Images captured on 
a Hitachi S-4700 general purpose SEM at 10 kV.  
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Figure 8.4. A rudimentary map of RISC associated proteins with proposed regulatory 
mechanisms. A complete list of proteins involved in this regulatory process has yet to be 
determined.
17
 a) The RISC complex interferes with translation initiation by blocking the 
attachment of the 40S ribosomal unit to eIF4F and cap, or prevents the joining of the 40S and 
60S ribosomal units. b) Proposed mechanism for translation blockage post-initiation are 
numerous, ranging from proteolysis of ribosomal units, ribosomal knock-off, or blockage of 
nascent peptide elongation.   
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Appendix 
General Figures 
 
  
 
Figure A1. a) Each 6 x 6 mm sensor chip contains an array of 32 microring sensors, of which 
24 are active and 8 are thermal reference controls. The 200 µm spacing between sensors enables 
the rings to be individually addressed with standard spotting technologies. b) False color                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
SEM image of the interface between the microring structure and the adjacent linear waveguide as 
seen through the annular opening in the fluoropolymer cladding layer. The microring diameter is 
30 µm and the waveguide separation is 200 nm.
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Figure A2. Four-channel cartridge top design, enabling 4-plexed fluidic interface with the sensor 
surface. a) Top view shows ports for securing the cartridge top to the assembly holder with three 
screws, as well as the optical window. b) Internal view shows a cutaway of the various fluidic 
channels. c) Bottom view shows the alignment holes, as well as the fluidic ports which interface 
with the chip. d) Side view shows the vertical placement of horizontal fluidic channels.   
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Figure A3. Various gaskets were designed to accommodate 1, 2 or 4 fluidic channels to be 
interfaced with the sensor surface. Note the Maverick chip design is shown, containing 128 
active sensor rings. a) The Mylar gasket is identical across all designs, except for a variable 
region which interfaces with the sensor surface (outlined in red). b) The one channel design 
permits all sensors to be addressed with one solution. c) Four channel design permitting 
simultaneous delivery of four different solutions. Note the creation of 16 control sensors which 
do not interface with any fluidics. d) The two channel design enables two separate solutions to 
be introduced simultaneously.
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Figure A4. a) Three identical models of the current optical scanning instrumentation, 
commercially known as the Maverick system. Each unit contains complete optical scanning 
instrumentation and integrated fluidics; however, they share a common laser source. b) An array 
of sensor chips, each containing 128 active sensor rings and 4 control rings. c) An individual 
chip sized next to a U.S. dime for scale. d) SEM image of four individual microrings. Note the 
annular openings in the fluoropolymer cladding layer surrounding each ring, as well as the 
underlying linear waveguides barely visible beneath the cladding.  
